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HIV protease inhibitors (PI) are core components of Highly Active Antiretroviral 
Therapy (HAART). HIV PIs are extremely effective at suppressing viral load, but have been 
linked to lipodystrophy and dyslipidemia, which are major risk factors for cardiovascular 
disease. Recent studies indicate that activation of endoplasmic reticulum (ER) stress is an 
important cellular mechanism underlying HIV PI-induced dysregulation of lipid metabolism. 
xv 
 
However, the exact role of ER stress in HIV PI-associated lipodystrophy and dyslipidemia 
remains to be identified.  
Hepatocytes and adipocytes are important players in regulating lipid metabolism and the 
inflammatory state. Dysfunction of these two cell types is closely linked to various metabolic 
diseases. In this dissertation research, we aimed to define the role of activation of ER stress in 
HIV PI-induced dysregulation of lipid metabolism in adipocytes and hepatocytes and further 
identifty the potential molecular mechanisms. Both cultured and primary mouse adipocytes and 
hepatocytes were used to examine the effect of individual HIV PIs on ER stress activation and 
lipid metabolism. The results indicated that HIV PIs differentially activate ER stress through 
depletion of ER calcium stores, activating the unfolded protein response (UPR). UPR activation 
further lead to an alteration of cellular differentiation through downstream transcription factor 
CHOP. At the same time, HIV PIs also altered adipogenesis via differential regulation of the 
adipogenic transcription factor PPARγ. HIV PI-induced ER stress was closely linked to 
dysregulation of autophagy activation through CHOP, and upstream ATF-4, signaling pathways. 
In hepatocytes, the integrase inhibitor raltegravir abrogated HIV PI-induced lipid accumulation 
by inhibiting ER stress activation and dysregulation of autophagy pathway.  
 Our studies suggest that both ER stress and autophagy are involved in HIV PI-induced 
dysregulation of lipid metabolism in adipocytes and hepatocytes. The key components of ER 
stress and autophagy signaling pathways are potential therapeutic targets for HIV PI-induced 
metabolic side effects in HIV HAART-treated patients.   
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CHAPTER I: Background 
I. HIV and Consequential Difficulties 
 A. Human Immunodeficiency Virus 
 The overwhelming impact the Human Immunodeficiency Virus (HIV) has on the world 
is undeniable – by the end of 2009 there were 33.3 million people living with HIV in the world, 
with 1.8 million deaths in that year alone (1). The first identification of Acquired Immuno 
Deficiency Syndrome (AIDS) in the United States was in 1980, and since then, more than 27 
million people have died from complications of infection. In addition, the high rate of deaths can 
be directly attributed to the lack of available medications – only 36% of the infected population 
received adequate antiretroviral therapy (2).  
Besides the known political and monetary issues at hand, there are multiple HIV viral 
subtypes and sub-subtypes that have been described and overwhelm pharmaceutical availability. 
In fact, most research completed on HIV therapies has occurred, and continues to occur, in 
Europe and America, targeting the HIV-1 strain, although much of the world population is also 
afflicted by HIV-2. In addition, HIV-1 has 3 clades (M, O, and N), of which M is most common 
in the United States. M has 9 subtypes, and under these, there exist sub-subtypes which 
recombine to form circulating recombinant forms (CRFs) in multiply-infected individuals 
(Figure 1). Differences even within the strain related CRFs can be the basis seen in differences of 
cellular tropisms, viral fitness, and effect in each individual‟s therapy.  
 The ability of HIV to rapidly mutate due to the imperfect enzyme used for genome 
replication has resulted in a multitude of strains resistant to therapies on the market. To combat 
viral strain mutations, Highly Active Antiretroviral Therapy (HAART) has increased in  
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Figure 1. Diagram of HIV subtypes. Depiction of HIV-1 and -2 subtypes and clades. Reprinted 
by permission from Macmillan Publishers Ltd: [Nature Reviews Microbiology] (3), copyright 
(2007). 
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complexity and effectively decreased deaths from opportunistic infections in those that are 
candidates for this treatment. This century has seen the ability of HAART to turn a deadly virus 
into a chronic infection. Due to polymorphic differences in individual strain enzymes, that some 
individuals are infected with less common strains, and diverse side effect profiles, physicians 
must seriously consider which drugs to prescribe to each individual in their clinic.  
 B. FDA Approved Antiretrovirals in Sequence of Viral Cycle  
 The first essential step in HIV infection of immune cells (T cells or macrophages) is 
fusion of the viral and cellular membranes. This process occurs through interaction of the viral 
glycoprotein, gp120, and the CD4 molecule on the cell surface. After the initial interaction 
between these two proteins, viral proteins utilize a secondary receptor interaction through 
CXCR4 (T-tropic) or CCR5 (M-tropic). Maraviroc is a relatively recently approved 
antiretroviral that inhibits fusion via binding to, and therefore preventing interactions, to CCR5. 
Another, less commonly prescribed, is Fuzeon (enfuvirtide), which binds to the viral gp41. 
 After entry into the cellular cytoplasm, the viral genome (two copies of a single-stranded 
RNA) is reverse-transcribed into DNA by the viral enzyme, reverse transcriptase (RT). The first 
anti-HIV drugs to come on the market inhibited this enzyme. There are currently three classes of 
inhibitor, nucleotide and nucleoside analogs (NRTI), as well as non-analogues (NNRTI), and 
those drugs that can act as both. NRTIs are analogues to deoxynucleotides which are 
incorporated into the growing DNA chain. NRTIs lack one significant motif of 
deoxynucleotides, a 3‟-hydroxyl group, which is essential in linking each deoxy in the chain. 
Without this hydroxyl group, NRTIs cause a halt in synthesis, terminating the chain. NNRTIs, on 
the other hand, bind directly to the RT itself, inhibiting the function of an essential enzyme. 
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 The next step is integration of the newly synthesized viral DNA strand and the host 
genome by the viral integrase enzyme. In 2007, the FDA approved Raltegravir, which directly 
inhibits this enzyme, thereby preventing viral genome integration and latency of HIV in the host 
cell. 
 Upon host cell activation, often in times of stress such as infection and inflammation, the 
integrated virus cuts itself from the host genome, and begins the viral replication cycle. Here, the 
virus utilizes the host enzyme RNA polymerase to produce multiple copies of packagable RNA 
strands from the viral DNA sequence. At the same time, the host cell machinery is recruited to 
synthesize viral proteins that will be necessary for virion production and release. After protein 
production and the beginning of packaging, the viral enzyme protease cleaves long HIV proteins 
into functional segments (see Section II). Mature virions are subsequently released when 
immature particles bud from the membrane and form mature infectious virions with the help of 
protease. HIV protease inhibitors (PI) essentially inhibit viable virion production by inhibiting 
the action of this essential viral enzyme. 
 Please see Figure 2 for a depiction of HIV life cycle and how each class of anti-HIV 
drugs inhibits replication of the virus in a host cell. 
C. History Leading to Current Drug Class Recommendations 
 Zidovudine, an NRTI, was the first drug approved in 1987. As is the case of the 
following approvals of zalcitabine, stavudine, and didanosine, the NRTIs seemed effective, yet 
the development of resistant strains caused a rebound in opportunistic infections in patients.In 
1995, a major turning point occurred with the approval of HIV PIs ritonavir, saquinavir, and 
indinavir. Not only did these drugs work independently to help reduce viral load, but  
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Figure 2. Targeting HIV Lifecycle. Current marketed anti-HIV therapies target different stages 
of HIV life cycle, from fusion, reverse transcription, integration, and viable virion budding. Drug 
classes are labeled to the targets they inhibit. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Medicine] (4), copyright (2003). 
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combination therapy with NRTIs drastically decreased opportunistic infections. This regimen is 
now known as HAART, and most frequently includes two NRTIs with one PI, though 2 NRTIs 
combination therapy with NRTIs drastically decreased opportunistic infections. This regimen is 
now known as HAART, and most frequently includes two NRTIs with one PI, though 2 NRTIs 
with 1 NNRTI, or 3 NRTIs are also used. With the constant battle of resistant strains in the 
current HIV-infected population, addition of integrase or fusion inhibitors can increase efficacy 
of these regimens. 
       D. Consequences of Mutations 
 The continuous development of drugs has allowed successful combat towards resistant 
strains. Resistance in individual strains is not rare due to an inherently high mutation rate of HIV 
resulting from the imperfect reverse transcriptase enzyme. Yet, the probability of mutation 
leading to resistance to a given antiretroviral increases when patients are inconsistent in the 
taking the prescribed drug.  
 The variety of mutations seen in individual infectious viruses can be divided into 
subclasses, primary (major) or secondary (minor). The most significant mutation in the case of 
HIV drug resistance is that of secondary mutations. In this instance, a point change occurs, 
confirring resistance to a drug. These mutations are dependent on the background genetics of the 
particular viral strain and the resulting fitness of that virion after such a mutation. For instance, a 
single amino acid change in subtype F1 will be needed for resistance to a PI. This point mutation 
differs from the one needed for subtype G2 to confer resistance. Genetic diversity must be taken 
into account to understand mutations resulting in drug resistance. One significant example – non 
B type HIV will not mutate as much as B type HIV at specific amino acids needed for resistance 
to PI because efficiency of replication drops more than half compared to the respective wild type.  
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 These genetic barriers allow a clinician to use a patients viral genotype to determine 
which HAART regimen will be most effective in decreasing viral load. In addition, genotyping 
can be repeated after a few years of treatment to determine what drugs to add or switch to 
decrease selction of mutated strains. Unfortunately, this process can inevitably end as the 
physician uses all available drugs due to mutating strains and/or individual non-compliance. 
II. HIV Protease 
 The HIV genome is a single-stranded mRNA, of which each virion carries two copies. 
There are 9 genes that encode 15 proteins, 3 of which are essential. The nonessential genes 
include vif, or viral infectivity factor which aids in stable reverse transcription; vpr, or encoding 
viral protein R which arrests cells in G2; vpu, or viral protein U which promotes virion release; 
rev, or regulator of viral gene expression which inhibits splicing of transcripts; and tat, or 
transcriptional activator which enhances RNA polymerase II. The essential genes are – gag, pol, 
and env which encode for structural proteins, essential enzymes, and envelope proteins 
respectively. During translation, gag is translated as a long 55 kDa precursor, and pol as a 160-
kDa Gag-Pol fusion protein. These polypeptides must be cleaved at specific moments in the HIV 
life cycle in order to produce functional proteins and viable virions. 
This essential activity is handled by HIV protease, which cleaves the polypeptides during 
virion budding. Protease recognizes substrates that have multi-folded domains, containing 
linking regions with non-homologous and asymmetric sequences. The crystal structure of 
protease was first shown in 1989 by Merck Sharp and Dohme Research Laboratories (5), giving 
both interesting knowledge about HIV and a structure-based drug design for inhibition of virion 
production.  
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Protease is an aspartic protease within the peptidase family A2 (retropepsin 
endopeptidase). It cleaves between either a tyrosine-phenylalanine or tyrosine-proline, which no 
human host cell enzyme accomplishes. Despite high sequence mutation, the catalytic triad (Asp-
Thr-Gly) is well conserved, though other regions may change due to both genetic variation and 
drug resistance. 
Protease contains a quartenary structure, and is a dimer by which each monomer consists 
of 99 amino acids (6), and the N- and C-termini of the dimers interdigitate to form a four-
stranded interface. Together, there are three domains – a terminal (or dimerization) domain, core, 
and flap. While the terminal and core domains are essential for stabilization and interface for the 
active site, the flaps are exposed loops that enclose the active site for ligand interactions. Despite 
the multi-domains of this enzyme, protease is quite stable due to a hydrophobic core, packing of 
side chains, and the Fireman‟s grip (a conserved aspartyl protease scaffold of H-bonds involving 
the catalytic residues). 
As protease is essential for the production of viable, infectious virions, it became the 
second target of inhibition for anti-HIV therapy. When PIs were introduced to the market, their 
effectiveness with NRTIs was almost immediately noted, and thus initiated the term of HAART. 
There are currently two generations of drugs, peptidic and non-peptidic (Figure 3).  The 
peptidomimetic class, though quite large and inherently diverse in structure, are related by a 
peptide bond present in each molecule, with a non-hydrolysable amino acid at the scissile bond. 
These molecules mimic the tetrahedral transition-state intermediate formed during the catalysis 
event, but become stuck due to inability of cleavage, inhibiting the entry of viral proteins (7, 8). 
Within this class, some (i.e. ritonavir) are less peptidic in nature, but exploit the symmetry of 
protease, enhancing stability while decreasing effectiveness. The non-peptidic class has moieties 
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to displace water in the active site cleft. This H2O molecule is thought to play a role in opening 
and closing the flap domains, thereby affecting substrate interaction and stability (7). 
Saquinavir (SQV) was the first PI approved by the FDA in 1995 (now as Invirase when 
boosted with Ritonavir). Indinavir (IDV) reached the market in 1996 (Crixivan), and due to a 
great outcome with NRTIs, set the bar for HAART. Ritonavir (RITV) was marketed that same 
year, but now is only given as a booster as it inhibits cytochrome P450 (the enzyme that 
metabolizes most PIs and subsequently decreases their bioavalability). Nelfinavir (NFV) was 
marketed in 1997, and subsequently became the first PI to be recommended for pediatric 
patients. In 1999, Amprenavir (AMPV – now prescribed as prodrug fosamprenavir) was 
introduced (Lexiva). 
Lopinavir (LOPV) entered the prescription option in 2000. It was structurally designed 
for mutated PIs seen often with a mutation of protease at Val82. It is similar to RITV (same 
core), but due to low bioavailability, it was prescribed only with a RITV combination. Now, the 
only form of LOPV available on the market is as a co-formulation pill, Kaletra (the first drug not 
available in single formulation). Kaletra was so successful in both drug-naïve and drug-
experienced patients, it became first-line therapy in 2006, and now has only been surpassed by 
Darunavir-RITV. Atazanavir (ATZV) was approved in 2003, and is now marketed under 
Reyataz. It was the first PI approved for once-daily dosing, increasing the pressure in 
development of more convenient PIs. 
 Non-peptidic PIs, Tipranavir (TRV) and Darunavir (DRV), have relatively recently 
reached the market – 2005 and 2006 respectively. TRV (Aptivus) development utilized coumarin 
as a template, and is now used in multiple resistant strains, but not in patients with little 
resistance due to a high side effect profile. DRV (Prezista) is now the first-line HIV PI. DRV  
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Figure 3. Planar structure of current HIV PIs. A) Peptidic and B) non-peptidic HIV PI 
subclasses were drawn in ChemDraw. Abbreviations are used in this dissertation. Figure revised 
with permission from Sage Publications: [Toxicologic Pathology] (9), copyright (2009). 
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design is based on AMPV (with a few stereochemistry changes to increase binding in resistant 
strains), and as such, the side effect list is low and effectiveness increased. However, both these 
second generation PIs must be taken in conjunction with RITV, whose lipid side effect is high. 
Despite this, the effectiveness of DRV combined with lowered long term side effects has resulted 
in surpassing prescription numbers of Kaletra in the past year. 
III. Side Effects of HIV Protease Inhibitors 
A. Metabolic Syndrome 
As the list of FDA approved antiretrovirals is long, so is the inventory of side effects. 
Even though the life expectancy of HIV-infected patients under HAART has been extended, the 
various HAART-induced side effects significantly affect quality of life. However, it is difficult 
to concretely determine if these effects are secondary to the therapies or the virus itself. 
In some cases, it may actually be both. One example of this is diminished bone density, 
observed in a large proportion of HIV infected individuals. It is already known that treatment-
naïve patients often have low bone mass, with as high as a 50% prevalence of osteopenia (10). 
There has even been proposed mechanisms of this phenomenon such as the induction of 
differentiation of bone absorbing cells (osteoclasts) (11, 12). To make matters worse, HAART 
treatment can further the reduction of bone density in a yet unknown manner (13). As in other 
side effects discussed, HIV itself can induce major pathology in individuals with no prevention, 
or even an exacerbation, by the drugs used to stop its replication. 
Despite these apparent complexities, there is still a large list of drug-attributable side 
effects. Most commonly, these include general side effects with the NRTI/NNRTIs, ranging 
from rash, anemia, nausea, vomiting, diarrhea, and sleep disturbances. More severely, it is not 
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uncommon to observe liver toxicities, pancreatitis and neuropathy in certain patients, often with 
underlying risk factors. Further, in the past decade, there has been increasing concern over long-
term HAART patients experiencing early-onset cardiovascular risk factors such as hypertension 
(HTN) and insulin resistance. With parallel observations in the American population, some 
attributed these to environmental factors not due to the drugs.   
Some large clinical trials, especially the Data Collection on Adverse Events of Anti-HIV 
Drugs (DAD), have elucidated many particulars of HAART side effects. One specific 
phenomenon noticed in the „90s of lipodystrophy (change of body lipid composition) and 
dyslipidemia (changes in blood lipid levels) were better explained. Now peripheral wasting is no 
longer attributed to viral wasting but to NRTIs (especially stavudine and zidovudine) (14-17); 
and fat accumulation is not just a physiological phenomenon but due to PI treatment (13, 18). 
Together, this HAART side effects has been termed HIV-associated lipodystrophy (19). This has 
pathophysiologically been defined as selective damage of adipose tissue with subcutaneous fat 
loss and/or central fat accumulation.  
Additional PI-specific side effects include dyslipidemia, glucose alterations, and insulin 
resistance, which can lead to diabetes (DMII), HTN, and cardiovascular dysfunctions (20-22). A 
bottom line through these multiple investigations is that myocardial infarction is directly 
correlated with PIs, and not other components of HAART (20, 23). Interestingly, these side 
effects are also components of the clinically defined Metabolic Syndrome. 
The Metabolic Syndrome is a diagnosable syndrome, and a high risk factor for 
myocardial infarctions and strokes. To be diagnosed, according to the National Heart Lung and 
Blood Institute (NHLBI) criteria (24), a patient must have 3 out of the 5 diagnosis: 
1) >35” central circumference in woman, or >40” in men. 
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2) A triglyceride level >150mg/dL (or on treatment). 
3) A high density lipoprotein (HDL) <50mg/dL in women or <40 in men (or on treatment). 
4) A blood pressure (BP) >130/85 (or on treatment). 
5) High fasting blood glucose level, or insulin resistance (or on treatment). 
Importantly, each component above is an individual risk factor for atherosclerosis. 
HIV PI-induced atherosclerotic cardiovascular complications are leading to an increased 
cause of mortality in HIV-1 infected persons in developed countries (25). During the last decade, 
an extensive effort has been put forth to study HIV PI-induced side effects.  Both in vitro and in 
vivo animal studies from our laboratory and others‟ have linked HIV PIs with the activation of 
endoplasmic reticulum (ER) stress and oxidative stress, as well as an increase in inflammatory 
cytokine production from several cell types including macrophages, hepatocytes, intestinal 
epithelial cells and adipocytes. However, the underlying cellular and molecular mechanisms 
remain to be fully identified and therapeutic strategies are currently unavailable. Understanding 
the root cause of these chronic side effects and implications for HIV-infected patients will be 
critical to the design of effective interventions to combat the metabolic and cardiovascular 
diseases in a population chronically exposed to HAART.   
B. HIV PI-Induced Dyslipidemia 
 Alterations in serum lipids of the HIV infected population have been noted since the 
beginning of the 1990s. Before treatments began, patients often had a decrease in LDL and HDL 
plasma concentrations. NRTI treatment alone seemed to increase LDL to presumable baseline 
levels, without any effect on HDL, yet multi-drug treatments tended to increase serum 
triglycerides. In the late 1990s, effort was put forth to tease apart the effect of infection versus 
therapies on this phenomenon.  
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 Two hypotheses began these studies. First, the initial rise in serum lipid levels of HIV 
patients observed by clinicians at the start of treatment could have been partly due to immune 
reconstitution phenomena (26). This is a robust inflammatory response when HIV viral load 
decreases a few months to a year after initiation of treatment. At the same time, there has been an 
increase in average serum lipid levels in the general population due to poor diet and increasing 
age, and the HIV-HAART cohort is no different.  
 Despite these facts, it has been found in numerous long- and short-term studies, as well as 
in healthy versus HIV-infected persons, that HAART, specifically PIs, induces dyslipidemia (20, 
22, 27-32). Often, clinicians combat this phenomenon with lipid-lowering drugs. At the same 
time, research has been attempting to determine which anti-HIV drugs induce the most change in 
lipid composition, and the mechanism underlying these changes.  
Lipid homeostasis is centrally controlled by the liver. When fats are consumed in the diet, 
lipids are packaged into chylomicrons in the intestines whose final fate is the liver through an 
apoE endocytosis pathway. In order to effectively transport these to peripheral tissues, the liver 
packages triglycerides (TG) and cholesterol into very low density lipoproteins (VLDL). VLDLs 
circulate and the TGs inside are taken up by muscle and adipose tissue after hydrolysis by lipase. 
The remnants are called intermediate density lipoproteins (IDL) which can be endocytosed by 
cells or further converted to low density lipoproteins (LDL) by lipases on the surface of cells. 
LDLs are cholesterol rich particles endocytosed through apoB-100, mostly in the liver or adipose 
tissue, and pathologically by macrophages. Another type of lipoprotein is high density (HDL), 
which is a way peripheral tissues „send back‟ lipids, cholesterols, and proteins to the liver in an 
attempt not to be overloaded with these potentially toxic substances, as well as signal to the liver 
to stop synthesizing VLDLs. 
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 HAART appears to affect many aspects of this pathway. Some studies have found that 
NNRTIs may even be able to increase HDL (33), a clinical advantage for dyslipidemic patients 
leading some to want to alter regimens to decrease PIs and increase NNRTIs (34, 35). In fact, 
there were successful studies in switching from PI-based treatments to NNRTI or NRTI-only 
regimes with success in attenuating dyslipidemia (35-37). However, the effectiveness of PIs 
against HIV cannot be disputed. When PIs were added to the regimen in the mid-90s, there was a 
drastic decrease in patients who succumbed to opportunistic infections. The benefits of PIs far 
outweigh the side effects, but determining the mechanism behind these side effects may lead to 
alternative therapies in conjunction with PI use, or better-designed PIs.  
IV. Endoplasmic Reticulum Stress 
A. HIV PI-induced Metabolic Diseases and NAFLD Connection 
In HIV PI-induced metabolic dysfunctions, many features are similar to those observed in 
nonalcoholic fatty liver disease (NAFLD). NAFLD is a clinical term to describe a phenomenon 
in which patients have a fatty liver similar in all aspects to an equivalent alcoholic subject. 
Induction of NAFLD has been described in a range of conditions, such as obesity and diabetes, 
as well as induction by a variety of drugs. Donnelly and colleagues were able to demonstrate that 
the majority of hepatic lipids in patients with NAFLD come from peripheral non-esterified fatty 
acids (NEFA) (predominately from adipose tissue) and de novo lipogenesis (DNL) in the liver, 
not the diet (38).  
Patients receiving HIV PIs acquire metabolic complications that are too similar to 
NAFLD patients to ignore a connection. Indeed, HIV PIs have been clearly shown to alter lipid 
and carbohydrate metabolism pathways, the underlying mechanism of NAFLD (39). Although 
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HIV PI-induced NAFLD is not an entity of its own, many patients taking HIV PIs may have 
NAFLD with absolutely no symptoms, as does the majority of the overweight population. 
However, other patients progress to nonalcoholic steatohepatitis (NASH), which occurs with 
excess inflammation and scarring, potentially causing severe damage to the liver. In fact, many 
studies have found NASH in greater than 50% of HAART-treated patients undergoing liver 
histopathological assessments (40-42). Above all, NAFLD/NASH is most likely part of HIV PI-
induced metabolic diseases due to the strong correlations of hyperglycemia, insulin resistance, 
and dyslipidemia. Indeed, a connection is apparent between western diet-induced NAFLD and 
HIV PIs – the induction of endoplasmic reticulum (ER) stress. 
ER stress activation has been linked to various human diseases such as diabetes, 
cardiovascular diseases, and NAFLD/NASH (43-48). Concurrently, recent studies have shown 
that HIV PIs induce ER stress in many cell types including hepatocytes, macrophages and 
intestinal epithelial cells (49-56). Our laboratory has also identified that HIV PI-induced ER 
stress is partially due to depletion of ER calcium stores (51), and is linked to upregulation of 
sterol regulatory element binding proteins (SREBP) and dysregulation of lipid metabolism in 
hepatocytes (49, 57, 58). The similarities of HIV PI-induced ER stress and underlying ER stress 
in NAFLD must be further probed in order to discover the mechanism underlying HIV PI side 
effects. 
    B. Endoplasmic Reticulum Stress and the Unfolded Protein Response 
Numerous cellular pathways can be altered in times of stress, leading to cellular 
aberrations and dysfunction. In the realm of over-nutrition and its complications, ER stress is 
arguably the most common and important (59-62). ER stress is linked to multiple harmful 
pathways including the cellular inflammatory cascade and lipid metabolism dysregulation since 
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the ER is central for protein folding, secretions (e.g. cytokines), calcium homeostasis, and lipid 
synthesis.  
Inducing ER stress is relatively effortless via depletion of ER calcium stores, changes in 
ER lipid membrane composition, reactive oxygen species (ROS), or accumulation of misfolded 
proteins. When triggered, the ER signals to the cell through the unfolded protein response (UPR) 
to aid in increased productions of proteins needed for protein folding, while decreasing 
transcription and increasing degradation of other non-essential proteins. If the UPR is unable to 
return the ER to homeostastic conditions, it will trigger apoptosis. 
 A central component of the UPR is an ER chaperone protein, BiP/GRP78. In homeostatic 
conditions, BiP/GRP78 is bound to three ER membrane resident proteins, but an insult that alters 
ATP in the lumen, decreases ER calcium stores, or increases a demand of protein folding causes 
GRP78 to unbind. The three proteins, ER transmembrane kinase/endoribonuclease
 
(IRE1), 
doubled-stranded RNA-activated protein kinase-like ER
 
kinase (PERK), and activating 
transcription factor 6 (ATF-6), triggers a cascade upon their release which ultimately leads to the 
activation of transcription factors that upregulate protein chaperones, proteasome components, 
and with continuous activation, turns on GADD-153/CHOP (C/EBP homologous protein) which 
can activate apoptosis (see Figure 4). 
1. IRE1 
 Upon release from GRP78, IRE1 transautophosphorylates, activating its RNase activity. 
Its target is X-box-binding protein 1 (XBP-1) transcript, of which it removes an intron, and 
XBP-1 is re-ligated into XBP-1
s
. There are multiple targets of XBP1
s
, including ER protein 
chaperones and upregulation of itself (63-65). However, beyond the traditional genes it activates, 
XBP-1 action has now been shown to be more diverse. 
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 In fact, XBP-1‟s ability to induce many ER proteins, and increase expansion of the rough 
ER (66) has demonstrated its necessity in ER biogenesis. Specific and elaborate knockout 
models have demonstrated this further when the ER was poorly developed and secretory cells 
subsequently failed to function (67, 68). Sriburi et. al have found that overexpression of XBP-1
s
 
in pre-adipocytes induces upregulation of the rate limiting enzyme in phosphatidylcholine 
synthesis (CTP:phosphocholine cytidylyltransferse or CTT) (66, 69). As this is the major 
phospholipid found in the ER membrane, it follows that XBP-1 increases ER biogenesis by both 
stimulation of ER proteins and membrane components.   
2. PERK 
 The PERK pathway is another UPR leg. When released, PERK transautophosphorylates, 
activating its kinase domain. The major result of this is phosphorylation of eukaryotic translation 
initiation factor 2α (eIF2α). In the phosphorylated state, this essential component of the 
translational machinery cannot recycle GTP, inhibiting general translation but at the same time 
increasing the translation of mRNAs which contain internal ribosome entry sites, such as 
activating transcription factor (ATF)-4, BiP/GRP78, and SREBP-1 (70-72).  
 ATF-4 is a well studied protein involved in the UPR [reviewed in (73)]. This 
transcription factor is heavily involved in increasing amino acid metabolism and protein 
transport [reviewed in (74) and (75)]. Importantly, ATF-4 also upregulates stress-related 
transcription factors ATF-3 and CHOP. CHOP is a central transcription factor involved in 
cellular perturbations, including inhibition of adipocyte differentiation (76-78), and ultimately 
inducing apoptosis. However, this is another example of the necessity of balance, as although 
high induction of ATF-4 will lead to CHOP activation, complete absence will affect adipose 
lipogenesis (79).  
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Figure 4. Depiction of the UPR. At times of ER stress, the UPR is activated to aid in return to 
homeostasis. Shown are the central proteins and downstream transcription factors involved in 
this pathway. BiP (GRP78) - ER protein chaperone; PERK, ATF-6, IRE-1 - ER transducer 
proteins; ATF-4, XBP-1
S
, ATF-6 - downstream transcription factors. 
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SREBPs are additional transcription factors found in the ER membrane. There are three 
isoforms - SREBP-1a, -1c, and -2. SREBP-1c is involved in fatty acid synthesis and lipogenesis, 
-2 in cholesterol synthesis, and -1a in both pathways. The SREBPs are retained in the ER via 
insulin-induced gene (Insig) binding to SREBP cleavage activating protein (SCAP)-bound 
SREBP. At times of sensed decreases in cholesterol or fatty acids, SCAP-SREBP dissociates 
from Insig and relocates to the Golgi where SREBP is cleaved by two site proteases (S1P and 
S2P). The active form then translocates to the nucleus, activating genes for synthesis such as 3-
hydroxy-3-methylgutaryl-CoA (HMG-CoA) synthase, HMG-CoA reductase, squalene synthase, 
acetyl-CoA carboxylase, and fatty acid synthase, as well as upregulation of themselves. Thus, 
ER stress induction not only alters protein production, but also cholesterol and fatty acid 
synthesis. 
 Normally, SREBPs are released when there is a sense of depletion of cholesterol or lipids 
in the ER membrane. However, SREBP1 processing is also regulated through PERK-eIF2α. In 
fact, knockout of PERK substantially decreases active SREBP1 in mammary glands (80). This is 
most likely a result from the recent finding that SREBP1 contains an internal ribosome entry site 
(70). Therefore, activation of ER stress will redundantly lead to active SREBP1 through both 
upregulation of translation and release protein from the membrane.  
3. ATF-6 
 There are two genes encoding ATF-6, α and β. Both produce functional ATF-6 ER 
transmembrane proteins that can play redundant roles for one another. When either/both are 
released from GRP78, they translocate to the Golgi via a localization signal that was hidden 
when in the bound form. In the Golgi, ATF-6 is cleaved by the same proteases that process 
SREBPs, releasing the active cytoplasmic domain which is a transcription factor. ATF6α 
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heterodimerizes with XBP-1
s
 and upregulates genes with the ER stress-response element in their 
promoters, including GRP78 (81) and other ER chaperone proteins as well as XBP-1 and CHOP 
[reviewed in (82)]. 
    C.  ER Stress and Induction of Apoptosis 
 When activation of the UPR fails to bring a cell back to homeostasis, chronic ER stress 
can induce apoptosis. Activation of apoptosis occurs through a few routes, one of which is the 
transcription factor CHOP, and another is IRE1 activation (83, 84) (Figure 5). In addition, there 
exist multiple caspases resident in the ER (85), but it is still not elucidated how directly these 
caspases are involved in UPR-induced apoptosis, or if the mitochondrial apoptotic pathway is 
more essential. A major basis for confusion lies in the fact that calcium leaks from the ER at this 
late stage, triggering the mitochondrial stress pathway (86, 87).  
 Multiple investigators have noted the link of CHOP and apoptosis induction (88, 89). 
Indeed, overexpression of CHOP promotes cell death while overexpressing GRP78 can block 
CHOP-mediated cell cycle arrest and apoptosis (90). This role of CHOP may be directly 
attributed to CHOPs ability of transcriptionally repressing anti-apoptotic Bcl-2 (91, 92). CHOP 
also transcriptionally activates ER oxidase 1α (ERO1α), which oxidizes the ER, promoting 
disulfide bond formations. However, an accumulation of ERO1α may promote hyperoxidation in 
the lumen, inducing release of Ca
2+ 
and downstream apoptotic inductions (89, 93, 94). 
D.   ER Stress and Activation of the Inflammatory Cascade 
 Many inflammatory pathways can be traced to the activation of mitogen-activated protein 
kinases (MAPKs). MAPKs are serine-threonine protein kinases expressed in most cell types. The  
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Figure 5. Potential pathways between ER stress activation and cellular apoptosis. After 
prolonged ER stress, cells may undergo apoptosis do to inability to return to homeostasis. As 
demonstrated in the current literature, after prolonged ER stress, apoptosis can be induced 
through CHOP upregulation (A). In addition, activated IRE1 can lead to upregulation of CHOP, 
activating apoptosis downstream (B, C). Reprinted by permission from Macmillan Publishers 
Ltd: [Nature Publishing Group] (87), 2004. 
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three „most important‟ and well known MAPK pathways are Extracellular Signal-Regulated 
Kinases (ERK), c-Jun NH(2)-terminal protein Kinases (JNK), and p38 kinases. ERK 1 and 2 are 
involved in „pro-growth‟ cascades, often being triggered by growth factors and cytokines. The 
p38 kinases are heavily involved in cytokine expression in immune cells, and as such, are targets 
of research in areas such as asthma and autoimmunity. The pathway of interest here, JNK, is 
activated upon stress responses that inhibit protein synthesis, such as ER stress (95). Activation 
of the JNK pathway is often investigated during drug research since it can be activated in 
numerous ways, induces inflammatory cytokine production, and is linked to cell death/apoptosis 
(96, 97). 
 Although it was known that ER stress could activate JNK (95), it was Urano et. al who 
demonstrated it was through the IRE1 pathway (83). This direct connection has given a secure 
base of an ER stress activation and inflammatory disease link. HIV PI-induced risk factors of 
atherosclerosis, as well as atherosclerosis itself, have inflammatory components. Therefore, the 
issue of ER stress-induced inflammation will continue to be discussed in subsequent sections. 
V. Autophagy  
 A.  Autophagy Pathways  
 Autophagy was first defined in yeast, and has since been described in all eukaryotics. In 
yeast, autophagy serves to aid in times of starvation, while induction of the pathway in mammals 
is increasingly more diverse but is still essentially a self-protective cellular pathway. In 
mammals, autophagy can be activated by multiple stimuli including viral infection, perceived 
starvation, organelle dysfunction, and even ER stress. However, just as in the case of the UPR, 
autophagy has the ability to increase cellular damage or cell death when over-stimulated. This 
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has added autophagy as a third class of cell death (98), beyond the classical apoptotic and 
necrotic pathways. 
 There are three main subdivisions of autophagy - macroautophagy, microautophagy, and 
chaperone-mediated autophagy. These three pathways differ by how cytoplasmic components 
are delivered to the lysosome. Macroautophagy is the classical pathway first described in yeast, 
where cytoplasmic constituents are sequestered in autophagosomes, which later fuse with a 
lysosome to degrade the material for recycling or energy. In contrast, microautophagy occurs 
when a lysosome engulfs the material directly through invagination of its own membrane (99, 
100). Chaperone-mediated utilizes a specific protein signal (KFERQ) that is recognized by 
HSC70 chaperone to traffic a protein directly to the lysosome [reviewed in (101)]. In addition, as 
the autophagic field expands, other pathways are continuing to be identified. However, it is not 
clear if these subsets are separate autophagic pathways or just alterations from the three 
pathways described above. For example, mitophagy, when mitochondria are selectively degraded, 
is most likely one selective form of microautophagy (99, 102). 
 Macroautophagy is the classical and well-understood pathway of autophagic research. It 
is non-specific in its uptake of material, and may be a major pathway by which lipid stores are 
regulated in cells (103). As it is the focus during our investigations, it will be the implied 
pathway when speaking of autophagy induction. 
1. Formation of Autophagosomes 
 As stated above, cell death can occur through autophagy. Visualization of a cell in the 
midst of death can allow determination of which pathway is taken. In necrosis (accidental death), 
swelling of the cell and its organelles occurs due to loss of plasma membrane integrity and a 
consequent influx of ions and fluid. Apoptosis (self-destruction) is noted by shrinkage of the cell 
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and its organelles as the plasma membrane remains intact longer. In addition, apoptotic cells 
often have chromatin condensation, nuclear fragmentation, and blebs of membrane later in time. 
Autophagy is unique in that the cells appear under normal morphology at low magnification, yet 
upon close inspection, there is vacuolization in the cytoplasm and autophagosome formation. 
 At initiation of autophagy, autophagic-specific proteins begin to aggregate at a cistern-
double membrane termed the pre-autophagosomal nucleation site (PAS) (104). This membrane 
than elongates and encloses around the cytosolic component(s), and is termed the 
autophagosome (105). Via vesicle-mediated transport, the autophagosome starts to accumulate 
lysosomal membrane proteins and pumps (106), and later fuses with a lysosome at the outer 
membrane, leaving the inner membrane to contain the cytoplasmic content within the lysosome 
(107). The final step is degradation of the inner membrane and components by hydrolases, and 
transport of products into the cytoplasm for metabolic purposes. 
 Each vesicle in this pathway can easily be defined by its properties. The initial 
autophagic vacuole (AVi), or autophagosome, is at physiologic pH without any lysosomal 
proteins. In the degradative autophagic vacuole (AVd) or late autophagosome, the vesicle is 
acidic and contains lysosomal proteins. Another distinguishing factor of these two vesicles from 
other organelles is their smoothness of membranes compared to the lysosome and ER, and their 
half-lives are actually only 8 minutes (108). After outermembrane fusion of the autophagosome 
with a lysosome, the vesicle is determined an autophagolysosome (109). 
2. Few Key Proteins 
 There are currently at least 31 proteins identified to be specifically involved in autophagy 
(110) (see Figure 6 for a simplification of their involvement). Most of these proteins were first 
identified in the yeast model, and are named autophagy-related genes (Atg). Many of these have 
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analogues in mammalian cells, and have been named differently when found in these models, 
confusing the nomenclature of present day investigations. Both names will be given here to 
clarify the discussion below. 
 In addition to Atgs, other proteins involved in autophagy induction but not specific to 
autophagy also exist. For macroautophagy, the most classically understood activation is that of 
nutrient deprivation. In a nutrient-rich environment, growth factors stimulate the eukaryotic cell, 
and activate P13K Class I proteins. These proteins activate AKT, which results in activation of 
serine/threonine protein kinase target of rapamycin complex 1 (TORC1), an indirect inhibitor of 
Atg1 and direct inhibitor of Atg13. Hence, lack of nutrients leads to Atg1 activation. 
Active Atg1/ULK1 and Atg13 associate with each other and translocate to the PAS. 
Inhibition by TORC1 can occur at this point via phosphorylating Atg13, destabilizing this 
complex. Nevertheless, after Atg13-Atg1/ULK1 is associated with the membrane, Atg17/FIP200 
is localized to the complex, which leads to the recruitment of the transmembrane protein Atg9. 
Atg9 is particularly important as it membrane sequesters, allowing elongation of the PAS (111). 
 In addition to Atg9, the Atg13-Atg1 complex also activates Atg6/Beclin1, allowing the 
interaction with P13K class III proteins. The Atg6-PI3K complex recruits Atg14, and together 
activates the next complex that includes Atg12. Atg12 is conjugated to Atg5 via the catalysis of 
Atg7 (an ubiquitin E1-like enzyme) and Atg10 (E2-like). Atg12-Atg5 interacts with Atg16L, 
oligomerizes, and is involved in the recruitment of Atg8/LC3.  
3. LC3 and Importance in Autophagy Detection 
 LC3 was first identified as microtubule associated protein light chain 3 (MAP-LC3). It is 
a constitutive cytosolic protein, activated when cleaved by a cysteine-protease (Atg4). Once 
cleaved, Atg7 (E1 like) and Atg3 (E2-like) catalyze the conjugation of exposed C-terminal  
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Figure 6. Schematic diagram depicting the molecular aspects of autophagosome formation. 
Shown is a simplified depiction of autophagy induction to autophagosome formation. As eluted 
to in the text, the complexity of autophagy, and numerous proteins involved, complicates the 
ability to draw the pathway as known today. Modifed by permission from Experimental Biology 
and Medicine(112),  2011.  
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glycine to phosphatidylethanolamine (PE) (112, 113). In this conformation, LC3 can associate to 
both the inner and outer limiting membranes of the phagosome. It is important to note that 
activation of LC3 is necessary, but not sufficient, as many other proteins and processes 
contribute to vacuole formation (113). 
 LC3 has been used extensively in autophagy research. During Western blot, one can 
analyze activation of LC3 as the free cytosolic form (I) migrates a Bis-tris gel slower than the 
lipidated form (II). During autophagy, the II:I ratio increases as more LC3 is activated (114). 
Another common method utilizes a plasmid expressing GFP-tagged LC3. After stably 
transfecting a cell line, autophagy increase can be followed by fluorescent-punctate formations in 
the cytoplasm as the expressed GFP-LC3 relocates to autophagosomes (115). 
B.    Autophagy and ER Stress 
 Autophagy and ER stress pathways are not disconnected from one another as previously 
assumed. In contrast, activation of both can aid in cell survival at times of stress. Autophagy 
offers an alternative pathway for degradation of proteins when ER-activated proteasomes can no 
longer handle the load (116-121). In addition, activation of cell death of each pathway may be 
interlinked. Classic knowledge is based on ER stress activating apoptosis through CHOP 
upregulation [reviewed in (89)] and autophagy-mediated cell death via a completely separate 
process. However, recent findings demonstrate that these two cell death pathways are interlinked 
[partially reviewed in (122)].  
Prolonged UPR activation has been shown to lead to autophagy-induced cell death (117), 
and inhibition of autophagy increases cell viability with prolonged ER stress (123-125). The 
exact mechanism of how ER stress induces autophagy is still being investigated. Recently, it was 
found that ER stress activation can inhibit Akt phosphorylation, the upstream inducer of 
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autophagy at times of perceived starvation (126). However, the responsible protein(s) are still not 
known, and may even be cell-type specific [reviewed in (127)].  
Another link is hypothesized to occur through the PERK pathway of the UPR (128, 129). 
Some studies have shown that PERK phosphorylation of eIF2α leads to an upregulation of LC3 
(120). Yet, it has not been elucidated if this is directly due to eIF2α phosphorylation inducing 
LC3 translation, or through ATF-4 activation increasing Atg12 transcription (130, 131).  
  Even more, one study has seen a strong link between activation of ER stress, increased 
autophagy induction, and increased SREBP activity leading to lipid overload in hepatocytes (57), 
although a mechanism was not proposed. Another group has demonstrated the capability of 
SREBP-2 to directly upregulate the expression of autophagy essential proteins (132), giving 
significance to a previous finding that cholesterol depletion leads to autophagy induction in 
multiple cell lines (133). Although SREBPs are not a current forefront of proposed activators of 
autophagy, it is probable that at times of cellular stress SREBPs are involved in processing lipid 
droplets through the autophagic pathway for ATP production. 
VI. Adipocytes 
A.   Cellular Properties  
      1.         Physiology 
In the last two decades, the complexity of adipose tissue has become apparent. 
Investigations surrounding the biological impact of obesity, insulin resistance, and the Metabolic 
Syndrome have surged, resulting in a more intricate understanding of „fat.‟ Now we know that 
adipose tissue (AT) is not only highly specialized to store energy for long term, but also is a 
central endocrine organ. Therefore, AT is inherently involved in the interplay of inflammatory 
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cascades and energy metabolism, which are important players in metabolic disorders. Even 
more, sick fat, or adiposopathy, has been coined an independent endocrine disease (134). 
 AT is an assortment of adipocytes, macrophages, and endothelial cells. In addition, these 
different cell-types are connected to one another through a complex mixture of proteins and 
proteoglycans in the extracellular matrix. Nevertheless, there is no rejecting the centrality of 
adipocytes in this tissue. 
 To understand the adipocyte, it is important to grasp the path it takes to become a mature 
cell. Adipocytes begin first as mesenchymal stem cells (MSCs) (although this has recently been 
debated as touched upon later). MSCs are multipotent stem cells, and as such, can follow 
multiple pathways to terminate as an osteoblast, chorocyte, or adipocyte (135, 136). 
Determination of lineage is dependent on small molecule signals and the extracellular 
environment (137), though complete understanding of this process is still lacking (136). Within 
adipogenesis, the normal pathway begins with MSCs proliferating and then differentiating into 
adipose-derived stem cells (ASCs) (138), most likely through activation via bone morphogenic 
protein 4 (BMP) (139). ASCs continue with proliferation and differentiation into fibroblast-like 
pre-adipocytes which are particular cells that can migrate, proliferate, and further differentiate 
into round adipocytes (140). 
 Pre-adipocytes are fibroblastic in both morphology and gene characteristics. In fact, a 
common cell line used in the study of adipocyte metabolism and differentiation is 3T3-L1, which 
is also commonly utilized in fibroblast studies. Induction of differentiation from the pre-
adipocyte to mature adipocyte is rather simple, and can translate between cell cultures of 
differing species with slight modifications. The mechanism of a differentiation adipocyte is 
nonetheless a bit complex. 
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  2.    Differentiation 
 Understanding of adipogenesis began with cellular models, though more is now known 
through tissue modeling and in vivo studies. In vitro, the initiation of differentiation occurs at 
growth arrest via cell-cell contact. In tissue, this occurs through a combination of cell contact 
with other pre-adipocytes, as well as signals from neighboring adipocytes and stromal cells. 
After induction, the profile of genetic expression changes through adipogenic transcription 
factors, including peroxisome proliferator activated receptor γ (PPARγ), retinoid X receptor 
(RXR), and CCAAT enhancer binding proteins (C/EBP)α and β. 
   a. C/EBPs 
 The C/EBP family is named after their ability to interact with a cytidine-cytidine-
adenosine-adenosine-thymidine (CCAAT) box motif on DNA, present in many promoters. There 
are six members in the family, of which α, β, δ, and δ are involved in adipocyte differentiation. 
C/EBPβ and δ are involved early in the differentiation process – their maximal protein levels in 
3T3-L1 culture is within four hours of induction, and only lasts two days (141, 142). C/EBPβ is 
transcriptionally activated by cAMP response element binding protein (CREBP) (143), and 
transcriptionally activates C/EBPα and PPARγ for the next steps of differentiation. C/EBPβ and 
δ may have a redundancy in action, as knockout of either one alone results in normal adipose 
physiology in mice, but a double knockout have markedly reduced AT mass (144). After 
activation, both C/EBPα and PPARγ autoinduce, and coinduce, to keep levels high throughout 
differentiation (145-147). 
   b. PPARγ 
 PPARγ is arguably the most important of these factors. For one, overexpression of 
PPARγ in fibroblasts induces adipogenesis without any other stimulation, while a dominant 
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negative mutant of the protein results in inhibition of full differentiation (148). Knockout of 
PPARγ in mice results in embryonically lethal day 10 due to malformation of the placenta. The 
heterozygote mouse model gives us more information as these mice develop very minimal AT 
(149). 
 PPARγ is a member of the PPAR family, which also includes α and β/δ nuclear receptor 
members. Upon activation with ligands, these PPARs dimerize with RXR, and act as 
transcription factors to control lipid metabolism and fuel dispersion. In AT, PPARγ increases 
insulin sensitivity as well as regulates TG storage, besides its role in adipogenesis (150). As 
such, a dominant-negative form of PPARγ in adipose tissue leads to insulin insensitivity, 
decreased glucose metabolism, and increased release of FAs – which can also be an issue 
clinically (151). 
 There are two isoforms of PPARγ, of which the second is dominant in adipocytes 
(PPARγ2), and most important in adipogenesis (152). There are five domains of the protein: A/B 
at the N-terminus, C which is the DNA-binding domain (DBD), flexible hinge region (D), ligand 
binding domain (E) and F at the C-terminus. The DBD binds to peroxisome proliferator hormone 
response elements (PPREs) on the genomic DNA (sequences of which are 
AGGTCAXAGGTCA). 
 PPARγ has a distinct and broad range of ligands including prostaglandin, polyunsaturated 
fatty acids (FA), non-steroidal anti-inflammatories, and the glitazone class of diabetic 
medications. Once activated, PPARγ goes on to transcriptionally activate a large number of 
adipose genes including adipocyte fatty acid-binding protein aP2 (153), lipoprotein lipase (154), 
lipid droplet-associated protein cidec (155), lipase ATGL (156), and perilipin (157). The trend of 
these genes revolves around lipid metabolism and lipid droplet formations.  
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  c.       Other Important TFs 
 Another protein that has been marked for involvement in adipogenesis is ADD1 
(adipocyte determination and differentiation-dependent factor)/SREBP1. ADD1 and SREBP-
1a/1c are all encoded in the same gene via alternative promoters, thus giving the protein involved 
here a double label (158). As discussed above, SREBPs are heavily involved in cholesterol and 
lipid synthesis, and ADD1/SREBP-1c does much the same within the first day of adipogenesis 
(159). 
  3.     Lipid Droplet 
 The complexity of lipid droplet (LD) formation has been increasingly realized in the past 
decade. LD is now considered a dynamic intracellular organelle by many experts (160). In 
adipocytes, the LD is large (most other cells it is only 1/50
th
 of that found in adipocytes). At its 
core, the droplet is composed of TGs and cholesterol esters, surrounded by a phospholipid 
monolayer. In addition, there is a coat of proteins with unique functions to help package the TGs, 
as well as protect the droplet. 
  a.  LD Proteins 
The knowledge of LD protein functions are in the beginning stages, while control of their 
expression and the targeting to the LD are unknown. The most studied protein is perilipin, which 
is so similar to adipose differentiation-related protein (ADRP, also called adipophilin) and tail-
interactin protein (TIP47) in sequence that these three proteins are placed into one protein family 
(PAT for Perilipin/ADRP/TIP47). In addition, two more proteins have been added to this family, 
S3-12 and OXPAT, which also share the N-terminal motif of the PAT domain.  
Perilipin is a regulator of lipolysis. The half life of perilipin associated to a LD is about 
40 hours, while free perilipin is quickly degraded (161). At this position, perilipin is also 
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associated with Comparative Gene Identificant-58 (CGI-58) (162), which together inhibit 
hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) from gaining access to 
the inner TGs.  
In unstimulated conditions, perilipin remains associated with CGI-58 on the LD droplet, 
and HSL is sequesterd in the cytosol. With cellular stimulations that increase cAMP levels (ex. 
catecholamines and glucocoricoids), protein kinase A (PKA) is activated and multi-
phosphorylates perilipin (163), as well as HSL. These phosphorylations result in activation of 
lipolysis two fold. First, phosphorylated perilipin no longer associates with CGI-58. Released 
CGI-58 then activates ATGL, allowing its interaction with LD. ATGL cleaves TG and releases 
one FA and diacylglycerol (163). At the same time, phosphorylated HSL colocalizes with 
phosphorylated perilipin (164), where it cleaves the diacylglycerol to release another FA and 
monoacylglycerol. The last is cleaved by monoacylglycerol lipase to release the last FA and a 
glycerol (165). 
In addition to perilipin and CGI-58, other LD proteins include TIP47, a ubiquitously 
expressed protein. TIP47 coats early forming LDs (166, 167), and has also been shown to 
compensate for loss of ADRP (below) (168). Hickenbottom et. al were able to obtain the crystal 
structure of TIP47 in 2004, and found that there are many parallels of TIP47 and apoliproteins A 
and E structures, as well as a high structural match with N-terminal apoliprotein E (164). This 
finding is functionally important, demonstrating structural similarities of cellular LDs and serum 
lipid droplets that may be exploited in the future.   
ADRP is another ubiquitously expressed protein (169), constitutively bound to the LD. 
Functionally, ADRP replaces TIP47 on the small LDs. During the progression of differentiation, 
ADRP RNA and protein levels decrease while perilipin proteins increase and coat larger LDs of 
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late adipogenesis (166, 167, 170). However, in other cell types that store lipids, such as 
hepatocytes, ADRP and perilipin both equally coat the LD. As such, ADRP can compensate for a 
loss of perilipin at least to an extent (170-172). 
 b.  LDs and the ER  
Formation of LDs is at this time only hypothesized and not concretely described. One 
highly supported model portrays the LD to bud off the ER membrane at points of neutral lipid 
accumulations. Others hypothesize the LD and ER remain attached, allowing the accumulation 
and recycling of proteins (173). 
In an elegant study done by Robenek et. al, freeze-fracture replica immunolabeling 
(FRIL) was used to identify where LD proteins were located (174). In their images, the ER 
appears to be holding the LD „like an egg-cup,‟ with the ER adjacent to, and not interconnected 
with, the LD membrane. ADRP and perilipin were found to be located in the limiting membrane, 
at the interface of the core lipid and cytoplasm, and ADRP was found in the ER membrane in 
concentrated areas that were the closest distance to LDs.  
Despite the controversy of the origin of the LD, the importance of the ER in LD 
biogenesis and maintenance remains. Of particular interest in this arena is 
CTP:phosphocholinecytidylyltransferase (CCT), the rate limiting enzyme for 
phosphatidylcholine (PtdCho) synthesis (a major lipid in LD, the other being 
phosphatidylethanolamine). This enzyme, as well as others involved in this pathway, is enriched 
at the RER, however, it is unclear what signal occurs to stimulate/inhibit CCT. What is known is 
that lack of CCT can result in fusion of LDs (175). 
      B.    Adipose Tissue 
 The majority of the population despises AT due to its depleasing asthetic nature.  
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 Figure 7. Depiction of the lineage and maturation of adipocytes. The start of adipogenesis 
can be traced to the mesenchymal stem cell (MSC) differentiating to an adipose-derived stem 
cell (ASC). Pre-adipocytes are then induced by small molecules such as insulin growth factor 
(IGF)-1 receptor activation, as well as cell-cell contact. Transcription factor C/EBPβ is 
subsequently induced, leading to the activation of PPARγ and C/EBPα transcription factors. At 
this point, upregulation of proteins necessary in lipid droplet formation occur. The last stage 
depicted here is activation of hydrolysis at the lipid droplet by cellular cAMP increases (see 
Section VIA. 3a.). 
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However, AT is a complex organ responsible for organ insulation, excess energy storage, and is 
heavily involved in the endocrine system (176, 177). The condition of AT can determine 
lipidemia and insulin sensitivity, as well as the inflammatory state of the body. 
 There are slight differences between AT depots, and this may stem from embryogenesis. 
AT is often suspected to arise from the mesoderm (178), but some fat pads may actually be 
generated from the neural crest (179). The differences between depots are seen both chemically 
and physiologically. It was found in the late 1990s that preadipocytes isolated from different 
depots have different adipogenic induction responses (180) and gene expressions (181), but these 
differences are still not well understood.  
Physiologically, it has been long understood that those with increased visceral adipose 
mass have a higher risk of cardiovascular disease, although those with the same BMI but more 
subcutaneous mass do not have the same risk. However, the differences that lead to detrimental 
risks are still not understood. Basic researchers have probed the physiology of visceral versus 
subcutaneous depots for a decade now with no concrete results. In HIV treatment, different drugs 
have differential effects on fat tissue - the RTIs seem to decrease subcutaneous depots while the 
HIV PIs increase visceral adipose mass (182) (termed HAART-induced lipodystrophy). The 
result is a substantial increased risk of cardiovascular disease in HAART-treated patients, and 
this can be attributed directly to PIs (22). 
 C. ER Stress in the Adipocyte 
 1. Basal Involvement of the UPR in Adipogenesis 
 As previously discussed, ER stress does not have a clear-cut product. Although the UPR 
is understood to aid a cell in returning to homeostasis, it can lead to detrimental cellular effects 
when overstimulated, and even when understimulated. One such example of this is XBP-1
s
. In 
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the adipocytes, the close interplay of ER biogenesis and LD formation relies on tight control of 
XBP-1
s
. As previously discussed, overexpression of XBP-1
s
 can lead to upregulation of CTT 
(66, 69), and knockout inhibits pre-adipocyte differentiation with only XBP-1
s
 (not unspliced) 
able to rescue this phenotype (183).  
In vivo, XBP-1 knockout mice die in utero (67). Therefore, to study the importance of 
XBP-1 in AT, we must turn to a model that expresses XBP-1 only in the liver. These mice also 
prematurely die. In fact, death occurs during the neonatal starvation period, partially due to 
negligible white adipose mass (69).  
 In addition to the role XBP-1 may play in CCT and LD biogenesis, XBP-1
s
 has been 
shown by Sha et. al to upregulate C/EBPα (183). Conversely, C/EBPβ increases transcription of 
XBP-1. Therefore, XBP-1 is integral in the differentiation process, playing roles in both 
maturation of the cell and transcriptional activities. 
 Beyond the IRE1-XBP1 pathway, other components of the UPR may be involved in 
adipogenesis, although more investigations need to be completed to clarify these mechanisms. 
For the ATF6 pathway, knockout mice of either ATF6α or β do not show any striking 
physiological changes as there is redundancy between the two isoforms. However, it is proposed 
ATF6α is the more essential isoform for the ER stress pathway as ATF6α and not β induces 
genes with the ER stress-response element in their promoters (184). More important in this 
section, ATF6α can upregulate XBP-1. As ATF6α and XBP-1s can heterodimerize, it should be 
determined if this formation is important in XBP-1 upregulation of C/EBPα or CCT. 
 SREBP-1c is another transcription factor heavily involved in adipogenesis. Although not 
deemed a UPR component, SREBPs can be activated during ER stress. SREBP-1c has a dual 
name of adipocyte determination and differentiation 1 (ADD1). Overexpression of 
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ADD1/SREBP1c leads to an increase of LD formation in pre-adipocytes (185), and this may be 
due to activation of a lipid activating PPARγ (186). However, conditional overexpression in 
mice inhibits normal white adipose tissue growth (185). In vivo, PPARγ levels were lowered 
compared to wild-type mice. The paradoxical differences of in vivo and in vitro models may be 
due to timing of knockdown of SREBP1c, but this needs to be further investigated, especially as 
SREBP1c has more recently been shown to directly activate C/EBPβ (187).  
Lastly, the PERK pathway has also been found to be important during differentiation of 
adipocytes in vitro. PERK to ATF-4 activation has been shown to be important in activation of 
genes involved in lipogenesis (80). Knockdown of this pathway does not inhibit adipogenesis, 
but reduces the accumulation of lipids involved in this process. More significantly, ATF-4 
activates CHOP, a known inhibitor of adipogenesis. CHOP can heterodimerize with C/EBP 
transcription factors (hence it‟s name). When in this conformation, the C/EBPs can not bind to 
their normal DNA targets, ultimately leading to inhibition of their actions, including activation of 
adipogenesis (76, 78).  
2.   UPR Activation in AT and Disease 
 Activation of the UPR has the potential of inducing deleterious cellular effects. In AT, 
the majority of this is manifested as inhibition of pre-adipocyte differentiation and induction of 
the inflammatory cascade, of which both are induced by HIV PIs. 
 The description of the intrinsic involvement of the UPR in adipogenesis above 
demonstrates how alteration of the UPR can influence differentiation. Direct examples of this 
have been shown in previous studies. For example, Basseri et. al treated murine 3T3-L1 cells 
with the chemical chaperone 4-phenylbutyrate, a repressor of the UPR, which attenuated 
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differentiation in this cellular model (188). At the same time, Shimada et. al demonstrated that 
the compound K-7174 could inhibit differentiation through overactivation of ER stress (189).  
HIV PIs have been shown to differentially affect adipogenesis (28-36). However, results 
in the literature are contradictory and lack mechanistic explanations. For example, a few results 
state RITV does not inhibit differentiation of adipogenesis, and others state it significantly 
inhibits this pathway. Reasons for such contradiction derive from differences in differentiation 
techniques and subjectivity of certain assays. In addition, most studies focused on the possibility 
of inhibition of differentiation, and not the mechanism of this phenomenon. From the above 
information give, it could follow the mechanism underlying HIV PI-induced alteration in 
adipogenesis is induction of ER stress. 
Many metabolic diseases have been shown to have underlying pathology in AT. In 
addition to altering capacity of lipid storage, these diseases also have underlying inflammation. 
As previously noted, there is now known to be a direct link between the UPR and inflammation. 
One of the first cell-types demonstrated to have this link was macrophages. Here, it has been 
repeatedly demonstrated that lipid-laden macrophages (the core of an atherosclerotic plaque) 
secrete multiple pro-inflammatory cytokines such as TNF-α and IL-6. In addition, HIV PIs can 
induce this pro-inflammatory state directly in this cell type through the activation of the UPR and 
upregulation of the mRNA binding protein HuR (51, 52, 190, 191).  
 Investigations into mechanisms underlying obesity and diabetes has demonstrated how 
inflammation in AT can detrimentally alter human physiology. With increasing overload, 
adipocytes begin to hypertrophy, becoming stressed and signaling this with a release of 
proinflammatory cytokines. These cytokines cause an infiltration of circulating macrophages, 
which engulf over-stressed or dying cells, forming characteristic crown-like structures. 
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Interestingly, HIV patients on HAART therapy appear to be in the same state as an obese 
individual in terms of inflammation and dysfunction in AT. Patients often have a decrease in 
insulin sensitivity, as well as having dyslipidemia and liver disease as previously discussed.  
 The inflammatory cascade has been shown to be induced by HIV PIs in adipocytes (192-
194). In addition, this activation may be an underlying factor of inhibition of differentiation. In 
fact, exposure of pre-adipocytes to TNF-α alone is enough to inhibit induction of PPARγ and 
C/EBPα (195). However, the mechanistic induction of the inflammatory cascade in adipocytes is 
the key to determine how HIV PIs have these detrimental affects.  
 Even beyond the potential of inhibiting differentiation, induction of inflammation can 
lead to insulin resistance in AT (196, 197). This connection is already widely known, and will 
not be discussed in further detail here. For an in-depth discussion of the connection between 
inflammation and insulin resistance, please see reviews [(198, 199)]. Instead, our focus now 
turns to ER stress link with insulin resistance. 
 A key study in this field was done by Djedaini and colleagues. When a human adipocyte 
cell line was treated with LOPV, there was an increase of ER stress activation as well as a 
decrease of IRS1 phosphorylation (54). What linked these two phenomena was eIF2-α 
phosphorylation. When cells were treated with salubrinal, a small molecule that specifically 
inhibits eIF2-α phosphorylation, there was a slight decrease in IRS1 phosphorylation. However, 
when they added minimal concentrations of LOPV with salubrinal, there was a significant 
decrease of IRS1 phosphorylation, suggesting a synergistic effect of the two drugs and the role 
eIF2α plays in LOPV-induced adipocyte insulin resistance.  
 Activation of the UPR leading to a decrease in insulin signaling may only be part of the 
story. Others have shown that HIV PIs can actually directly inhibit the glucose transporter (200). 
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It has been proposed that this inhibition induces a starvation-like state in the cell with the 
decrease of intracellular glucose, causing activation of ER stress. This would lead to a decrease 
in insulin signaling, propagating insulin resistance further. At this point, adipocytes would rely 
heavily on lipids, hydrolyzing triglyceride stores and thus increasing NEFA release, causing 
lipotoxicity and insulin resistance at the physiological level. More research is clearly needed to 
determine which pathway or proteins HIV PIs induce/inhibit when they first come into contact 
with an adipocyte. Only then can we be certain of the consequences of a given structure on the 
drugs currently on the market. 
      D. Autophagy and Lipid Metabolism in the Adipocyte  
 In adipocytes, the importance of autophagy and cellular lipid metabolism goes beyond 
what was previously discussed. Of one particular note is that components of the autophagosome 
may be necessary for lipid droplet formations (201). Shibata et. al have demonstrated that LC3-II 
does not only colocalize to autophagasomes, but also LDs in hepatocytes and cardiac myocytes, 
suggesting a flux of lipid metabolism in the cell dependent on this pathway (201). These findings 
were followed with an investigation in murine adipocytes, demonstrating that LC3 colocalizes to 
LDs in differentiating cells (202). In addition, siRNA of LC3 drastically decreased the ability of 
adipogenesis (202).  
Beyond Shibata et. al‟s study, knockout models have demonstrated how essential 
autophagy is in adipogenesis. Baerga et. al were able to establish this by first showing the 
significant increase of autophagosome formations during induction of adipogenesis, followed by 
the inhibition of differentiation in a knockout atg5 mouse model (203). Using this model, Baerga 
et. al saw both in vitro and in vivo that inhibition of autophagy restrained maturation of pre-
adipocytes, resulting in a marked reduction of WAT in neonatal mice. Interestingly, when 
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knockout murine embryonic fibroblasts were induced to differentiate, cells that began to mature 
died through apoptosis, while those in the same culture that did not begin to differentiate 
remained alive. This study was followed by another with an adipose-specific deletion of atg7 
(204), a gene encoding an essential protein upstream of Atg5. Interestingly, WAT tissue of this 
knockout model was more characteristic of BAT in both morphology (smaller cells and LDs) and 
enzyme levels. The importance of Atg7 in adipogenesis was confirmed by Sing et. al who 
knockdown the same gene but used slightly different cell lines and mouse model (205). 
However, both groups came upon the same finding that the autophagic pathway is essential in 
adipogenesis.  
The trigger of autophagy activation during adipogenesis is not currently known. PPARγ 
may be involved. In one cancer cell line, it was found that PPARγ targets can then activate the 
autophagy pathway (206). However, there is another study that contradicts these findings (207), 
and such investigations have not yet been repeated in an adipocyte model. Nonetheless, the 
summation of above experiments does demonstrate that autophagy is essential in adipogenesis 
and LD formation. Differing, a decrease of autophagy in the liver leads to lipid overload in 
hepatocytes. Intuitively, the difference lies in the biology of the two cell types, where adipocytes 
are normally storing lipids and hepatocytes are not. In metabolic disease states, it is easy to 
conceive how dysregulation of autophagy could ultimately lead to fatty liver with increased TG 
storage in the liver and decreased storage in AT. 
In addition to its role in adipogenesis, autophagy may help control the inflammatory 
cascade in adipocytes. Adiponectin, the adipocyte-specific anti-inflammatory cytokine, is 
negatively correlated with diseases such as atherosclerosis and insulin resistance. In 
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overexpanded or stressed tissue, there is a decrease of adiponectin secretion (208), and an 
increase of macrophage-inducing TNF-α, IL-6, and MCP-1 as discussed previously. 
HIV PIs have been repeatedly reported to decrease adiponectin, from the RNA level to 
secretion. Interestingly, adiponectin can alleviate ER stress (209). Zhou and colleagues have 
shown that ER stress initiation is sufficient to decrease adiponectin release. In animal models, 
they reported stabilization of adiponectin decreased obesity-induced ER stress in AT. Moreover, 
induction of autophagy could alleviate ER stress responses in the cell, stabilizing adiponectin 
secretions. More investigations are neded to determine if upregulation of autophagy could 
ultimately lead to therapeutic options for metabolic diseases. 
However, the understanding of HIV PI-induced metabolic disease does not just center at 
AT lipid metabolism and inflammation, but also other key organ systems including the liver. 
Interplay between the liver and AT is central in lipidemia, serum glucose levels, and potential of 
fatty deposits in the liver. Therefore, the next section will focus on how HIV PIs disrupt normal 
liver metabolism. 
VII.     Liver 
The liver is centrally involved in many metabolic diseases due to its role in lipid 
homeostasis, bile acid synthesis, and gluconeogenesis. In HIV PI-induced metabolic alterations, 
the liver plays a substantial role since it is the first organ to come in contact with this drug class, 
and responsible for their metabolism. Therefore, a majority of investigations focusing on HIV PI 
side effects have focused at the liver and hepatocytes for underlying mechanisms to explain 
disease.  
 Interestingly, some of this work has found that HIV PIs have a similar affect in the liver 
as a Western diet, inducing components of NASH. As discussed in Section IV A, a central factor 
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of NASH is accumulation of hepatic lipids from NEFA and DNL, not the diet as intuitively 
thought. In HIV PI treatment, alteration of AT lipid metabolism can lead to an overload of lipid 
dumping at the liver, which may be the mechanism underlying HIV PI-induced NASH. 
 In addition, insulin resistance is another central manifestation of NASH. In respect to 
HIV PI-induced NASH, it has been hypothesized that although HIV PIs can induce insulin 
resistance in both adipocytes and hepatocytes, HIV PIs first target a decrease in peripheral 
glucose uptake, and chronic treatment alters hepatic glucose production (210, 211). In fact, 
chronic inflammation may be the underlying instigator of insulin insensitivity, especially at 
induction of macrophage infiltration in AT (212). The resulting alterations of lipid metabolism in 
AT, with continuous pathophysiology in the liver, ultimately leads to insulin resistance and liver 
steatosis. 
 While pathology is occurring in AT as discussed previously, HIV PIs also induce insulin 
insensitivity in hepatocytes. Interestingly, the ability of HIV PIs to induce the UPR may be the 
mechanism underlying the hepatic insulin insensitivity (44). In NASH mouse models, as well as 
human liver biopsies of NAFLD patients, a link between increased IRE1α and JNK has been 
found (213, 214). It is hypothesized that the instigator of ER stress (whether it be increased need 
of protein folding or TG synthesis, or drugs such as HIV PIs) increases IRE1α. IRE1α then 
activates JNK, inducing the inflammatory cascade. In addition, JNK inhibits insulin receptor 
action by phosphorylating insulin receptor substrate (IRS)-1.  
 Insulin also inhibits VLDL secretion through suppression of ApoB100 packaging of TGs 
(215-217). Loss of insulin sensitivity would potentially lead to increased VLDL secretion. 
However, during HIV PI pathology, this may not simply be the case. Instead, activation of ER 
stress itself can lead to degradation of ApoB100 (218), which may occur through the autophagy 
46 
 
pathway (219). In addition, HIV PIs stimulate active SREBP-1 (49, 220, 221), the transcription 
factor important in de novo lipogenesis. Therefore, increased stimulation to release VLDLs due 
to loss of insulin sensitivity may not be able to compensate for the increased buildup of TGs in 
hepatocytes. 
 Many investigators in this field have proposed that much of HIV PI-induced hepatocyte 
pathology is through ER stress and the UPR (49, 222-224). However, autophagy may also be an 
important player as it now understood to be centrally involved in lipid metabolism. When 
autophagy is directly inhibited in hepatocytes, lipids accumulate in droplets (205), and this is not 
due to increased triglyceride synthesis nor decreased VLDL secretions (225). Mice lacking 
autophagy in the liver have enlarged lipid laden livers with increased triglyceride and cholesterol 
levels (205).  
 At this time, the connection of UPR, autophagy, and hepatic lipid metabolism is not well 
elucidated. Rather, only speculative links of the three have been made. What is clear by the 
information reviewed here is that both the UPR and autophagy are central in cellular homeostasis 
and lipid regulation. Therefore, disruption of one, or both, can have detrimental effects in both 
the AT and liver.  
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CHAPTER II: Materials and Methods 
Materials 
Antibodies: Antibodies against C/EBP homologous protein (CHOP), activating 
transcription factor-4 (ATF-4), X-box-binding protein-1 (XBP-1), Lamin B, phosphorylated and 
total AKT, HuR, CUGBP-1, and horseradish peroxidase (HRP)-conjugated donkey anti-goat IgG 
were bought from Santa Cruz Biotechnology (Santa Cruz, CA). LC3B antibody was obtained 
from Cell Signaling (Danvers, MA). p62, as well as HRP-conjugate goat anti-rabbit and anti-
mouse IgG, were purchased from Bio-Rad (Hercules, CA). 
Protein Assay and Western Blot Analysis: Bio-Rad protein assay reagent, Criterion XT 
Precast Gel, and Precision Plus Protein Kaleidoscope Standards were obtained from Bio-Rad 
(Hercules, CA). Chemiluminescence Reagent was purchased from PerkinElmer Life Sciences. 
For ELISA, all antibodies and avidin-HRP were purchased through eBioscience (San Diego, 
CA), while the standard recombinant mouse TNF-α and IL-6 were obtained from BioLegend 
(San Diego, CA). 
RNA Analysis: RNeasy MinElute Cleanup Kit was purchased from Qiagen. High-
Capacity cDNA Reverse Transcription Kit came from Applied Biosytems. 
Chemicals and Drugs: Ritonavir, lopinavir, and darunavir were obtained from the 
National Institutes of Health (NIH). MK-0518 (Raltegravir) was obtained from Merck. 
Thapsigargin (TG), Dimethyl Sulfoxide molecular biology grade (DMSO), 3-Isobutyl-1-
methylxanthine (IBMX), rosiglatizone, phosphatase inhibitor mix, dexamethasone, and 
hydrocortisone were obtained from Sigma Aldrich (St. Louis, MO).  
Stains: Oil Red O and Nile Red powder were obtained from Sigma Aldrich.  
 
48 
 
Cell Culture Techniques  
Maintenance and Products: All cell lines and primary cells were maintained in 5% CO2 
at 37ºC. Dulbecco‟s Modified Eagle Medium (DMEM) and tryspin with 0.25% EDTA was 
purchased from Gibco (Invitrogen). Newborn Calf and Fetal Bovine Serum were from Atlanta 
Biologicals (Lawrenceville, GA). Penicillin-Streptomycin was bought through CellGro 
(Manassas, VA).  
Murine NIH 3T3-L1: Cells were obtained from ATCC (Manassas, VA), and maintained 
in DMEM containing 10% Newborn Calf Serum (NCS) and 1% Penicillin-Streptomycin (P-S). 
When cells reached 80% confluency, they were subcultured by removing media, washed with 
Phosphate Buffer Saline (PBS), and trypsinized with 0.25% Trypsin-EDTA. To induce 
differentiation, cells were grown to confluency, at which time media was changed to DMEM 
containing 10% Fetal Calf Serum (FCS), 1% P-S, plus 0.5 µM IBMX, 0.8 μM insulin, and 1 µM 
dexamethasone. Cells were cultured for three days and media then changed to DMEM with 10% 
FCS/1% P-S, and 0.8 μM Insulin. After two days, media was subsequently changed to DMEM 
with 10% FCS/1% P-S and cultured until 80% of cells visually appeared differentiated (at least 8 
total days) (226). 
Human Simpson-Golbai-Behmel Syndrome (SGBS) pre-adipocytes were a kind gift from 
Dr. Martin Wabitsch, University of Ulm, Germany (227). SGBS cells were maintained in 
DMEM/F12 with 10% FCS/1% P-S, Biotin, and Pentothenate. Cells were induced to 
differentiate at confluency in serum free DMEM/F12 with 0.01 mg/mL Transferrin, 2x10
-8
 M 
insulin, 1x10
-7
 M cortisol, and 0.2 nM T3. For the first 3 days, this media was also supplemented 
with 25 nM dexamethasone, 500 µM IBMX, and 2 µM rosiglitazone, then these three 
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components were not used for the rest of differentiation. Cells were used in experiments after 
80% of cells visually appeared differentiated (average 2 weeks). 
Adipocyte stem cells (ASC) were a kind gift from Dr. Shawn E. Holt, Virginia 
Commonwealth University. ASC cells were maintained and induced to differentiate in the same 
manner as 3T3 cells, except the DMEM used was low glucose instead of normal high glucose. 
293-FT cells were obtained from ATCC (Manassas, VA). Cells were maintained in 
DMEM containing 10% FCS, 1% P-S, and 1% Non-Essential Amino Acids (NEAA), and kept 
under selection with G418 Neomycin.  
Human HepG2 cells were obtained from ATCC (Manassas, VA). Cells were maintained 
in 10% FBS/1% P-S with 1% NEAA. Cells were subcultured at 90% confluency using 0.25% 
trypsin-EDTA. Cells were treated at 70% density. 
Isolation of Primary Adipocytes: After mice were euthanized, the gonadal fat pad was 
excised from mice and placed in 37°C KRH buffer (1 mM CaCl2, 1.2 mM MgS04, 1.2 mM 
KH2PO4, 1.4 mM KCl, 2 mM Pyruvic Acid, 10 mM HEPES with 4 mM NaHCO3, 130 mM 
NaCl and 0.8333% BSA in water) (228). Tissue was minced until all fragments were no bigger 
than 1 mm and placed in 1 mg/mL Type 1 collagenase (Worthington Biochemical) in KRH, and 
digested for 30 min in a rotating water incubator at 37°C. Suspension was filtered through a 20 
µM flat filter, washed two times in fresh KRH to remove bound collagenase, and full adipocytes 
removed from the top layer with a Pasteur pipette. The remaining solution was centrifuged at 300 
g for 5 min, supernatant removed, and pellet resuspended in Primary Medium (DMEM 
containing 10% FBS, 1% P-S, 3 µM Biotin, 100 µM ascorbic acid, 4 nM insulin and 8.3 mM L-
glutamine). Full adipocytes were also plated in Primary Medium, as well. 
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After confluency of pre-adipocytes, cells were induced to differentiate by adding 1 
µg/mL insulin, 1 μM dexamethasone, 0.5 mM IBMX, and 1 µM rosiglitazone to Primary Media 
for 3 days, then media was supplemented with insulin and rosiglitazone for 3 days. Cells were 
thereafter cultured with Primary Media for 6 more days for full differentiation to occur. 
Isolation of Primary Hepatocytes: Primary hepatocytes were isolated from male Sprague-
Dawley rats (250-300 g), as well as C57BL/6 WT and CHOP-/- mice using the collagenase-
perfusion technique of Bissell and Guzelian (229). Trypan blue exclusion was used to determine 
cell viability (>90%) before plating monolayers on collagen-coated plates (60-mm or 6-wells). 
Cells were cultured in serum-free Williams‟ E medium containing dexamethasone (0.1 µM), 
penicillin (100 units/mL), and thyroxine (1 µM). Media was changed and cells treated 6 hours 
(for rat) and 4 hours (for mouse) after plating. 
In Vitro Studies 
 Nuclear Protein Extraction: For UPR activation analysis in adipocytes, nuclear extract 
was isolated from cells (230). Cells were rinsed with PBS and scraped with 1mL cold PBS, 
pelleted at 100 g x 10 min, and resuspended in Buffer A (10 mM HEPES, 1 mM EDTA), 0.5 
mM DTT, 0.25 mM PMSF, 50 mM NaF, 2 mM NA metavanadate, and 5 mg/mL leupeptin and 
pepstatin). Suspension was homogenized through a needle/syringe then centrifuged at 1000 g for 
10 min and supernatant placed in a separate tube with 0.5 M NaCl and left on ice for 1 h before 
flash frozen. Pellet was washed in 250 mL Buffer A with 250 mM  sucrose and pelleted at 1000g 
for 10 min, resuspended in 100 mL Buffer A with 0.5 M NaCl, and 10 µL of 10% NP-40, left on 
ice for 1 h and centrifuged at 5000 g for 5 min. The nuclear extract was flash frozen. Proteins 
were later resolved on a 10% Bis-Tris gel at 100 V, and transferred at 360 mA.  
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 Western Blot Analysis - Autophagy: For LC3 and p62 analysis, total cell extract was 
obtained by washing cells with cold PBS followed by scraping with RIPA buffer (1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 0.25 mM PMSF, 5 mg/mL Aprotinin, and 1 mM sodium 
orthovanadate). Cells were lysed using an automatic homogenizer at 4ºC for 1 min, and samples 
were left at 4°C for 30 min before spun at 8,000 g for 8 min. Supernatants were stored at -80°C. 
Proteins were later resolved on a 12-15% Bis-Tris gel at 100 V and transferred at 90 mA 
overnight at 4ºC.  
 For both ER stress and autophagy analysis, immunoblots were blocked for one hour at 
room temperature with 5% nonfat milk in Tris-buffered saline (TBS). Membranes were 
incubated with primary antibodies in 2.5% milk-TBS, (5% BSA-TBS with 0.5% Tween-20 for 
LC3B). Secondary antibodies were incubated in 2.5% milk-TBST. Immunoreactive bands were 
detected using horseradish peroxidase-conjugated secondary antibody and chemiluminescence. 
The density of immunoblot was analyzed using Image J or Quantity One (Biorad) computer 
software. 
 RNA Isolation and Real-Time Quantitative RT-PCR: Total cellular RNA was isolated 
from adipocytes after treatment using Qiagen RNeasy MinElute Kit, or hepatocytes using 
Promega RNA Elute Kit. Total RNA (2 μg) was used for first-strand cDNA synthesis using 
High-Capacity cDNA Reverse Transcription Kit. The primers for mRNA levels analyzed are 
shown in Tables 1 and 2. iQ SYBER Green Supermix (Bio-Rad) was used as a fluorescent dye to 
detect the presence of double-stranded DNA. The mRNA values for each gene were normalized 
to internal control β-actin mRNA. The ratio of normalized mean value for each treatment group 
to vehicle control group was calculated.  
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Target mRNA Forward Primer Reverse Primer 
Actin ACCACACCTTCTACAATCAG ACGACCAGAGGCATACAG 
Adiponectin GATGCAGGTCTTCTTGGTC CCCACACTGAACGCTGAG 
ATF-4 CCTAGGTCTCTTAGATGACTATCTGGA
GG 
CCAGGTCATCCATTCGAAACAGAGCA
TCG 
ATG12 AAGATGTCGGAAGATTCAGAG TCCTACAGCCTTCAGCAG 
BECN1 TCTAAGGAGTTGCCGTTATAC CCAGTGTCTTCAATCTTGCC 
C/EBPα GACAAGAACAGCAACGAG GTCAACTCCAGCACCTTC 
C/EBPβ CGACGAGTACAAGATGCG CTGCTCCACCTTCTTCTG 
CHOP GTCCCTGCCTTTCACCTTGG GGTTTTTGATTCTTCCTCTTCG 
CUGBP1 CCTGGCTGGTCTGAACAC CCCTGCTGAACTGGTGAG 
CYP27A1 GACACTGCCGCCTTCATC GCCATTCAGGTATCGCTTCC 
CYP7A1 CAGAAGCATAGACCCAAGTG GTAGCAGAAGGCATACATCC 
FXRα GGACGGGATGAGTGTGAAG ATCTGTGGCTGAACTTGAGG 
HMGCOAR GCCGTCATTCCAGCCAAG CGTTGTAGCCGCCTATGC 
HuR ACACTGAACGGCTTGAGAC ACCCTGGAGTTGATGATTCG 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
LPL GTCTAACTGCCACTTCAACC CACCCAACTCTCATACATTCC 
LXRα GCTCTGCTCATTGCCATCAG TGTTGCAGCCTCTCTACTTGGA 
Perilipin ACGAGGAGGAGGAAGAAGAG AGGTCACTGCGGAGATGG 
PPARα ATGGAGACCTTGTGTATGGC GGCAGCAGTGGAAGAATCG 
PPARγ ACTCGCATTCCTTTGACATC TCGCACTTTGGTATTCTTGG 
SREBP-1c CCACTAGAGGTCGGCATGGT TCCCTTGAGGACCTTTGTCATT 
TNF-α GCCTCCCTCTCATCAGTTC ACTTGGTGGTTTGCTACG 
VSP34 CTCTCCTCTCATTACACCAACC CATCAGCAAATCCTCATCATCG 
ULK2 GAGCAGCAGCAGAGCAAG GCCAGCATAACACCACAGG 
XBP-1sp TGAGTCCGCAGCAGGTG GACAGGGTCCAACTTGT 
XBP-1usp CGCAGCACTCAGACTATG TTCCTCCAGACTAGCAGAC 
Table 1. Real-time RT-PCR primers specific for mouse mRNA. Real-time RT-PCR primer 
sequences used for mouse-specific mRNA analysis in this dissertation. Sequences are written 5‟ 
to 3‟. 
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RAT 
Target mRNA Forward Primer Reverse Primer 
Actin TATCGGCAATGAGCGGTTCC AGCACTGTGTTGGCATAGAGG 
ATF-4 GGTTCTCCAGCGACAAGG GGTTTCCAGGTCATCCATTC 
ATG12 CCCAGAAACAGCCATCCC GTCTCCTACAGCCTTCAGC 
BECN1 ACGCTGTTTGGAGATGTTG TTCTGCCACCACCTTTCG 
CHOP GGAGCAGGAGAATGAGAG GACAGACAGGAGGTGATG 
CYP27A1 TGGAGCAAGTGATGAGAC CAAACTATGACGCAGATGG 
CYP7A1 GACACAGAAGCATTGACC GTAACAGAAGGCATACATCC 
HMGCOAR GGACCAACCTTCTACCTCAG ACAACTCACCAGCCATCAC 
SREBP-1 CATCAACAACCAAGACAGTG GAAGCAGGAGAAGAGAAGC 
ULK1 CCAGCAACATCCGAGTCAAG ACATAGGAGAGCCACAGAGC 
VPS34 AACAAGCAGCACACTCTCAG CCAACCAATCCACCTTCACC 
 
HUMAN 
Target mRNA Forward Primer Reverse Primer 
Actin GCGTGACATTAAGGAGAAG GAAGGAAGGCTGGAAGAG 
ATF-4 CAACAACAGCAAGGAGGATG AATTGGGTTCACCGTCTGG 
CHOP CTGAATCTGCACCAAGCATGA AAGGTGGGTAGTGTGGCCC 
SREBP-1 GGTCGTAGATGCGGAGAAG TGATGGAGGAGCGGTAGC 
XBP-1sp GCTGAAGAGGAGGCGGAAG GAAAGGGAGGCTGGTAAGG 
XBP-1usp TCCGCAGCACTCAGACTAC TCCAAGTTGTCCAGAATGCC 
 
 
Table 2. Real-time PCR primers specific to Rat and Human mRNA, respectively. Real-time 
RT-PCR primer sequences used for rat and human-specific mRNA analysis in this dissertation. 
Sequences are written 5‟ to 3‟. 
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 Enzyme-Linked Immunosorbent Assay (ELISA): For analysis of cytokine secretions, 
ELISA method was utilized. Cells were treated with HIV PIs for the noted times, and culture 
media collected. Cells were lysed with total lysis buffer and total protein concentrations of viable 
cells determined using Bio-Rad Protein Assay. 96-well plates were coated with antibody against  
IL-6 or TNF-α for 2-3 h at 37ºC, and then blocked overnight. 100 µL of diluted samples were 
added the next day, followed by addition of Biotin-conjugated anti-antibody. After washing, 
Avidin-HRP was added prior to the substrate. Plates were read at 450 nM after termination of 
enzyme reaction by adding 100 µL 2 N H2SO4. Total amounts of cytokine were normalized to 
total protein of cells and expressed as ng/mg proteins. 
 Analysis of Apoptosis by Annexin V and Propidium Iodine Staining: 3T3-L1s were 
treated with HIV PIs for 24 h, and culture media and trypsinized cells were collected and spun at 
2,000 rpm for 5 min. Cells were stained with Annexin V-FITC and propidium iodine using BD 
ApoAlert Annexin V kit, according to the protocol recommended by the manufacturer. Stained 
cells were analyzed by two-color flow cytometry. Annexin V-FITC and propidium iodide 
emissions were detected in the FL1 and FL3 channels respectively of a Cytomics FC 500 flow 
cytometer (Beckman Coulter, Fullerton, CA). Analysis was stopped at a 20,000 cell count. 
 SGBS cells were plated in 6-well dishes, and treated with HIV PIs for 24 h. Cells were 
stained with Annexin V-FITC and propidium iodine using the same kit and protocol as above. 
Images were immediately acquired using a FITC filter, followed by a TRITC filter on 
fluorescent miscroscope (Olympus, Center Valley, PA) using a 40 × objective lens.  
 Assay of Endoplasmic Reticulum Calcium Pools: Non-differentiated 3T3-L1 cells were 
grown on 22 x 40-mm coverslips and treated for 24 h. Cells were loaded with 4 µM Fura-2 AM 
and ER calcium stores were analyzed by stimulation with 1 μM thapsigargin (TG). Fluorescent 
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images (510-nm emission after alternate 340- and 380-nm excitation) before and after addition of 
TG were collected at 15-ms intervals through a cooled CCD camera. The 340:380 ratios of 20 
individual cells in these images were analyzed using TILLvisION v3.1 imaging software. The 
standard curve generated using a Fura-2 calcium imaging calibration kit to convert Fura-2 
fluorescence measurements into estimates of free Ca
2+ 
concentration (51). 
 Nile Red staining: Cells were plated on 60-mm glass coverslips in 6-well dishes, and at 
confluency, were treated with relevant HIV PIs while concurrently being induced to differentiate. 
After the noted times, cells were fixed in 3.7% paraformaldehyde-PBS for thirty min, rinsed with 
PBS, and stained with working solution of Nile Red (100 ng/mL) for 10 min. Samples were 
washed three times with PBS, 15 min each, and coverslips mounted. Images were obtained with 
a 40× objective using a FITC filter on a fluorescent microscope (Olympus, Center Valley, PA). 
 Oil Red O staining (ORO): Cells were plated on 60-mm glass coverslips in 6-well dishes, 
and at confluency, were treated with relevant HIV PIs while concurrently being induced to 
differentiate. After the noted times, cells were fixed in 3.7% paraformaldehyde-PBS for 30 min, 
rinsed with PBS, and stained with working solution of Oil Red O (5 mM) for 2 h followed by 
three washes of PBS 15 min each. Coverslips were mounted and images obtained using a 40 × 
lens objective of a light microscope (Motic BA200).  
 MATLAB Assessment of lipid droplet: 3T3-L1 cells were plated on 60-mm glass 
coverslips in 6-well dishes, and at confluency, were treated with HIV PIs while concurrently 
being induced to differentiate. After 14 days, cells were fixed in 3.7% paraformaldehyde-PBS for 
30 min, and rinsed in PBS. Cells were mounted and images obtained using a 40 × objective of an 
upright light microscope (Motic BA200). Images were processed using a previously published 
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custom-made MATLAB (MathWorks) code (231), and the lipid droplet number, areas, and %-
area occupied were then determined. 
 PPARγ Promoter Activity: A PPARγ luciferase reporter and firefly luciferase assay 
system (Promega) were used in this experiment. 293 cells were transfected with either pGL3-Luc 
control vector or pGL3 containing a PPARγ responsive element (PPRE) tagged to luciferase 
using Fugene transfection reagent (Roche). Luciferase catalyzes coelenterazine to 
coelenteramide, releasing light, immediately after transcription. Therefore, after treatment with 
HIV PIs for 24 h, cells were lysed in luciferase lysis buffer (containing DTT) obtained from the 
manufacturer. 40 µg of protein was used to measure with 80 µL luciferase assay by a 
luminometer. The GFP fluorescence was detected first, followed by injection of substrate to 
detect luciferase activity. Activity was normalized to GFP from viable cells.  
mRNA Stability: 3T3-L1 cells were treated with vehicle control (DMSO) or HIV PIs for 2 
h before the addition of actinomycin D (5.0 or 10.0 µg/mL) (time 0). Total cellular RNA was 
extracted at 0.25, 0.5, 1, 2, 4, and 6 h after actinomycin D addition. PPARγ mRNA levels were 
determined by real-time RT-PCR as previously described. Results are expressed as the 
percentage of the mRNA at time 0.  
 In Vitro Pulldown: Biotinylated mRNA construction: Primers for both the PPARγ 3‟UTR 
(1564-1769, 205 bp) and CDS (46-1563, 1517 bp) were designed to include a T7 promoter 
sequence as well as restriction enzyme sites. For 3‟UTR, forward primer: 
5‟CCAAGCTTCTAATACGACTCACTATAGGGCTGGATGGAGGAAAGTCCCACC3‟ and 
reverse primer: 5‟AATGTGGTAATTTTTAATATTA3‟. CDS forward primer: 
5‟CCAAGCTTCTAATACGACTCACTATAGGGCTGGATGGGTGAAAACTCTGGG3‟ and 
reverse primer: 5‟AATACAAGTCCTTGTAGATC3‟. 1 µg template was then added to a PCR 
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mixture containing T7 RNA polymerase and biotin-cytidine 5‟-triphophate (CTP). This product 
was purified with DNase, a G-50 column, and RNA precipitation.  
Analysis of RNA binding proteins bound to biotinylated RNA were done as previously 
described (232). Briefly, 120 µg of total cell lysate protein from 3T3-L1 cells treated for 24 h 
with HIV PIs was added to paramagnetic streptavidin-conjugated Dynabeads M-280 (Dynal, 
Oslo, Norway). 0.6 µg biotinylated PPARγ 3‟UTR or CDS were incubated for 30 min at RT, 
after which beads were washed to remove non-specific binding. The mixture was subsequently 
boiled and protein separated on a 10-12% Tris-HCl SDS PAGE gel. The membranes were 
blotted with antibodies against HuR, CUGBP-1 and Actin for loading control. 
 RNA Immunoprecipitation: To assess the association of endogenous HuR and CUGBP1 
with endogenous PPARγ mRNA, immunopreicipitation (IP) of RNA binding protein complexes 
was performed. 3T3-L1 cells were treated with HIV PIs or DMSO control for 24 h, and then 
harvested in PBS with rubber policemen. Cells were pelleted, and resuspended in approximately 
two cell pellet volumes of polysome lysis buffer (PLB: 100 mM KCl, 5 mM MgCl2, 10 mM 
HEPES, 0.5% Nondiet P-40 with 1 mM DTT, 100 U/ml RNaseOUT, 0.2% 
vanadylribonucleoside complex, 0.2 M PMSF, 1g/ml pepstatin A, 5 g/mL bestatin, and 20 g/mL 
leupeptin). Protein G-Sepharose beads were swollen 1:1 (v/v) in NT2 buffer (see above) 
supplemented with 5% BSA. 5 mg cellular 3T3-L1 proteins were added to 100 µL aliquot of 
preswollen protein A bead slurry and incubated for 4 h at RT in the presence of excess (30 µg) 
antibody (IgG1, anti-HuR, or anti-CUGBP-1).  Proteins were digested via Proteinase K (0.5 
mg/mL) at 55ºC for 20 min, and bead-free supernatants were extracted with 
phenol:chloroform:isoamylalcohol. RNA was precipitated with 1/10
th
 volume 3 M NaAc (pH 
5.2), 150 µg/mL glycogen, and 2.5 volumes of 100% ethanol. The precipitates were dissolved in 
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15 µL nuclease-free water. RNA in IP materials was reverse transcribed and used to detect 
presence of PPARγ mRNA by real-time RT PCR.  
 Effect of CUGBP1 and HuR overexpression on 3’UTR PPARγ: The 3‟UTR of PPARγ 
was cloned into pEGFP-C3 expression vector. 293 cells were stably transfected with pEGFP-C3-
mPPARγ-3‟UTR. CUGBP1 was cloned into pcDNA3.1 vector and HuR into pcDNA3-TAP. 293 
stable cells of GFP-PPARγ-3‟UTR were transfected with either pcDNA3-CUGBP1 or pcDNA3-
HuR-TAP using FuGENE HD (Roche) for 48 h according to the manufacture‟s protocol. GFP 
protein expression was than determined by Western blot analysis. 
 Monodansylcadaverine (MDC) Stain: Cells were plated in 6-well dishes with coverslips, 
and treated with HIV PIs or vehicle control for 24 or 48 h. Cells were then stained with 25 µM 
MDC (Sigma) in PBS for 10 min at 37°C, followed by fixation in 3.7% paraformaldehyde-PBS 
for 15 min. Cells were washed and mounted in the dark with antifade mounting media. Images 
were obtained with both 40 and 60 × objective lenses with a DAPI filter on a fluorescent 
microscope (Olympus, Center Valley, PA). 
 Transmission Electron Microscopy (TEM): 3T3-L1, HepG2, and RPH cells were plated 
on Permanox Quantity dishes (Nalgene Nunc International, Rochester NY), and treated with HIV 
PIs for 24 or 48 h. Cells were rinsed with PBS and fixed with 2% glutaraldehyde for 1 h, rinsed 
in 0.1 M cacodylate buffer, and fixed for another hour with 1% osmium tetroxide in 0.1M 
cacodylate buffer. Samples were further washed, dehydrated with gradient ethanol and infiltrated 
with a 50/50 mixture of 100% ethanol/PolyBed 812 resin for overnight, and further infiltrated 
with pure PolyBed. Samples were embedded using fresh PolyBed 812 and polymerized in a 60ºC 
oven for 2 days. Samples were sectioned with a Leica EM UC6i Ultramicrotome (Leica 
Microsystems) and stained with 5% uranyl acetate and Reynold‟s Lead Citrate, followed by 
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scoping using a JEOL JEM-1230 TEM (JEOL USA) with a Gatan Ultrascan 4000 digital camera 
(Gatan Inc, Pleasanton CA). 
 Construction of GFP-tagged LC3B Stable Cell Line: A pEGFP-C3 vector containing 
LC3B was a kind gift from Dr. Sarah Spiegel (Virginia Commonwealth University). 2 x 10
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Cells were transfected with 2 µg of plasmid with 5 µL FuGENE HD for 24 h according to the 
manufacture‟s protocol. Stable clones were selected with 60 µg of G418. 
 Retroviral – GFP-LC3: GFP-LC3BI under SV promoter in the retroviral vector pBABE 
was purchased from AddGene. Plasmid was replicated in E. coli α-competent cells and purified 
with a ZR plasmid mini prep (Zymo research), and DNA eluted with 0.1 TE (pH 8.0). Retroviral 
particles were constructed in 293-FT cells by cotransfection with 1 µg pBab3-puro-GFP-LC3BI 
(or control vector), 0.1 µg pCMV-VSV-G, and 0.9 µg pMDLg/pREE using CaCl2 and HEPES 
mixture. Infectious particles were harvested from culture supernatants 72 h after transfection and 
media was passaged through a 0.45 µM filter. Particles were purified by adding PEG 6000 
(8.5%) with 0.4 M NaCl O/N at 4ºC, rotating. Samples were centrifuged at 4800 rpm for 30 min, 
and viral particles resuspended in sterile PBS at 1:100 of original volume of media. 
3T3-L1 cells were infected with GFP-LC3 retrovirus at a 1:50 PFU in the presence of 8 
µg/µL of polybrene for 48 h. Stably infected cells were selected with puromycin (5 ng/mL).  
 Lentiviral - ATF-4 shRNA:   Small hairpin RNA (shRNA) specifically targeting mouse 
ATF-4 in a lentiviral vector, TRC1-pLKO.1-puro vector, was purchased from Sigma. Sequence 
of ATF-4 shRNA used was target to the coding region: 
5‟CGGACAAAGATACCTTCGAGTCT3‟. Plasmid was replicated in E. coli α-competent cells 
and purified with a large-scale purification of DNA by cesium chloride gradient. Briefly, 1 liter 
of transformed bacterial cells were pelleted and resuspended inTris-EDTA with 25% (w/v) 
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sucrose. Cells were lysed in the presence of lysozyme, EDTA, and RNase, followed by Triton-X. 
Supernatant was collected after spinning at 25,000 rpm for 2 h, and cesium chloride added. After 
addition of ethidium bromide, samples were spun at 4,000 rpm for 15 min to remove protein, and 
then spun for 18-20 h at 45,000 rpm. The lowest band identified as DNA was collected, and 
ethidium bromide removed with water saturated butanol. Sample was dialysized O/N in 
deionized water containing 0.01 M Tris-HCl, 0.001 M EDTA, and 0.03 M NaAc. Plasmid was 
purified with phenol/chloroform extraction followed by ethanol precipitation. Plasmid was 
resuspended in Tris-Hcl/EDTA (TE pH 8.0).  
 Lentiviral particles were constructed in 293-FT cells. Cells were transfected with 3 µg 
pCMV-VSV-G, 2 µg pCMV-RSV-Rev, 5 µg pMDLg/pREE, and 10 µg pLKO1-ATF4shRNA or 
plasmid or control scramble using CaCl2 and HEPES mixture. Infectious lentivirus was 
harvested from culture supernatants 24, 48, and 72 h after transfection. Particles were purified as 
described above. 3T3-L1 cells were infected with lentivirus in the presence of 8 µg/µL of 
polybrene at a 1:50 PFU for 48 h. Successfully infected cells were selected with puromycin (5 
ng/mL). Silencing was confirmed by Western blot analysis and real-time RT-PCR.  
 Lentiviral - CHOP shRNA: CHOP small hairpin (sh)RNA was designed through siRNA 
Target Finder (Ambion). The sequences of 3 CHOP shRNAs were as follows: shRNA1 is 5‟-
CTGGAAGCCTGGTATGAGGA-3‟, shRNA2 is 5‟-GGAAACGGAAACAGAGTGGTC-3‟, 
and shRNA3 is 5‟-GCAGGAAATCGAGCGCCTGAC-3‟, with shRNA1 used in the majority of 
experiments shown here and elsewhere (53). shRNA was placed in pLentiLox, and plasmids 
purified the same as above. The recombinant lentiviral particles were produced following the 
same protocol as above for ATF-4 shRNA. 3T3-L1 cells were infected in the presence of 8 
µg/µL of polybrene lentivirus at a 1:50 PFU for 48 h. Successfully infected cells were selected 
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with neomycin (30 µg/mL). Silencing was confirmed by Western blot analysis and real-time RT-
PCR.  
 Lentiviral - CHOP overexpression: For overexpression of CHOP, the mouse cDNA of 
CHOP was subcloned into pLVX-AcGFP-N1 (Clonetech) from BamHI and EcoRI sites and N-
terminus of CHOP was fused with GFP. Lentiviral particles were packaged and tittered as 
previously described (232). 3T3-L1 cells were incubated with lentivirus at a multiplicity of 
infection of 50 for 48 hours in the presence of polybrene (8 µg/mL). Cells were selected with 
puromycin (5 ng/mL). Efficiency was confirmed by real-time RT-PCR and Western blot 
analysis. 
In Vivo Studies 
 Mouse Care and Treatments: C57BL/6 male mice were purchased from Jackson 
Laboratories. CHOP knockout mice, with a C57BL/6 background were previously acquired by 
our laboratory. All mice were housed under identical conditions and given free access to water 
and food. The VCU Animal Care Facility complies with all Federal and State laws regarding the 
use and care of experimental animals, and with Public Health Service Policy on Humane Care 
and Use of Laboratory Animals (NIH Guide for Grants and Contracts, Vol. 14, No. 8, June 255, 
1985). The American Association currently accredits the facilities and care program for 
Accreditation of Laboratory Animal Care (AAALAC - #00036). It is also USDA inspected (#52-
R-0007) and Animal Welfare Assurance #A3281-001.  
Animals were kept under full-time veterinary supervision. Mice were weaned at 4 weeks 
of age and fed ad libitum a standard mouse chow diet. At 8 weeks of age, mice were divided into 
control and HIV PI treated groups, and gavaged for 8 weeks. All mice were fed on a high fat diet 
(HFD) during treatments to both mimic a typical patient on HIV PI treatment, and obtain more 
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adipose at time of sacrifice. Mice were observed daily for signs of distress, injury, and illness, 
and if had such signs, were immediately euthanized. At the end of the time point, mice were 
euthanized by anesthesia before harvesting any tissue, which is consistent with the 
recommendations by the Panel on Euthanasia of the American Veterinary Medical Association. 
 Western Blot Analysis: For analysis of protein expression, adipose or liver tissue was 
lysed (100 mg) in total lysis buffer (TLB; 1 mL) (20 mM Tris-HCl, 1% NondietP-40, 150 mM 
NaCl, 2 mM EDTA, 0.10% SDS, 20 mM NaF, 1 mM NaVO4, and 2x protease and phosphatase 
inhibitor (Sigma)) via homogenization immediately after obtaining from -80ºC storage. Samples 
were centrifuged at 6,000 rpm for 6 min and the lipid layer removed. Cells were spun again, and 
supernatants aliquoted in 100 µL in -80ºC. For protein concentration measurement, samples were 
diluted 1:10 in TLB and measured using BioRad Protein Assay. 100 µg of protein was boiled 
and separated on 10% SDS-PAGE gel for UPR activation analysis, or 12% SDS-PAGE gel for 
autophagy activation analysis. Immunoblots were treated the same as for in vitro analysis.  
 RNA Isolation and Real-Time Quantitative PCR: For analysis of mRNA levels, adipose 
or liver tissue was lysed (100 mg) in Qiazol Tryzol Reagent (1 mL) (Qiagen) via homogenization 
immediately after obtaining from -80ºC storage. 200 µL of chloroform was added to each 
sample, vigorously shaken, and centrifuged 15 min at 12,000 rpm. Supernatant was placed in 
new tubes, and 2.5x 100% ethanol, 0.3 M NaAc, and 150 µg/mL glycogen added. Samples were 
placed O/N at -20ºC. The next day, samples were spun for 15 min at 12,000 rpm and pellets 
washed with 70% ethanol. Pellets were dried and resuspended in 15 µL nuclease-free water. 
Samples were reverse transcribed and analyzed by real-time RT-PCR (as in in vitro).   
 Immunohistochemistry of Adipose Tissue: Adipose tissue was fixed in 10% neutral 
buffered formalin immediately after isolation from animals. Samples were washed in PBS and 
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transferred to 70% ethanol. Formalin-fixed tissues were then embedded in paraffin, and 
sectioned at 5 µM. Paraffin on slides was heated in an oven at 45ºC for one h, and deparaffinized 
by running a xylene-drenched q-tip over slices. Slides were immersed in 0.3% v/v 
H2O2/methanol for 10 min and washed in deionized water. Samples were blocked by first 
washing in 50 mM PBS-0.02% Tween 20 and processed with a Vectastain Elite ABC Kit 
(Vector Laboratories). Briefly, tissue was covered in blocking solution (10% serum) for 20 min, 
blotted, and incubated for 1 h with primary antibody (anti Mac-2, Cederlane Laboratories). 
Samples were washed, and then incubated for 30 min with diluted biotinylated secondary 
antibody (anti-Rat). After washing, samples were incubated for 30 min with ABC reagent, 
washed for 5 min, and DAB (3, 3‟-diaminobenzidine) substrate added for 2 min. Samples were 
counterstained in hematoxylin for 20 s, dehydrated through increasing concentrations of ethanol 
to xylene and coversliped with Permount. Images were obtained using a Motic BA200 
microscope (Motic Instruments, Inc, Baltimore, MD). 
Statistical analysis 
Student‟s t test was employed to analyze the differences between sets of data. Statistics were 
performed using Prism 5 (GraphPad, San Diego, CA). All numerical results are represented as 
mean ± standard error (SE) from at least three separate experimental data sets.  
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CHAPTER III:  HIV Protease Inhibitors Dysregulate Adipogenesis through Endoplasmic 
Reticulum Stress Activation and Alteration of PPARγ mRNA Stability 
STUDY RATIONALE 
Our laboratory has a long standing interest in the metabolic side effects of HIV protease 
inhibitors (PIs). Although the inclusion of HIV PIs in patient treatment has had a profund impact 
in the clinical history of HIV, PIs are linked to deleterious effects including early induction of 
insulin resistance, dysregulation of lipid metabolism, and inflammation, all of which are 
cornerstones of cardiovascular disease (15, 22, 31).  
 During the last decade, an extensive effort has been put forth to study the mechanism 
underlying HIV PI-induced side effects. Both in vitro and in vivo animal studies from our 
laboratory and others have linked HIV PIs with the activation of endoplasmic reticulum (ER) 
stress, oxidative stress, induction of apoptosis, and inflammatory cytokine production in several 
metabolically important cell types (51-53, 233-235). One tissue of particular interest is adipose 
tissue (AT) as pathology in AT can be central in the inflammatory state, insulin resistance, 
dyslipidemia and altered body morphology (134, 236-238). However, HIV PI-induced pathology 
in AT is not well understood. Investigators have focused on the ability of HIV PIs to 
differentially alter adipocyte maturation, but results have been contradictory, confusing, and lack 
elucidation of underlying mechanisms (21, 192, 193, 239-245).  
Activation of ER stress induces the unfolded protein response (UPR), extensively shown 
to alter cellular lipid metabolism when upregulated (58, 80, 246-248). ER stress can also lead to 
the cellular inflammatory response (83, 95) and even apoptosis (88, 89). Therefore, strong 
activation of this pathway can result in multiple cellular aberrations, leading to detrimental 
effects in metabolically active tissue such as AT. 
65 
 
In this study, we attempt to elucidate the underlying mechanism of HIV PI-induced lipid 
metabolism dysregulation in adipocytes. Here, we demonstrate multiple deleterious effects of 
HIV PIs in adipocytes such as alteration of differentiation, induction of inflammation, and cell 
death, all of which may be linked to HIV PI-induced ER stress. We also show how HIV PIs alter 
gene regulation during adipogenesis, further explaining the phenomenon of HIV PI-induced 
adipocyte lipid metabolism dysfunction. 
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RESULTS 
HIV PIs activate the UPR in murine and human adipocytes, in a time and dose-dependent 
manner 
 HIV PIs ritonavir (RITV) and lopinavir (LOPV) have been reported in separate studies to 
induce ER stress and to disrupt lipogenesis in adipocytes (54, 241). Our previous studies have 
shown that activation of ER stress plays a critical role in HIV PI-induced dysregulation of lipid 
metabolism in macrophages and hepatocytes (49, 51). In order to determine whether HIV PIs 
have similar effects on the UPR activation in adipocytes as they do in other cell types, mouse 
3T3-L1 pre- and mature adipocytes were treated with seven available HIV PIs for various time 
periods (1-24 h) and the protein levels of the UPR-specific genes, CHOP, ATF-4, and XBP-1, 
were detected by Western blot analysis. We found only some HIV PIs induced UPR activation in 
mature adipocytes, and had less effect on pre-adipocytes. LOPV, RITV, saquinavir (SQV), and 
indinavir (IDV) induced significant activation of the UPR, while amprenavir (AMPV), darunavir 
(DRV) and tipranavir (TPV) only had modest or no activation. We therefore split these HIV PIs 
into two groups: ER stress inducers and non-inducers. Interestingly, those in the non-inducer 
group have much lower incidences of inducing dyslipidemia in patients compared to those in the 
inducer group (249, 250). 
Based on the most updated January 2011 guidelines of US Department of Health and 
Human Services for Use of Antiretrovial Agents in HIV-1-infected Adults and Adolescents, HIV 
PIs are still listed as key components of preferred HAART regimens and will continue to be 
important drugs for the foreseeable future. With the ability to maintain viral load suppression 
superior to some other HIV PIs, LOPV coformulated with RITV (4/1) has remained a frequently 
used treatment in the clinic. As LOPV/RITV is also in the ER stress inducer group and is known 
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to induce metabolic side effects in the clinic, we focused on this combination during the 
subsequent studies. 
Shown in Figure 8, we found UPR activation by these HIV PIs peak between 4 and 7 h. 
To determine if this activation was specific (i.e. dose-dependent), we treated 3T3-L1s with 
increasing doses of HIV PIs at 6 h, and found LOPV and LOPV/RITV dose-dependently 
increased CHOP and ATF-4 expression in differentiated adipocytes (Figure 10A,B), but had no 
significant effect on XBP-1 protein expression (data not shown). In human SGBS adipocytes, 
both RITV and LOPV increased CHOP and ATF-4 expression in a similar manner (Figure 10C). 
3T3-L1 pre-adipocytes had comparatively less activation of the UPR than mature adipocytes 
(Figure 9). In addition, RITV was the more significant activator of the UPR in pre-adipocytes, 
compared to LOPV‟s higher activity in mature adipocytes. These differences may be attributable 
to the variation of cell type physiology.  
To ascertain if HIV PI-induced increase of UPR transcriptional factors also occurs at the 
transcriptional level, we treated both pre- and differentiated 3T3-L1s 1-24 h and obtained total 
RNA. mRNA levels of UPR essential genes were determined by real-time RT-PCR. We found a 
peak increase of mRNA levels at 4 h. As shown in Figure 11, 3T3-L1 and SGBS cells treated 
with HIV PIs for 4 h demonstrated a dose-dependent increase of CHOP and ATF-4. 
Interestingly, LOPV tended to be a more significant activator of the UPR in this assay as well. 
To determine if this phenomenon was specific to cell culture, we treated C57BL/6 4 
week-old male mice fed a high fat diet with LOPV/RITV 4:1 (38mg/kg) or control solution for 2 
months. Mice were sacrificed, and the gonadal fat pad analyzed for UPR protein and mRNA 
levels. In Figure 12, we demonstrate HIV PI LOPV/RITV increased both protein and mRNA 
levels of UPR ATF-4, CHOP, and spliced XBP-1 in vivo. 
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Figure 8. HIV PIs time-dependently activate the UPR in differentiated 3T3-L1s. 
Differentiated 3T3-L1s were treated with AMPV, RITV, LOPV, or LOPV/RITV (12.5 μM) for 
1-24 h. Representative immunoblots from four separate experiments against CHOP, ATF-4, and 
Lamin B of nuclear extracts. 
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Figure 9. HIV PIs dose-dependently activate the UPR in non-differentiated 3T3-L1s. Non-
differentiated 3T3-L1s were treated with increasing concentrations of RITV, LOPV, or 
LOPV/RITV. A) Representative immunoblots against CHOP, ATF-4, and Lamin B from nuclear 
extracts of cells treated 6 h. B) Density of immunoblots were determined by Image J. Relative 
protein levels were normalized using Lamin B as loading control. C) Relative mRNA levels of 
CHOP and ATF-4 of cells treated for 4 h and analyzed by real-time RT-PCR. β-Actin was used 
as an internal control. B,C) Values are means ± SE of four independent experiments. *p<0.05, 
**p<0.005 
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Figure 10. HIV PIs activate the UPR in differentiated murine and human adipocytes.  
Differentiated 3T3-L1s (A, B) and SGBS (C) were treated for 6 h with increasing concentrations 
of RITV, LOPV, and LOPV/RITV. Representative immunoblots against CHOP, ATF-4, and 
Lamin B from nuclear extracts are shown. B) Density of immunoreactive bands were determined 
by Image J with Lamin B as loading control. Values are mean ± SE of three independent 
experiments; *p<0.05.  
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Figure 11. HIV PIs induce transcriptional increase of UPR genes in adipocytes. 
transcriptional level of UPR genes in adipocytes. Differentiated 3T3-L1s (A) and SGBS (B) 
were treated with increasing doses of RITV, LOPV, or LOPV/RITV for 4 h. mRNA levels were 
analyzed by real-time RT-PCR with β-Actin internal control. Values are mean ± SE of three 
independent experiments; *p<0.05, **p<0.005. 
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Figure 12. LOPV/RITV induces ER stress in vivo. C57BL/6 male mice were gavaged with 4:1 
LOPV/RITV or control solution for eight weeks. At time of sacrifice, gonadal fat pads were 
obtained and analyzed for protein (A) and mRNA levels (B). Values are mean ± SE from two 
independent experiments; n=5 normal chow (NL Diet), n=6 high fat diet (HFD) and 
LOPV/RITV. 
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Effect of HIV PIs on ER calcium stores in adipocytes 
 ER stress can be activated by a number of insults, one of which is depletion of ER 
calcium stores leading to altered cellular calcium homeostasis. Thapsigargin (TG), a 
sarcoplasmic/ER calcium ATPase inhibitor, depletes the ER calcium stores and activates the 
UPR in many different cells (251, 252). We have previously shown RITV depletes ER calcium 
in macrophages leading to UPR activation (51). We further examined the effect of LOPV and 
RITV (12.5 μM) on ER calcium stores in adipocytes by treating 3T3-L1s for 24 h. The ER 
calcium content was determined using the fluorescent calcium indicator fura-2/AM as described 
previously (51). As shown in Figure 13, both RITV- and LOPV-treated cells markedly reduced 
the response to TG compared to DMSO control, indicating that ER calcium stores were depleted.   
 
HIV PIs induce cell death in adipocytes 
 We have previously shown that HIV PI-induced ER stress is correlated to the induction 
of cell apoptosis in both macrophages and hepatocytes at clinically relevant concentrations (49, 
52). We further examined whether HIV PIs would have a similar affect in adipocytes, which 
could potentially account for dysregulation of lipid metabolism in patients. Non-differentiated 
and differentiated 3T3-L1s were treated with different concentrations of HIV PIs, vehicle control 
DMSO, or positive control thapsigargin (TG) for 24 h. Cells were collected, stained with annexin 
V-FITC and propidium iodide, and analyzed by flow cytometry. As shown in Figure 14, both 
LOPV and RITV increased cell death dose-dependently in differentiated 3T3-L1s. As similar to 
our other assays, non-differentiated 3T3-L1s did not have as significant an increase of HIV PI-
induced cell death, but the trend remained the same (data not shown). In addition, differentiated 
SGBS cells demonstrated a much similar phenomenon as murine adipocytes (Figure 15). 
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Figure 13. HIV PIs deplete ER calcium stores in 3T3-L1s.  Non-differentiated 3T3-L1s were 
treated with RITV or LOPV (12.5 μM) or DMSO control for 24 h. ER calcium stores were 
assessed by Fura-2 AM fluorescence ratio of 340:380 nm in individual cells before and after 
addition of thapsigargin 100 nM. Representative tracing for a summation of at least 15 cells is 
shown, out of two independent experiments. 
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Figure 14. HIV PIs induce cell death in differentiated 3T3-L1s.  Differentiated 3T3-L1s were 
treated with increasing concentration of HIV PIs, vehicle control (DMSO) for 24 h, then stained 
with Annexin V-FITC and propidium iodide. The percentages of apoptotic and necrotic cells 
were analyzed by flow cytometry. A) Represenative plots. B, C) Relative amount of apoptotic 
and necrotic cells. Values are mean ± SE for four independent experiments. Statistical 
signficiance relative to vehicle control (0): *p<0.05. 
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Figure 15. HIV PIs induce cell death in SGBS cells.  Non-differentiated SGBS cells were 
treated with 25 µM HIV PIs, DMSO control, or positive control thapsigargin (TG) for 24 h. Cells 
were stained with Annexin V-FITC and propidium idodide, and images obtained using a 
fluorescent microscope with a 40 × objective.  
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HIV PIs activate the inflammatory cascade in adipocytes 
 Inflammation is a major cornerstone of metabolic diseases, as well as atherosclerosis. It is 
well demonstrated that inflammation in AT is an underlying issue in diabetes mellitus (196, 199). 
We have previously demonstrated that HIV PIs activate the inflammatory cascade, as well as 
stabilize mRNA transcripts of IL-6 and TNF-α in macrophages (232). To determine if this was 
also true in adipocytes, we treated murine 3T3-L1s with HIV PIs for 12, 24, and 48 h, and 
analyzed culture media by ELISA. At 48 h, there was an increase of IL-6 secretion from these 
cells. This was found to be a dose-dependent occurrence in mature adipocytes, while pre-
adipocytes did not demonstrate this phenomenon (Figure 16).  
In addition to pro-inflammatory cytokine secretion, crown structure formation is another 
hallmark of inflamed AT. Resident macrophages are activated by over expanded and stressed 
adipocytes (253-255), and call in circulating macrophages. Activated macrophages than attempt 
to engulf dying or stressed cells, and can be visualized in tissue stained with anti-macrophage 
antibodies. We wanted to determine if HIV PIs can induce this inflammatory response in our 
animal model. Therefore, gonadal AT of C57BL/6 mice treated with LOPV/RITV for 8 weeks 
was fixed, dehydrated and placed in paraffin. 0.5 μM slices were stained for presence of 
macrophages, and counterstained for nuclei visualization. As seen in Figure 17, there was only a 
slight difference found between control and mice treated with HIV PIs. This is most likely due to 
the already stressed tissue from mice being fed a high fat diet for a long period, as this diet has 
already been shown to induce crown structure in AT (256). However, it was promising to find 
the slight increase of crown-like structures in LOPV/RITV treated mice, supporting the 
hypothesis that HIV PIs increase AT inflammation. 
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Figure 16. HIV PIs increase inflammatory cytokines in differentiated 3T3-L1s. A) Non-
differentiated and B) differentiated 3T3-L1s were treated with increasing concentrations of 
RITV, LOPV, or LOPV/RITV for 48 h. Culture media analyzed by ELISA. Relative IL-6 levels 
were determined with total cellular protein as control. Values are mean ± SE from three 
independent experiments. Statistical significance relative to DMSO control (0); *p<0.05, 
**p<0.005. 
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Figure 17. LOPV/RITV slightly increases inflammation in vivo. C57BL/6 male mice were fed 
a high fat diet and gavaged with 4:1 LOPV/RITV or control solution for 8 weeks. Gonadal fat 
pads were fixed, stained with anti-Mac2, and counterstained for nuclei. Images were acquired 
using a light microscope with 20 × and 40 × objective lenses. 
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Effects of HIV PIs on intracellular lipid accumulation in adipocytes 
 Previous studies have shown that HIV PIs can affect adipocyte differentiation, but with 
contradictory results (242, 257, 258). To specifically determine the effect of individual HIV PIs 
on adipocytes differentiation, we first monitored the effect of HIV PIs on intracellular lipid 
droplet formation using Nile Red, a fluorescent dye that specifically stains lipid droplets (259). 
As shown in Figure 18A, when murine pre-adipocytes were induced to differentiate while 
concurrently treated, HIV PIs differentially affected intracellular lipid accumulation. 
Specifically, RITV increased lipid accumulation compared to control, while LOPV and 
LOPV/RITV inhibited lipid accumulation. We further verified our observations using another 
common neutral lipid stain, Oil Red O in 3T3-L1 cells (Figure 18B). Similar results were 
obtained with human SGBS cells stained with Oil Red O (Figure 18C). To increase accuracy and 
avoid subjectivity, we also quantitated both the number and size of lipid droplets that 
accumulated in 3T3-L1 cells when induced to differentiate in presence of HIV PIs using a 
MATLAB program previously written and published (231) (Figure 19). These combined 
findings enabled us to more definitively ascertain the effect of HIV PIs on adipocyte 
differentiation compared to what was previously published in the literature, as well as determine 
the extent of effect at the LD level.  
 
HIV PIs alter PPARγ at the transcriptional and posttranscriptional levels 
 To ascertain the mechanism underlying LOPV-inhibition of differentiation and RITV- 
induction of differentiation, we first analyzed the activity of the PPARγ promoter in the presence 
of HIV PI treatment. As discussed previously, PPARγ is an essential transcription factor 
involved in adipogenesis. Although we expected LOPV to inhibit PPARγ, and RITV to either 
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have no affect or induce the promoter leading to more lipid accumulation, we found all HIV PIs 
to significantly inhibit promoter activity (Figure 20). We further analyzed PPARγ mRNA levels. 
In non-differentiated cells, mRNA levels could not be accurately assessed as PPARγ is not yet 
upregulated at this stage. In differentiated 3T3-L1s, we found significant decreases of PPARγ 
mRNA at 4 h, with complete rebound by 6 h of treatment (Figure 21A). However, RITV induced 
an increase of mRNA stability compared to DMSO control (Figure 21B).  
In attempt to elucidate how RITV inhibits PPARγ promoter activity but increases mRNA 
stability, we investigated the role of RNA binding proteins in 3T3-L1s treated with LOPV and 
RITV. We have previously shown that HIV PIs can increase the stabilizing mRNA binding 
protein HuR in macrophages, leading to increased translation of IL-6 (191, 232), and 
hypothesized that LOPV/RITV may have a similar role in PPARγ stabilization.  
We therefore completed a pulldown assay in which 3T3-L1s were treated for 24 h with 
either RITV or LOPV (12.5 µM) or DMSO control. 5 mg of total cell lysate was incubated with 
biotinylated beads previously incubated with anti-HuR or anti-CUGBP1 antibody. Protein was 
digested and RNA precipitated. Bound mRNA was analyzed by real-time RT-PCR, using IgG1-
incubated bead samples as a control.  As shown in Figure 22, RITV and not LOPV significantly 
increased mRNA binding proteins to associate with PPARγ. In order to clarify this was a specific 
binding, we completed an in vitro binding assay. Supportive of the putative binding sites found 
in mRNA PPARγ sequence (Figure 23A), we found significant HuR and minimal CUGBP-1 to 
bind to the 3'UTR, and only HuR binding minimally to the CDS (Figure 24B).  
In addition, when 293 cells were transfected with plasmid containing the 3‟UTR of 
PPARγ in a GFP-expression vector, overexpression of either HuR or CUGBP-1 increased GFP  
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Figure 18. HIV PIs differentially affect adipocyte maturation. 3T3-L1 cells were induced to 
differentiate while concurrently treated with HIV PI. Cells were fixed after 8 days and stained 
with A) Nile Red and images acquired on a fluorescent microscope or B) Oil Red O (40 ×). C) 
SGBS cells were treated in the same manner as 3T3-L1s and stained with Oil Red O after 10 
days (40 ×). Images are representative of three individual experiments. 
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Figure 19. HIV PIs differentially affect LD number and size in differentiating 3T3-L1s. 
3T3-L1s were induced to differentiate in the presence of increasing concentrations of HIV PIs. 
After 2 weeks, cells were fixed and imaged using a 40 × objective on a light microscope. Images 
were analyzed via MATLAB for both lipid droplet (LD) number and diameter. Values are mean 
± SE of three independent experiments; *p<0.05, **p<0.005. 
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Figure 20. HIV PIs inhibit activity of the PPARγ promoter.  293 cells were transfected with a 
plasmid with the PPARγ promoter controlling luciferase expression for 48 h. Cells were 
subsequently treated with increasing concentrations of HIV PIs or control DMSO for 6 h. 
Relative luciferase activity was analyzed with total protein levels as control. Values were 
subtracted from treated 293 cells transfected with empty plasmid. Values are mean ± SE of ten 
independent experiments. *p<0.05, **p<0.001 compared to DMSO (0). 
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Figure 21. HIV PIs differentially alter PPARγ mRNA levels. A) Differentiated 3T3-L1s were 
treated with increasing concentrations of HIV PIs for 4 or 6 h. Relative mRNA levels were 
determined by real-time RT-PCR with β-Actin as internal control. Values are mean ± SE from 
four independent experiments: **p<0.005 compared to DMSO (0) control. B) 3T3-L1s were 
treated with 12.5 µM RITV or LOPV for 2 h, followed by the addition of ActinomycinD (10 µg) 
(time 0). Total RNA was isolated from cells at 0.5, 1, 2, 4, and 6 h, and PPARγ mRNA levels 
analyzed as above. Results are expressed as the percentage of the mRNA at time 0 using a two 
phase exponential decay analysis of n =2. 
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Figure 22. In vivo pulldown of PPARγ mRNA after treatment with HIV PIs in 3T3-L1 cells. 
3T3-L1 cells were treated with RITV 12.5 µM, LOPV 12.5 µM, or DMSO control for 24 h. 3 mg 
protein equivalent was added to preswollen and antibody labeled Sepharose beads, and rotated at 
RT for 4 h. RNA in IP materials was reverse transcribed to detect the presence of PPARγ 
mRNA. Values are mean ± SE from four independent experiments: *p<0.05, **p<0.001. 
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Figure 23. HuR and CUGBP-1 bind to PPARγ. A) Putative binding cites of HuR (Blue) and 
CUGBP1 (Pink) in the mRNA sequence of PPARγ. B) Biotinylated mRNA of the 3‟UTR and 
CDS of PPARγ were incubated with total 3T3-L1 protein lysates. mRNA-protein complex was 
pulled down with Streptavidin Dynabeads. Shown are representative immunoblots of four 
independent experiments against HuR and CUGBP-1 of IP material. The 3‟UTR of IL-6 and 
TNF-α are shown as positive control (results previously published (191, 232)). 
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Figure 24. 3’UTR PPARγ activity is increased with HuR and CUGBP-1 overexpression. 
293 cells were co-transfected with the 3‟UTR region of PPARγ inserted in a GFP-expressing 
vector with either (A) HuR or (B) CUGBP-1 under constitutive CMV control. Vectors with no 
insert were used as control. After 48 h, activity of 3‟UTR was determined with total cell lysates. 
Shown are representative immunoblots against GFP and Actin from three independent 
experiments. Last lane is no transfection control. 
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Figure 25. RITV increases HuR and CUGBP-1 translocation in 3T3-L1s. 3T3-L1 cells were 
treated with RITV (15 µM) or purified lipopolysaccharide (LPS – total 1 µg) for 24 h. Cells were 
fixed and stained with anti-HuR or -CUGBP-1, and images acquired using a confocal 
microscope with a 60 × oil immersion lens. Shown are representative images from two 
independent experiments. 
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expression compared to empty GFP plasmid (Figure 24). We also have preliminary data that 
RITV treatment of 3T3-L1s increases translocation of HuR and CUGBP-1, indicating activation 
of protein (Figure 25). Taken together, these results indicate RITV increases HuR and CUGBP-1 
activation and binding to PPARγ mRNA, which has the ability to then increase stability. This 
can ultimately lead to an increased in LD formations during adipogenesis.  
 
Effect of CHOP on HIV PI-induced alterations of intracellular lipid accumulation in 
adipocytes 
 The differential affects of RITV and LOPV on PPARγ mRNA stability needs to be 
further investigated. However, we still hypothesize that this, and other alterations, may be at least 
partially explained by HIV PI-induced UPR. Therefore, to identify this potential link, we isolated 
primary adipocytes from C57BL/6 wild-type and CHOP
-/-
 mice with a C57BL/6 background. 
Isolated primary adipocytes were induced to differentiate while concurrently treated with HIV 
PIs for 10-days. Intracellular lipid droplets were stained with Oil Red O.  As shown in Figure 26, 
similar to the findings in cultured murine and human adipocytes, LOPV and LOPV/RITV 
significantly inhibited intracellular lipid accumulation in wild-type mouse adipocytes. However, 
in the absence of CHOP, LOPV and LOPV/RITV had less effect on intracellular lipid 
accumulation. Also of note, AMPV (a non-inducer of ER stress) did induce lipid accumulation 
and its effect also was abrogated in absence of CHOP.  
 In addition, total RNA was analyzed from the gonadal fat pads of mice gavaged for eight 
weeks with LOPV/RITV and control solution. Preliminary data suggests a slight abrogration of 
HIV PI-induced lipid dysregulation and inflammation in AT with absence of CHOP (Figure 27). 
However, as CHOP
-/- 
does not result in a significant decrease of these pathologies, another 
pathway may also be involved in HIV PI-induced lipid dysregulation in adipocytes.  
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Figure 26. HIV PI-induced alteration of adipogenesis is abrogated in absence of CHOP. 
Primary murine pre-adipocytes were isolated from CHOP
-/-
 and wild type (WT) mice. Cells were 
induced to differentiate while concurrently treated with HIV PIs, and stained with Oil Red O 
after 10 days. Images were acquired with a 40 × objective lens. Representative images of two 
independent experiments are shown. 
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Figure 27. CHOP knockout may abrograte HIV PI-induced lipid metabolism dysregulation 
and inflammation in AT.  Male and female C57BL/6 WT and CHOP
-/-
 mice were fed a high fat 
diet and gavaged with either 4:1 LOPV/RITV or control solution for 8 weeks. mRNA from 
gonadal fat pads were analyzed by real-time RT-PCR with β-Actin as internal control. Value 
means ± SE are shown; n=6.  
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SIGNIFICANCE 
Although HIV PIs are extremely effective in decreasing viral load, HIV patients are at 
increased risk of developing metabolic syndrome and cardiovascular diseases on this regimen (9, 
22). Understanding the cellular mechanism underlying these complications is essential in 
development of alternative and improved therapies for chronically infected patients.  
The field of ER stress and the UPR has gained great attention during the last decade. The 
UPR signaling pathway plays an important role in regulating normal functions of various cells 
including hepatocytes, β-cells, and macrophages. Consequently, dysregulation of the UPR 
signaling pathway has been implicated in various human diseases such as diabetes, fatty liver, 
and cardiovascular diseases (45-47). Previous studies from our laboratory suggest that activation 
of ER stress represents an important cellular mechanism underlying HIV PI-induced 
inflammation and dyslipidemia (49-53, 190, 232). In addition, Djedaini et. al have recently 
shown a correlation of HIV PI-induced insulin resistance and the ER stress in adipocytes (54). 
However, little is currently understood of the mechanism underlying HIV PI-induced lipid 
metabolism dysregulation. 
 Here, we have shown that HIV PIs induce ER stress in a time and dose-dependent 
manner, similar to macrophages and hepatocytes (Figures 8-11). There was, however, a 
differential effect in differentiated versus non-differentiated adipocytes, likely owing to the 
fibroblastic-like physiology of preadipocytes. There has not yet been a study defining HIV PI-
induced alterations in fibroblasts, illuminating the nonsignificant induction of cell death and 
inflammatory response we found in 3T3-L1 preadipocytes. Nonetheless, we found slight 
increases in UPR protein and mRNA levels in our preadipocyte cell lines. We hypothesize this is 
do to our particular cell culture methods which commit the cell line to the adipocyte lineage. 
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In addition, not all HIV PIs activated the UPR to the same level, which may be explained 
by pharmacokinetic differences within this drug class. HIV PIs differ in molecular weight, 
ionization, and lipophilicity, all of which determine rate of transport through cellular membranes. 
While molecular weight and ionization for HIV PIs are similar and associated with passive 
diffusion, the lipophilicity (oil-water partition coefficient, or logP) differs. A strong correlation 
has been reported between log P and the intracellular accumulation of HIV PIs (260). The log P 
of AMPV and DRV are in the poor range of permeability while that of LOPV, RITV, ATZ, IDV, 
SQV, and NEFV are very permeable. These differences correlate strongly with our 
categorization of ER stress inducer and non-inducers. While pharmacokinetic studies have not 
been completed to determine the significance of these log P differences, the connection is 
notable and may be one molecular contribution to differences in dyslipidemia induction in the 
clinic.  
We have found that HIV PIs which induce high levels of the UPR also alter adipogenesis 
and lipid metabolism. Specifically, RITV and LOPV differentially affect both LD number and 
size (Figure 19). However, while RITV significantly decreased LD number, it also increased LD 
diameter. This data suggests LD fusion, as could occur at times of ER stress with alteration of 
CTT function (175). In addition, while higher concentrations of RITV increased lipid droplet 
formations, the physiological concentration in the clinical LOPV/RITV formulation inhibited 
lipid accumulation (6.25 µM). At the same time, LOPV dose-dependently inhibited 
differentiation. Taken together, there was a synergistic inhibition of LOPV-RITV in the 
clinically relevant 4:1 formulation at physiological concentration (12.5 µM). 
We hypothesized the induction of ER stress may be the cause of these alterations, as the 
ER and LD organelles are so closely intertwined (66, 69, 173, 174). Indeed, knockout of CHOP, 
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a downstream UPR transcription factor, abrogated HIV PI-induced adipogenesis dysregulation 
(Figure 26). In addition, we show preliminary data that this difference occurs in vivo. When 
CHOP
-/-
 mice are fed LOPV/RITV (4:1) for 8 weeks, the lipogenesis transcription factor 
SREBP-1c, as well as lipid protein lipase (LPL) is not upregulated in AT of CHOP
-/-
 as it is in 
wild-type mice.  
Some of the alterations in differentiation by HIV PIs can also be explained by affects on 
PPARγ. Particularly, we have found an increased binding of mRNA binding proteins HuR and 
CUGBP1 to PPARγ mRNA when 3T3-L1s were treated with RITV, but not LOPV (Figure 22). 
We have previously shown HIV PIs can increase HuR translocation from the nucleus to 
cytoplasm, indicating activation (232), and have seen similar occurrences in 3T3-L1s (Figure 
25). However, we have not yet determined a direct mechanism by which RITV results in 
activation of HuR and CUGBP1, although we hypothesize it is connected with our UPR 
activation findings.  
Some of our other findings also brought more questions. One example is from our AMPV 
treatments. AMPV is an ER stress non-inducer and shown in the clinic to have minimal lipid 
profile alterations. However, in cells treated with physiological concentrations (12.5 µM), we 
saw an increased lipid accumulation during adipogenesis which was abrogated with loss of 
CHOP. In addition, knockout of CHOP did not completely abrogate LOPV and RITV lipid 
metabolism alterations in vitro or in vivo, suggesting other pathways may be involved. 
It has recently been shown that autophagy is upregulated in visceral and not subcutaneous 
fat pads (261), a similar distribution of which HIV PIs also affect fat depots in patients. This 
pathway has also been shown to be involved in cellular lipid recycling and metabolism (205). 
We therefore began to investigate if HIV PI-induced dysregulation of adipocyte lipid metabolism 
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could be explained through this pathway. Our findings on this matter are intriguing, and can be 
found in the next chapter of this dissertation. 
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CHAPTER IV: HIV Protease Inhibitors LOPV and RITV Induce Autophagosome 
Accumulations in Adipocytes 
STUDY RATIONALE 
 Autophagy is a catabolic pathway in which intracellular components are degraded for 
energy production. Recently, autophagy has been shown to be strongly involved in lipid 
metabolism. Within adipocytes, autophagy aids in lipid store turnover and adipogenesis (262-
264). Loss of the autophagic pathway results in inhibition of differentiation in vitro and 
decreased white adipose tissue size and distribution in vivo.  
 Recent investigations have shown HIV PIs nelfinavir (NFV) and saquinavir (SQV) to 
induce autophagy in cancer cells (233, 234, 265). However, little is known whether HIV PIs can 
induce autophagy in adipocytes, and if this is involved in dysregulation of lipid metabolism. 
 There is growing evidence that ER stress can activate autophagy (119, 120, 125, 209). 
While this is hypothesized to occur for nascent protein degradation, other mechanistic inductions 
are ill-defined. We have previously demonstrated that HIV PIs significantly activate the UPR in 
adipocytes. Yet, not all HIV PI perturbations could be thoroughly explained by this pathway.  
We therefore began to investigate if autophagy induction is also involved in HIV PI-induced 
dysregulation of adipocyte lipid metabolism. After finding that autophagy is induced by these 
drugs, we further pursued how HIV PI-induced ER stress and autophagy are connected. 
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RESULTS 
Effect of HIV PIs on autophagy activation in adipocytes 
 LC3B western blot analysis is a common method in determining activation of autophagy 
(266). At autophagic induction, cytosolic LC3B-I is cleaved and lipidated to form membrane-
associated LC3B-II. To determine if HIV PIs increase the ratio of LC3BII:I, non-differentiated 
and differentiated 3T3-L1 cells were treated with HIV PIs (12.5 μM) for various time points (12, 
24, and 48 h), and total cell lysates separated on a 12% SDS-PAGE gel. Peak conversion was 
found to occur at 48 h, and cells were treated dose-dependently at this time point. Greater 
activation of LC3B was found in differentiated 3T3-L1s than non-differentiated (Figure 28), but 
both were significant. Similar results were seen in a human adipocyte cell line (ASC) (Figure 
29).  
 
HIV PIs increase autophagosomes in 3T3-L1s 
Although immunoblotting LC3B is a frequent method used in autophagy detection, there 
remain many pitfalls in this assay that cannot be simply addressed in one experiment (12, 13). 
Therefore, we further confirmed the effect of HIV PIs on autophagosome accumulation using 
electron microscopy, the current gold standard of autophagy induction. As shown in Figure 30, 
there was a significant increase of autophagosome density with LOPV, LOPV/RITV, and RITV 
treatments in 3T3-L1 cells. 
 
Second Generation HIV PI Darunavir does not activate autophagy 
 Darunavir (DRV), with RITV boost, now surpasses LOPV/RITV prescription numbers in 
the clinic. In fact, the newest HIV treatment guidelines recommend treatment-naïve patients 
beginning HAART regimens containing HIV PIs to be treated with DRV/RITV (4:1). As there is  
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Figure 28. HIV PIs increase LC3B II:I ratio. A) Non-differentiated and B) differentiated 3T3-
L1s were treated with increasing concentrations of HIV PIs for 48 h. Representative 
immunoblots against LC3B and Actin are shown. Densitometry was determined using Quantity 
One. Values are means ± SE from four independent experiments; * p<0.05, ** p<0.005 
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Figure 29. HIV PIs increase LC3B II:I ratio in human ASCs. Human adipose stem cells were 
induced to differentiate and then treated with increasing concentrations of HIV PIs for 48 h. 
Representative immunoblots of LC3B and Actin from two separate experiments are shown. 
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Figure 30. HIV PIs quantifiably increase autophagosomes in 3T3-L1 cells. Non-
differentiated 3T3-L1s were treated with 12.5 µM HIV PIs, 50 nM Rapamycin (RM), or DMSO 
control for 48 h. Cells were processed for transmission electron microscopy as described in 
“Methods.” A) Representative images for each treatment at 2,000 × and 4,000 ×. B) The density 
of autophagosomes were determined by point counting at 4,000 ×. Statistical significance 
relative to vehicle control: **p<0.05x10^5.  
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currently no clinical evidence suggesting DRV has metabolic side effects, and we previously 
found little activation of the UPR by DRV, we tested whether DRV induces autophagy similarly 
as LOPV/RITV. As shown in Figure 31, DRV did not significantly increase LC3B conversion or 
autophagosome formation compared to control.  
Effect of HIV PIs on autophagic flux 
 The increase of autophagosome number does not always indicate increase of autophagic 
activity. Accumulation of autophagosomes can be caused by an increase in the induction of 
autophagy and/or an impairment of autophagolysosomal maturation. We therefore examined the 
effect of HIV PIs on autophagic flux.  
 Monodansylcadaverine (MDC) is an autofluorescent drug that naturally accumulates in 
lower pH vesicle membranes, which is characteristic of late autophagosomes (115). When non-
differentiated 3T3-L1 cells were treated with HIV PIs and subsequently stained with MDC, HIV 
PI treatment did increase punctate staining, but did not appear to be dose-dependent (Figure 32). 
In addition, results did not appear to quantitatively define HIV PI-induced autophagosome 
induction as our previous assays. As MDC staining is already cited to not be the most reliable 
assay due to high dependence on intracellular pH, vacuole pH, and therefore differences in 
cellular environment, we continued our investigations to a p62 analysis. 
p62 is nuclear membrane protein found to have an LC3-interacting region (LIR) by 
which it binds to specific residues of LC3. p62 can serve as a link between LC3B and 
ubiquitinated substrates, and has been proposed to be specifically degraded through the 
autophagic pathway (267, 268). Therefore, the activity of autophagy should inversely correlate 
with p62 protein levels. As seen in Figure 33, when differentiated 3T3-L1 adipocytes were 
treated with HIV PIs, there is an accumulation of p62 at higher (25 µM) concentrations.  
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Figure 31. Darunavir does not significantly activate autophagy in 3T3-L1s. A) Differentiated 
3T3-L1s were treated with increasing concentrations of darunavir (DRV) or DMSO control for 
48 h. Density of immunoreactive bands against LC3B and Actin was determined by Quantity 
One. Value means ± SE are shown. B) Non-differentiated 3T3-L1s were treated with 12.5 µM of 
DRV for 48 h, and cells analyzed by electron microscopy. Representative images at 2,000 ×  are 
shown.  
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Figure 32.  HIV PIs increase late autophagosome accumulation without dose-dependence. 
Non-differentiated 3T3-L1 cells were treated with HIV PIs (12.5 or 25 µM), rapamycin (RM) 50 
nM, or DMSO control for 24 h. Cells were stained with 25 µM MDC for 5 min at 37ºC. Images 
were acquired on a fluorescent microscope with a 60 × objective. Micrographs were desaturated 
for easier visualization of punctuate. Images are representative of four separate experiments. 
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Figure  33.  Effect of HIV PIs on p62 degradation. Differentiated 3T3-L1s were treated with 
increasing concentrations of HIV PIs for 48 h, and total cell lysates analyzed. A) Representative 
immunoblots of p62 and Actin. B) Relative protein level of p62 was determined by Quantity One 
using Actin as loading control. Values are mean ± SE of three independent experiments. 
Statistical significance relative to DMSO contol (0); *p<0.05, **p<0.005. 
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However, this may be attributable to inhibition of the proteasome (see Discussion).  
To further follow this observation, we examined the effect of HIV PIs on degradation of 
GFP-tagged LC3B. When cells are transfected with a plasmid containing this construct, green 
punctuate are formed at the induction of autophagy as GFP-LC3BII accumulates at 
autophagosomes, versus a homogenous cytoplasmic green from GFP-LC3BI (Figure 34A). 
However, as these autophagosomes mature into autolysosomes, the LC3B on the internal 
membrane is degraded while GFP is released into the cytosol. This can be tracked by Western 
blot analysis. We found an accumulation of GFP when 3T3-L1 cells infected with a retrovirus 
containing this construct were treated with HIV PIs, with more accumulation at 48 than 24 h 
(Figure 34 B,C). This suggests that the fusion of autophagosomes with lysosomes is being 
completed in the presence of HIV PIs.  
 
Effect of CHOP and ATF-4 on HIV PI-Induced Autophagy 
 In order to identify the potential link between HIV PI-induced ER stress and subsequent 
autophagy induction, we first examined the effect of CHOP on HIV PI-induced autophagy stress 
by overexpressing and knocking down CHOP with constructed lentiviral vectors (see Methods). 
With knockdown of CHOP, we saw a decrease of total LC3B protein levels, while 
overexpression had little affect (Figure 35A). In addition, there was a slight decrease of total 
LC3B, and insignificant alterations of LC3BII:I when 3T3-L1s overexpressing CHOP were 
treated with HIV PIs (Figure 35B).  
 There is current growing evidence of a PERK-autophagy link (120, 130, 269). As ATF-4 
is upstream of CHOP, and HIV PIs significantly increased ATF-4 in our model, we next  
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Figure 34. Effect of HIV PIs on GFP-LC3B cleavage. A) 3T3-L1 cells were stably transfected 
with a plasmid containing GFP-tagged LC3B, and treated with HIV PIs, rapamycin (RM), or 
vehicle control (DMSO) for 48 h. The fluorescence images were recorded using a 60 × oil lens 
with FITC filter. Micrographs are desaturated for easier visualization. B) 3T3-L1 cells were 
infected with a retrovirus containing GFP-LC3B and treated with individual HIV PIs (12.5 µM) 
for 24 or 48 h. Shown are representative immunoblots against GFP and Actin. C) 3T3-L1 cells 
infected with retroviral GFP-LC3B were treated with HIV PIs (12.5 or 25 µM) for 48 h. 
Representative images of GFP-LC3 and free GFP are shown.  
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Figure 35. CHOP and HIV PI-induced LC3B. A) 3T3-L1s were infected with lentivirus 
containing either shRNA against CHOP (shCHOP1), recombinant GFP-CHOP (CHOP-over), or 
control virus for 48 h. Total cell lysates were used for Western blot analysis. Shown are 
representative immunoblots against CHOP, LC3B, and Actin as loading control. B) 3T3-L1 cells 
were infected with recombinant constitutively active CHOP or control virus. Stable colonies 
were treated with HIV PIs (12 or 25 µM), DMSO control (0), or positive controls (TG and RM 
50 nM) for 24 h. Shown are representative immunoblots against LC3B and Actin from two 
separate experiments.  
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examined whether ATF-4 is the connecting link of HIV PI-induced UPR and autophagy. Using a 
lentiviral shRNA specifically targeting mouse ATF-4, mRNA ATF-4 level was successfully 
down-regulated by more than a 50% in 3T3 cells (Figure 36A). The downregulation of ATF-4 in 
3T3-L1s inhibited both LOPV- and LOPV/RITV-induced increases of total LC3B protein, but 
had no effect on RITV-induced increase of LC3B. In addition, conversion of LC3BII:I was not 
significantly altered in this model. However, the results demonstrate that HIV PI-induced UPR 
may lead to an increased ability of autophagosome formation with increased substrate LC3B.  
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Figure 36. ATF-4 and HIV PI-induced LC3B.  3T3-L1s were infected with lentiviral  shRNA 
specific to ATF-4, or scramble control. Stable colonies were selected using puromycin. A) The 
knockdown efficiency of shRNA was determined by real-time RT-PCR and Western blot 
analysis. B) Stable colonies of 3T3-L1 cells infected with control or shRNA lentivirus were 
treated with HIV PIs (12 and 25 µM), DMSO (0), or rapamycin (RM) 50 nM for 24 h. 
Representative immunoblots are shown. Relative protein levels of LC3B using Actin as loading 
control were determined with Quantity One. Values are mean ± SE of three independent 
experiments; *p<0.05 compared to vehicle control; ##p<0.005 compared to control shRNA.  
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SIGNIFICANCE 
 HIV PI therapy will not, and should not, be discontinued in the near future due to their 
high effectiveness in controlling viral load in patients. Instead, investigators now need to focus 
on inhibiting HIV PI-induced risks of metabolic syndrome and cardiovascular disease (22, 31, 
236). Elucidating the effects of this drug class can have on the metabolically important adipose 
tissue, and central adipocytes, is essential in development of improved therapies. 
In order to fully understand HIV PI-induced lipid metabolism dysregulation in 
adipocytes, we turned to the autophagic pathway. Autophagy has been recently identified as a 
new cellular target for dysregulation of lipid metabolism and accumulation (262). In addition, 
autophagy is also shown to be involved in body lipid profile and pathologically in metabolic 
diseases such as obesity (261, 270). 
  We have shown that some HIV PIs induce autophagy dose-dependently in mouse and 
human adipocytes (Figures 28, 29). In fact, the HIV PIs we have found that do not induce 
autophagy fall under the 'UPR non-inducer' subclass (i.e. DRV - Figure 31). In addition, 
autophagy activation did not occur to the same extent in non-differentiated as differentiated 
adipocytes, similar to our HIV PI-induced UPR results.  
 By using TEM, we have further supporting evidence that HIV PIs LOPV and RITV 
siginificantly upregulate autophagosome production (Figure 30). This upregulation does not 
seem to be through inhibition of autophagsome-lysosome fusion (Figures 33, 34). In this regard, 
we would like to address the accumulation of p62 with higher concentrations of HIV PI 
treatments. The nuclear membrane protein p62 has been proposed to be degraded specifically 
through autophagy. Therefore, the activity of autophagy should inversely correlate with p62 
protein levels (267, 271, 272). However, we disagree with the specificity of this assay as other 
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sub-populations of p62 may also exist (273). Particularly, one recent publication has 
demonstrated that p62 associates with the 26S proteasome, and inhibition of proteasome activity 
leads to p62 accumulation (274). HIV PIs have already been shown to inhibit the activity of the 
26S proteasome dose dependently, with LOPV and RITV inhibiting chymotryptic activity 50-
60% at 25 µM (223). In our findings, p62 did not accumulate until this concentration. In 
addition, HIV PIs did not inhibit autolysosome cleavage of the GFP-LC3 construct. Taken 
together, we do not believe HIV PIs are inhibiting autophagic flux, although further assays are 
needed to definitively ascertain this observation. 
 We have demonstrated that HIV PIs activate the UPR at an earlier time point than 
autophagy, and many similarities of activation occur for both pathways. Therefore, we next 
aimed to determine a link between HIV PI-induced UPR and autophagy. We began this 
investigation with CHOP, as we had seen abrogation of HIV PI-induced adipocyte lipid 
metabolism dysregulation with absence of CHOP. Indeed, CHOP knockout decreased total 
LC3B, but CHOP overexpression had only a slight effect on HIV PI-induced LC3B protein. 
However, this could be accounted for an already saturated system, and further incricate studies 
need to be completed to fully elucidate this result. 
 We next went upstream to ATF-4, as others have already shown a PERK-pathway 
connection with autophagy induction (120, 130, 269). We show ATF-4 knockout abrogates 
LOPV and LOPV/RITV upregulation of LC3B protein. As written in the final discussion, 
Rzymski et. al have recently shown ATF-4 to bind to the 5‟UTR of the LC3B promoter at times 
of hypoxia-induced ER stress (130). As with our studies, when ATF-4 was knockdown with 
siRNA there was a decrease in total LC3B protein levels. However, our results also suggest 
CHOP plays a major role in ER stressed-induced autophagy. While CHOP is downstream of 
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ATF-4, if the findings of Rzymski et. al hold true, knockdown of CHOP should have little to no 
affect on LC3B levels. We did not find this to be the case, and have additional data that suggests 
CHOP plays a major role in ER-stress induced autophagy in hepatocytes (Chapter 5). Therefore, 
CHOP may act separately independently of ATF-4 in activating autophagy, as has been 
suggested by others (275).  
 HIV PI cellular alterations are indeed complex, but our studies are beginning to piece 
together how HIV PIs induced lipid metabolism dysregulation. We have already shown HIV PIs 
to differentially activate ER stress and autophagy in adipocytes. We hypothesize inhibition of 
HIV PI-induced ER stress will relieve downstream activation of autophagy and lipid metabolism 
dysregulation. Such a hypothesis has translated well to another central cell type in lipid 
metabolism regulation, hepatocytes, as shown in the next chapter. 
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CHAPTER V: Raltegravir Inhibits LOPV/RITV-Induced Autophagosome Accumulation 
in Hepatocytes 
STUDY RATIONALE 
 Although HAART has drastically decreased the mortality of those living with HIV, it has 
also been linked to cardiovascular complications, with recent demonstrations that the PI 
component is much to blame (21-23, 276). In addition, many of these patients also have non-
alcoholic fatty liver disease (NAFLD), or even nonalcoholic steatohepatitis (NASH) (40, 41), 
which is correlated with HIV PI-induced insulin resistance and visceral fat hypertrophy. 
 Endoplasmic reticulum (ER) stress may be a central pathway involved in HIV PI-induced 
NAFLD. In nutrient-induced NAFLD, saturated fatty acids induce ER stress, activating 
deleterious pathways that lead to increased inflammation and insulin resistance (58, 246, 277, 
278). We have previously shown that HIV PIs induce ER stress and its signaling pathway, the 
unfolded protein response (UPR), leading to lipid metabolism dysregulation in hepatocytes (49, 
50, 222). Some HIV PI-induced lipid accumulation in hepatocytes is also directly attributed to an 
increased activation of sterol regulatory element binding protein (SREBP)-1, a lipogenic 
transcription factor activated at times of ER stress (70, 279). 
Autophagy is another cellular pathway now known to be involved in hepatocyte lipid 
metabolism regulation. Although autophagy was first defined as a degradative pathway to 
remove accumulated proteins, infectious particles, or supply the cell with ATP, it is now known 
that this pathway is also involved in lipolyis and LD turnover (205, 280). When autophagy is 
inhibited in hepatocytes, LDs increase (205) not due to increased triglyceride synthesis nor 
decreased VLDL secretions (225). In addition, mice lacking autophagy have enlarged lipid laden 
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livers with increased triglyceride and cholesterol levels (205). Therefore, we hypothesize that 
alterations in autophagy could be another underlying mechanism in HIV PI-associated NAFLD.  
Recently, we have demonstrated that the integrase inhibitor raltegravir (MK-0518) can 
inhibit HIV PI-induced lipid metabolism dysregulation in hepatocytes (222). In addition, we 
have shown HIV PIs to significantly induce autophagy in adipocytes. Using hepatic cell lines 
and primary cells, we aimed to determine if raltegraivir inhibits LOPV/RITV-induced lipid 
accumulation through autophagy. In addition, we further elucidated a link between HIV PI-
induced ER stress and autophagy. 
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RESULTS 
Raltegravir inhibits HIV PI-induced lipid accumulation in hepatocytes 
We have previously shown that HIV PIs with metabolic side effects in the clinic increase 
fatty liver in vivo, and alter lipid metabolism in hepatocytes in vitro (49, 222). In addition, we 
now have evidence that raltegravir can inhibit LOPV/RITV hepatocyte lipid accumulation as 
shown in both Figure 37 and (222). However, the mechanism behind this inhibition is not fully 
elucidated, only partially explained by an abrogation of UPR activation (222). 
 
HIV PI combination LOPV/RITV 4:1 induces autophagy in hepatocytes 
 As autophagy is now known to be a major pathway involved in lipid metabolism (205, 
225), we next tested if LOPV/RITV alteration of lipid metabolism in hepatocytes could also be 
explained by an alteration of autophagy. As previously mentioned, activation of LC3B from 
cytosolic (I) to cleaved and lipidated form (II) is frequently analyzed by Western blot to 
determine if autophagosome numbers are increasing (266). We found that in a both time and 
dose-dependent manner, LOPV/RITV did increase LC3BII:I ratio in rat and mouse primary 
hepatocytes (Figure 38), as well as a human hepatocyte cell line (HepG2 - data not shown). As 
24 h was the peak activation, we used this time point for subsequent experiments. 
 
Raltegravir inhibits LOPV/RITV induction of autophagy 
 We next wanted to elucidate if raltegravir, an anti-retroviral with little known clinical 
lipid side effects, activated autophagy similarly as LOPV/RITV which has a high clinical lipid 
side effect profile. Rat primary hepatocytes (RPH) were treated with increasing concentrations of 
raltegravir at 24 h. As seen in Figure 39A, there was actually a trend of decreasing LC3BII:I  
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Figure 37. Raltegravir abrogates LOPV/RITV-induced lipid accumulation in rat primary 
hepatocytes. RPH were treated with raltegravir (25 µM) and LOPV/RITV (25 µM) together or 
alone for 48 h. Cells were fixed and stained with Oil Red O and analyzed using a light 
microscope at with a 40 × objective lens. Shown are representative images from three 
independent experiments.  
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Figure 38. LOPV/RITV 4:1 increases LC3BII:I in rat and mouse primary hepatocytes. A) 
RPH were treated with 25 µM LOPV/RITV for 0, 1, 3, 6, 12, or 24 h and B) MPH were treated 
with increasing concentrations of LOPV/RITV at 24 h. Representative immunoblots of LC3B 
and Actin are shown. Densitometry was determined using Image J with Actin as loading control. 
Values are mean ± SE of three independent experiments; *p<0.05 and **p<0.005 compared to 
vehicle control (0). 
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Figure 39. Raltegravir abrogrates LOPV/RITV-induced LC3BII:I in hepatocytes.  RPH 
were treated with increasing concentrations of raltegravir with or without LOPV/RITV 25 µM 
(A) or increasing concentrations of LOPV/RITV with or without raltegravir 25 µM (B) for 24 h. 
Representative immunoblots against LC3B and Actin are shown. Densitometry was determined 
with Image J. Values are mean ± SE of three independent experiments; *p<0.05 compared to 
vehicle control; #p<0.05 and ##p<0.005 compared to same dose of single treatment. 
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ratio with raltegravir treatment. In addition, when added to increasing concentrations of 
LOPV/RITV treatments, raltegravir significantly inhibited LOPV/RITV dose-dependent increase 
of LC3BII:I. Increasing concentrations of raltegravir given with 25 µM of LOPV/RITV showed 
a dose-dependent decrease in LC3BII:I ratio (Figure 39A,B).  
HepG2 cells were treated with 25 µM raltegravir and/or LOPV/RITV for 24 hours, and 
mRNA analyzed by real-time RT-PCR. As shown in Figure 40, LOPV/RITV significantly 
increased the transcripts of proteins important in macroautophagy induction (Atg12 and Beclin1 
(BECN1)), while raltegravir abrogated this. ULK1 and VPS34, also essential proteins for 
macroautophagy, followed the same trend although increases in mRNA levels by LOPV/RITV 
were not statistically significant compared to control. 
 To ascertain if autophagosomes were indeed increased by LOPV/RITV, and if that 
increase was abrograted by raltegravir, we assessed treated RPH with both 
monodansylcadaverine (MDC) stain and transmission electron microscopy (TEM). MDC is a 
fluorescent dye that normally accumulates in high pH vacuoles, such as late autophagosomes. 
We found that indeed LOPV/RITV treatment increased MDC accumulations, and raltegravir 
significantly inhibited this (Figure 41). This held true for the gold standard of autophagy 
induction, TEM (Figure 42).  
 
Inhibition of autophagy induction by raltegravir is CHOP-Dependent  
 There is growing evidence of a UPR and autophagy link (129, 130). From previously 
acquired datat, we hypothesized raltegravir inhibition of LOPV/RITV-induced autophagy could 
occur via inhibition of UPR induction. We have previously shown HIV PIs induce CHOP at both  
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Figure 40. Raltegravir abrogrates HIV PI-induced autophagy at the mRNA level.  RPH 
were treated with raltegravir (25 µM) and LOPV/RITV (25 µM) separately or in combination for 
24 hours. Relative mRNA levels of Atg12, Beclin 1(BECN1), ULK1 and 2 were determined by 
real-time RT-PCR with β-Actin as internal control. Values are mean ± SE from three 
independent experiments. Statistical significance *p<0.05, **p<0.005 compared to vehicle 
control (-/-) and  #p<0.05 compared to LOPV/RITV alone. 
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Figure 41. Raltegravir abrogrates LOPV/RITV-induced late autophagosome accumalation 
in rat primary hepatocytes. RPH were treated with raltegravir (25 µM) and LOPV/RITV (25 
µM) separately or combined for 24 h. Cells were stained with MDC, and fluorescence images 
immediately acquired using a 60 × oil lens with a DAPI filter. Micrographs were desaturated for 
easier visualization of punctuates. Images representative of three independent experiments. 
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Figure 42. Raltegravir abrogates HIV PI-induced autophagy induction in hepatocytes. RPH 
were treated with raltegravir (25 µM) and LOPV/RITV (25 µM) separately or combined for 24 
h, and cells processed for transmission electron microscopy as described in “Methods.” A) 
Representative images at 4,000 ×. B) Density of autophagosomes were determined by point 
counting at 4,000 × using a 1.5 cm lattice. Point counts were completed in at least 15 cells per 
treatment, 4 images per cell. 
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time and dose-dependent manners in numerous cell types (49, 51, 53). In addition, we have 
shown that HIV PI-induced liver fat accumulation is altered in CHOP
-/-
 mice relative to their 
wild type counterpart. Raltegravir inhibited LOPV/RITV lipid accumulations in murine livers 
(222), and we had preliminary evidence this was altered with loss of CHOP. 
 Therefore, we turned to our CHOP
-/-
 model to determine if raltegravir abrogation of 
LOPV/RITV-induced autophagy was through the CHOP pathway. As seen in Figure 43, 
raltegravir failed to inhibit LOPV/RITV-induced LC3B conversion with the absence of CHOP. 
This demonstrates a vital role of the CHOP pathway in the mechanism underlying raltegravir 
inhibition of LOPV/RITV-induced autophagy.  
We repeated this investigation in vivo. As shown in Figure 44, preliminary data suggested 
raltegravir did inhibit LOPV/RITV-induced LC3B protein in C57BL/6 fed a normal diet. This 
was followed by a larger experiment in which C57BL/6 wild-type and CHOP
-/- 
male mice were 
treated with control solution, LOPV/RITV, raltegravir, or both (50mg/kg) for 4 weeks. Livers 
were isolated for protein analysis by Western blot. As seen in Figure 45, we saw a significant 
decrease of LOPV/RITV-increased total LC3B with raltegravir treatment, with was abrogated 
with loss of CHOP.  
 
LOPV/RITV and Raltegravir Effects on Autophagic Flux 
In our animal experiments, alteration of LC3BII:I was not as significant as total LC3B 
changes. While lack of raltegravir conversion was abrogated with loss of CHOP, all other 
treatments were not significant in both experiments (Figures 44, 45). Some of our hypotheses to 
explain these results include a low „n‟ for treatment groups, degradation of small-short lived 
proteins in our lysates, and/or an alteration of autophagy flux. We therefore further investigated  
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Figure 43. CHOP plays a central role in raltegravir inhibition of LOPV/RITV-induced 
LC3BII:I. MPH from wild-type and CHOP
-/-
 C57BL/6 male mice were isolated and treated as 
shown for 24 h. A) Representative immunoblots against LC3B and Actin. Denisty of 
immunoreactive bands was analyzed by Quantity One and relative protein levels determined with 
Actin as loading control. B) Ratio of LC3BII/I and C) total LC3B protein. Values are mean ± SE 
of three independent experiments. Statistical significance *p<0.05, **p<0.005 compared to 
vehicle control and #p<0.05, ##p<0.005 compared to equivalent treatment of wild-type cells. 
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Figure 44. Raltegravir inhibits LOPV/RITV-induced LC3B. C57BL/6 wild-type male mice 
were fed a normal chow diet and treated with LOPV/RITV (50mg/kg) and raltegravir (50mg/kg), 
separately or in combination for 4 weeks. Protein from liver samples was analyzed by Western 
blot. A) Immunoblots against LC3B and Actin. B) Relative protein ratios using Actin as loading 
control of total LC3B and LC3BII:I. Values are mean ± SE. n=5 for control (Con.), Raltegravir 
(Ral.), and LOPV/RITV, while n=3 for LOPV/RITV+Raltegravir.  
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Figure 45. Raltegravir lack of autophagy induction relies on CHOP. C57BL/6 wild-type and 
CHOP
-/-
 male mice were fed a high fat diet and treated with LOPV/RITV (50mg/kg) or 
raltegravir (50mg/kg) in combination or separately for 4 weeks. Protein from liver samples was 
analyzed by Western blot. A) Representative immunoblots against LC3B and Actin. B) Relative 
protein levels with Actin as loading control of total LC3B and LC3BII:I. Values are mean ± SE. 
n=5; *p<0.05, **p<0.005 compared to control; #p<0.05 and ##p<0.005 compared to wild-type. 
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how autophagy flux is altered in our models. 
As explained in Chapter 4, p62 is a nuclear membrane protein proposed to be specifically 
degraded through autophagy (267). We analyzed p62 levels of WT and CHOP
-/- 
MPH treated 
with increasing concentrations of LOPV/RITV with or without 25 µM raltegravir. As shown in 
Figure 46, p62 accumulated at higher concentrations of LOPV/RITV, even in the presence of 
raltegravir (which did not induce accumulation alone). Loss of CHOP abrogated this 
accumulation. While p62 accumulation may be partially explained by inhibition of proteasome 
by LOPV/RITV (Chapter 4), the CHOP pathway is shown here to also be involved in this 
accumulation. We therefore continue our studies to determine if LOPV/RITV did indeed inhibit 
autophagolysosome action.  
HepG2 cells were stably transfected with a plasmid containing GFP-tagged LC3B. As 
shown in Figure 47A, raltegravir successfully inhibited LOPV/RITV-induced GFP-punctate, 
supporting our previous results. When autophagosomes fuse with lysosomes, LC3BII is 
degraded, while the GFP is released to the cytoplasm as it is resistant to these proteases (281, 
282). When lysosomal activity is inhibited by pH neutralization (i.e. NH4Cl) or protease 
inhibitors (i.e. Leupeptin), GFP-LC3BII cleavage will not occur, and GFP will not accumulate in 
the cytoplasm. As shown in Figure 47B, addition of lysosomal inhibitors did decrease GFP 
accumulation compared to control. However, LOPV/RITV treatment slightly increased GFP 
accumulation. 
We further analyzed autophagy flux by inhibiting lysosomal action in RPH treated with 
LOPV/RITV and raltegravir. As shown in Figure 48, we have preliminary data suggesting both 
LOPV/RITV and raltegravir do not induce LC3B conversion. Rather, LOPV/RITV treated in the 
presence of lysosomal inhibitors did not induce LC3BII accumulation any more than lysosomal  
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Figure 46. p62 accumulates with high concentrations of LOPV/RITV treatment. MPH from 
wild-type and CHOP
-/-
 C57BL/6 male mice were isolated and treated as shown for 24 h. Shown 
are relative immunoblots against p62 and Actin. Relative protein levels of p62 were determined 
by Quantity One with Actin as loading control. Values are mean ± SE of three independent 
experiments. *p<0.05 **p<0.05 compared to DMSO control. 
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Figure 47. Affect of HIV PIs and raltegravir on GFP-LC3 cleavage in HepG2 cells. HepG2 
cells were stably transfected with a plasmid containing GFP-tagged LC3B. A) Cells were treated 
with 25 µM LOPV/RITV and 25 µM raltegravir (separately or in combination) for 24 h. 
Fluorescent images were acquired using a 60 × oil lens and a FITC filter. B) Cells were treated 
with 15 or 25 µM LOPV/RITV with or without 25 µM raltegravir for 24 h, in the presence or 
absence of lysosomal inhibitors (100 µM leupeptin/25 mM NH4Cl). LC3B-GFP and free GFP 
levels were determined by Western blot analysis using GFP antibody and Actin as loading 
control. Shown are representative images from at least three independent experiments. 
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Figure 48. LOPV/RITV and raltegravir may not increase LC3BI activation. RPH 
hepatocytes with pretreated with 25 mM NH4Cl/100 µM Leupeptin for 2 hours, followed by 25 
µM LOPV/RITV (L/R) or raltegravir (Ral.) for 24 h. Shown are representative immunoblots 
against LC3B and Actin. Densitometry was determined by Quantity One with Actin as loading 
control. 
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inhibitor alone. Rather, accumulation of LC3BII:I in previous Western blots may be due to an 
inhibition of LC3BII degradation instead of increased LC3BI activation. This inhibition may 
then be relieved with raltegravir. 
SIGNFICANCE 
 Debatably one of the most severe side effects of HIV PIs is the induction of NAFLD (42, 
283). Fatty liver can result in insulin resistance and dyslipidemia, contributing to the 
atherosclerotic risk in this patient population. Therefore, understanding the mechanism 
underlying HIV PI-induced fatty liver will aid in future alternative therapies. 
Autophagy is now understood to be central in cellular lipid metabolism. In addition, 
autophagy has been recently shown to play key roles in metabolic diseases such as obesity and 
NAFLD (99, 103, 284). In the liver, basal autophagy is important in degradation of misfolded 
proteins and nonfuctional organelles, but alterations in the pathway can lead to induction of 
inflammation, cell death (285), and lipid overload (205). These are in fact the same pathologies 
noted with HIV PIs (49, 191, 232). Therefore, we completed this study to investigate if HIV PI 
hepatic alterations could be due to alterations in autophagy. 
We show LOPV/RITV to time and dose-dependently increase autophagy. At this time, 
we cannot definitvely state whether the increase of LC3BII and late autophagosome 
accumulations are directly through induction of the pathway or inhibition of autophagolysosome 
action. Although p62 did dose-dependently accumulate in MPH with LOPV/RITV treatment, we 
believe this is in fact is due to HIV PI inhibition of proteasome activity (please see Chapter 4 and 
final Discussion). However, preliminary evidence with the use of lysosomal inhibitors 
demonstrates LOPV/RITV can not induce an increase of LC3B accumulation farther than 
lysosomal inhibition alone. Further studies using lysosomal inhibitors need to be completed to 
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fully elucidate if LOPV/RITV inhibits autophagolysosome action beyond its ability to inhibit 
proteasome action.  
What we found most intriguing was the integrase inhibitor raltegravir was able to 
abrogate LOPV/RITV-induced autophagy (Figures 39-42). We have previously shown 
raltegravir to inhibit LOPV/RITV lipid accumulations in hepatocytes (222), and this finding 
implied a novel mechanism underlying this phenomenon.  
HIV PIs significantly activate CHOP in multiple cell types including hepatocytes, as well 
as in vivo mouse models (49, 51, 53). Autophagy is now known to be induced through the UPR 
(116, 117, 128). We therefore investigated if raltegravir‟s ability to inhibit LOPV/RITV-induced 
autophagy was through the CHOP pathway. Indeed, the loss of CHOP abrogated this 
phenomenon (Figures 43-45), and this occurred for both total LC3B protein and LC3BII:I ratio 
increases. However, knockout of CHOP resulted in an increase of LOPV/RITV-induced 
LC3BII:I, with no alteration at the total LC3B level (Figure 43). This contradiction may be due 
to autophagolysosome inhibition, and we are currently investigating if this is the case.  
In short summary, addition of raltegravir suppresses LOPV/RITV-induced lipid 
accumulation through alterations of the autophagy pathway. This phenomenon is shown here to 
be through the UPR-CHOP pathway. Therefore, we hypothesize that inhibition of HIV PI-
induced ER stress by alternative therapies will significantly aid in reducing HIV PI-induced 
dysregulation of lipid metabolism that leads to clinical metabolic diseases.   
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CHAPTER VI: Final Discussion 
Successful therapy for HIV-infected patients has increased greatly in the past decade. 
HAART no longer just includes inhibiting viral reverse transcription and protease, but also 
inhibition of viral fusion and integration. The success of the HIV PI class in suppressing patient 
viral load is undeniable, especially in treatment-experienced patients (286, 287). Although the 
benefit of HIV PIs is greater than the risk, large side effects still remain. Unfortunately, these 
include long-term metabolic complications including dyslipidemia, insulin resistance, and 
lipodystrophy, all of which are high risk factors for atherosclerosis and heart disease (19, 21, 22, 
276). In order to decrease the risk to benefit ratio, the mechanism underlying HIV PI-induced 
metabolic side effects needs to be addressed and resolved through alteration of HIV PI structures 
or inclusion of alternative therapies in the regimen. 
Abnormalities seen in the clinic begin at the cell. Therefore, to understand how HIV PIs 
induce dyslipidemia and lipodystrophy, the mechanism by which HIV PIs modify cellular lipid 
metabolism needs to be elucidated. While it is often difficult to determine which cellular 
pathways are implicated in drug-induced pathologies, ER stress and autophagy are already 
shown to be directly involved in cellular lipid metabolism.  
We hypothesize HIV PIs dysregulate lipid metabolism in adipocytes by activating ER 
stress and autophagy. In addition, while we have previously shown HIV PIs to dysregulate lipid 
metabolism in hepatocytes through ER stress, autophagy dysregulation may also play a role. 
Finally, we surmise inhibiting HIV PI-induced ER stress will abrogate lipid metabolism 
dysregulation in these metabolically important cell types.   
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HIV PIs in Adipocytes 
 When it comes to investigating cellular mechanisms underlying HIV PI side effects, 
surprisingly little work has been accomplished in adipocytes. Until the last decade, the 
complexity of adipocytes and adipose tissue had hindered in depth studies in this field as well as 
metabolic disease research. In the 2000s, HIV PI affects in adipocytes focused on inhibition of 
differentation. As a result of these investigations, there was much contradiction as well as little 
insight into mechanistic explanations.   
 Contradictions began in 1998 with the first two major studies in this realm. Here, HIV PI 
alterations of adipogenesis showed opposite results with IDV and RITV. While using the same 
cell lines, very similar culture conditions, and Oil Red O staining, Gagnon et. al found IDV and 
RITV to potentiate differentiation (288), while Zhang et. al found inhibition (245). In addition, 
Zhang et. al also found AMPV, a drug with little metabolic side effects, to also inhibit 
differentiation.  
More results followed suit, and included almost all HIV PIs (156, 192, 193, 239-244, 
289, 290). Due to these inconsistencies, our studies began with preliminary results already 
published. We began simply by optimizing differentiation protocols for our cellular models to 
ensure downstream assays were finding conclusions in differentiated, and not partially 
differentiated, adipocytes. As pre-adipocytes are fibroblastic in nature, we felt a mixed cellular 
population would distort the results.  
Once our methods were confirmed, we did one large experiment to determine HIV PI 
affects on 3T3-L1 differentiation by treating cells while concurrently inducing adipogenesis. We 
found this assay to be extremely concentration-dependent, with some HIV PIs (IDV, SQV, NFV) 
inducing complete cell death at reported patient serum concentrations. This may explain 
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contradictions in the literature as such a large range of concentrations were used between 
investigators.  
It is important to note at this point the concentrations chosen in our studies. While plasma 
concentrations can vary greatly in patients due to a variety of factors such as health, 
individuality, and drug regimens, mean plasma concentrations are given in a number of clinical 
investigations. Of particular importance is what is deemed effective plasma concentrations of 
each HIV PI, as often the plasma concentration is 10 times higher than the mononuclear 
intracellular concentrations (291). For LOPV/RITV, the current published data states an average 
mean concentration of 6 µg/mL, and for LOPV a peak concentration at about 12.5 µg/mL, for 
those on LOPV:RITV 800/100 mg once a day or 400/100 two dimes a day (292, 293). Given the 
molecular weight, this translates to around 10 µM for RITV and 25 µM for LOPV. Other HIV 
PIs also do not differ much in clinical plasma concentrations compared to those treatments we 
show here as physiological (ex. IDV is 15 µg/mL which is almost 25 µM (294)). 
 For our studies, another important factor to consider is the actual accumulation of HIV 
PIs in non-target cells (i.e. hepatocytes and adipocytes). For Chapter 5, we are confident of the 
concentrations used as HIV PIs are susceptible to first-pass metabolism, and therefore 
concentrations experienced by hepatocytes is as high, if not higher, than that measured in patient 
serum. In addition, we have already shown HIV PIs to accumulate intracellularly in hepatocytes 
(49). 
 In terms of adipose tissue, it is key to realize that HIV PIs are highly lipophilic, and can 
accumulate in AT by passive diffusion and physical dissolution in the neutral fats (295). 
However, limited quantitative studies have confirmed the actual concentration of PIs in AT 
versus serum levels in patients. Others have shown HIV PIs to accumulate intracellularly in 
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cultered mouse and human adipocytes (244, 290, 296), and we have preliminary data suggesting 
the same in our cellular model. Although numerical concentration of HIV PIs in AT is not well 
published, we believe plasma concentration is highly representative given the above data, the 
accumulation by diffusion, and knowledge that AT is a well vascularized organ. 
 Therefore, when analyzing results from our investigations, and those in the literature, the 
clinically relevant concentrations must be considered. We are now confident of the results shown 
in Chapter 3 due to these above careful considerations, numerous repeats, and different assays 
used to analyze HIV PI-alteration of adipogenesis. Of particular significance is the clarification 
we found of RITV's effects on adipogenesis. We have found with Oil Red O staining, as well as 
analysis of LD size and numbers by MATLAB, that there is no increase of lipid accumulations 
compared to control at physiological concentrations of RITV (6.25 µM), while accumulations 
occur at higher concentrations. This may help explain both the contradictions in the literature, as 
well as the reason LOPV plus RITV combinations inhibit differentiation by 12.5-25 µM. 
  At the same time of these clarifications, we began investigating one cellular pathway 
involved in lipid metabolism, ER stress. In adipocytes, ER homeostasis is essential in LD droplet 
formations and lipolysis (see Chapter I VI A 3b). We therefore hypothesized that HIV PIs induce 
ER stress upstream of adipogenesis alterations in adipocytes.  
The unfolded protein response (UPR) is the signaling pathway induced at times of ER 
stress activation. In the beginning figures of Chapter 3, we show LOPV and RITV, as well as the 
clinically relevant combination LOPV/RITV (4/1), time and dose-dependently increased the 
UPR transcription factors ATF-4 and CHOP. We have also found that HIV PIs which do not 
induce the UPR (AMPV and DRV) have minimal metabolic side effects in the clinical. This 
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correlation encouraged the remainder of our studies as the UPR may be a potential therapeutic 
target. 
During this time, another group also found LOPV to induce ER stress in a human 
adipocyte cell line (SGBS) (54). Their investigations were able to correlate LOPV-induced ER 
stress and insulin signaling, but were unable to find a direct connection. While their results were 
only correlative and not involved in lipid metabolism, their findings are supportive of our 
studies. In addition, others have found the ability of ER stress activation to lead to inhibition of 
adipogenesis (189). This has been proposed to occur through CHOP.  
CHOP is a C/EBP-homologous protein (hence its name) and can therefore dimerize with 
C/EBPs. C/EBPβ is essential in the induction of adipogenesis, while C/EBPα is involved in 
maintenance of differentiation (Background VI A 2a). When CHOP dimerizes with the C/EBPs, 
it inhibits their homodimerization necessary for binding to target promoters (297, 298). This 
ultimately leads to inhibition of differentiation (76).  
We found that lack of CHOP abrogates HIV PI-induced alterations in adipogenesis. 
While in the literature many have published the ability of HIV PIs to alter adipogenesis 
(although with contradictions therein), we are the first to propose a substantial mechanism by 
which this may occur. We propose that an increase of ER stress can lead to upregulation of 
CHOP through transcription factor ATF-4, resulting in inhibition of differentiation by LOPV and 
LOPV/RITV. 
However, the ability of RITV to induce lipid accumulations at higher concentrations 
grabbed our curiosity. RITV at 6.25 µM did increase CHOP mRNA and protein levels in 
differentiated adipocytes (Figures 10, 11). However, by 12.5 µM, this increase was not as great 
as that induced by LOPV, especially at the protein level. We hypothesize that although these 
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differences are slight, they may be enough to cause differential results in adipogenesis 
progression. This would especially be the case if CHOP is competitively binding to C/EBPs 
during differentiation. Given that CHOP
-/-
 also abrogated RITV accumulations supports that both 
LOPV and RITV alterations in adipogenesis occur through the CHOP pathway. 
We also serendipitously came upon another potential mechanism to explain the 
differential affects of LOPV and RITV. This occurred when we were testing whether HIV PIs 
could increase IL-6 mRNA stability through HuR binding in adipocytes as they do in 
macrophages (232). While our results were non-conclusive in this regard, we surprisingly found 
that HuR and CUGBP-1 (CUGn triplet repeat RNA-binding protein) bound to PPARγ mRNA, 
and this was significantly increased with RITV, but not LOPV, treatment. 
AU-rich elements (AREs) in the 3' untranslated region (3'UTR) allow for rapid decay of 
short-lived mRNAs. RNA binding proteins such as HuR increase mRNA stability via binding to 
these regions (299, 300). CUGBP-1 binds to CUG oligonucleotides, leading to alternative 
splicing and alteration in translation (301, 302).  
 Both HuR and CUGBP-1 have previously been reported to play a role in adipogenesis 
through postranscriptional regulation of C/EBPβ. CUGBP-1 was the first shown to bind to 
C/EBPβ (301). This binding resulted in differential translation of the C/EBPβ transcript, leading 
to production of short dominant-negative isoforms which bind and inhibit action of full C/EBPβ 
proteins. In adipocytes, this leads to inhibition of differentiation (303). More recently, HuR has 
also been demonstrated to complex with C/EBPβ. Rather than increasing C/EBPβ mRNA 
stability, HuR binding slowed translocation to the cytosol, also contributing to a delay in 
differentiation (304, 305). Therefore, both of these mRNA proteins may negatively regulate 
adipogenesis.  
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While this work is intriguing, we are the first to demonstrate a potential role of these 
binding proteins on PPARγ postranscriptional regulation. We have identified putative binding 
sites for both proteins, and demonstrated binding through an in vitro pulldown. Importantly, 
RITV treatment in 3T3-L1s increased both HuR and CUGBP-1 binding, with more significant 
binding found at the 3'UTR.   
 It remains to be asked why so many who study this essential transcription factor failed to 
note such a regulatory mechanism of its action. In fact, we believe the substantial induction of 
binding with RITV treatment allowed us to come upon this finding. In addition, another inquiry 
remains as to why both proteins bind to the 3'UTR. Intuitively, this result seems contradictory as 
HuR is thought to stabilize mRNA transcripts while CUGBP-1 destabilizes. In reality, these 
distinct classifications may not hold, as we have discussed above HuR binding actually slows 
C/EBPβ shuttling. In addition, CUGBP-1 may increase translation of some transcripts (306). 
Therefore, there is potential that these proteins are not having opposite effects when binding to 
PPARγ.  
To boot, others in our laboratory have noticed competitive binding of HuR and CUGBP-1 
on IL-6 mRNA in macrophages (in progress). Therefore, there is the possibility that this 
competition is also occurring in our model. The regulation of mRNA binding proteins and their 
subsequent actions is currently not well defined, and continuously investigated due to potential 
roles they play in many cellular pathways and correlated diseases. While this field is growing, 
we hope to gain a greater prospective of how, and why, HuR and CUGBP-1 bind to PPARγ 
mRNA. 
 Although one HIV PI induced binding significantly and the other did not, both LOPV and 
RITV significantly inhibited PPARγ promoter activity in our assay. This result is supportive of 
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current literature (243, 258, 307, 308). In addition, our findings were not dose dependent, which 
is supportive of other results that HIV PIs do not directly bind to the PPARγ promoter (245). 
While it is clear HIV PIs inhibit PPARγ promoter activity, some have reported no change in 
mRNA or protein levels of PPARγ with RITV treatments (193, 241), perhaps explained by 
postranscriptional modifications. 
There are multiple lines of evidence that ER stress can lead to a decrease in PPARγ (309-
312). What is not known is which component of the UPR is leading to this inhibition, or if 
another factor is contributing to the phenomenon. SREBP-1c is a lipogenic transcription factor 
located in the inactive form at the ER membrane, and can be released at times of ER stress 
(Background IV B2). Others have shown that HIV PIs alter the nuclear lamin A/C maturation 
(239, 313, 314), essential for normal nuclear penetration of SREBP-1 (315, 316). We have 
previously shown SREBPs to be upregulated at times of HIV PI-induced ER stress (49), and 
believe the same occurs in AT (Figure 27). However, in adipocytes SREBP-1c may not be 
adequately translocated into the nucleus at times of HIV PI treatments, failing to stimulate 
PPARγ. At the same time, HIV PIs may be increasing the mRNA stability of what transcript is 
produced, allowing for a quick rebound of levels. Future studies need to be completed to analyze 
the timing of all these alterations, as well as the extent PPARγ protein levels are changed in the 
cytosol and nucleus of cells treated with HIV PIs.  
  The centrality of ER stress induction and HIV PI alterations in adipogenesis is apparent 
in our work. We also consider our MATLAB data directly correlated to ER stress induction. 
CTP:phosphocholinecytidylyltransferase (CCT), the rate limiting enzyme for 
phosphatidylcholine (PtdCho) synthesis, is enriched in the rough ER (Background VI 3 b). Lipid 
droplet (LD) fusion can occur at times of ER stress when there is a decrease of CCT (175). In 
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Figure 19, RITV significantly decreased LD number while increasing LD diameter. This data 
suggests LD fusion. We hypothesize the induction of ER stress is the cause of this specific 
phenomenon, as the ER and LD organelles are so closely intertwined (66, 69, 173, 174). 
However, more intricate studies are needed to elucidate this phenomenon. These investigations 
will not only aid in understanding how HIV PIs act in adipocytes, but also allow deeper 
clarification of LD physiology. 
HIV PIs in Adipocytes - Autophagy Induction 
 In order to further investigate HIV PI-induced lipid metabolism dysregulation in 
adipocytes, we turned to autophagy. We first began these studies when all the pathologies 
induced by HIV PIs could not be thoroughly explained through UPR induction. For instance, 
although we can visualize cell death in adipocytes chronically treated with HIV PIs, our 
apoptosis analysis was not as significant as expected (Figure 14). In addition, knockout of CHOP 
did not result in complete inhibition of LOPV and RITV alterations (Figures 26, 27). 
 At the same time of our ER stress studies, the role of autophagy in lipid metabolism was 
emerging in the literature. Autophagy has previously been shown to induce cell death and alter 
lipid metabolism (Background V A and VI D). In adipocytes, the significance of autophagy in 
physiology and pathology seems to be complex and only beginning to be understood. Recent 
work has demonstrated that knockdown of this pathway leads to inhibition of differentiation in 
vitro, and lack of white adipose tissue growth in vivo (203, 263). However, the control and 
intricacies of autophagy in fully differentiated adipocytes is not very well known. This is 
partially attributable to the essentiality of autophagy in differentiation, and therefore difficulty in 
knocking-down this pathway in mature cells and tissues through gene manipulation.  
143 
 
A few investigators have recently shown HIV PIs SQV, NFV, and an IDV analog induce 
autophagy in cancer cells (233, 234, 265). As seen in Chapter 4, we were able to demonstrate 
that HIV PIs ccan induce autophagy in metabolically important cells. Using multiple methods, 
we show that both RITV and LOPV induce autophagosome accumulations in both non-
differentiated and differentiated adipocytes. In contrast, DRV, a second generation HIV PI which 
is not known to induce lipid metabolism alterations in the clinic, did not significantly increase 
either the UPR or autophagy (Figure 31).  
 Autophagic flux is just as important as autophagosome formation. If autophagosomes fail 
to fuse with, or be processed in, lysosomes, an accumulation of autophagosomes will occur and 
present as an induction of autophagy. There is often criticism when investigators fail to probe for 
alterations in autophagic flux, especially in the emerging field studying autophagy in 
adipogenesis (280). LC3B has been demonstrated to localize at LDs (201, 317). Therefore, 
autophagosomes may not only be engulfing LDs when recycling lipids, but LDs may also fuse 
directly to these vesicles. If flux is inhibited, there would be a lack of full lipid recycling. This 
would obviously lead to pathology on its own. 
We found no evidence of inhibition of autophagosome maturation in our model. When 
analyzing our EM images, we visualized both early and late autophagosomes, as well as apparent 
autolysosomes (single membraned with highly degraded substances). We also examined for 
successful cleavage of GFP-LC3B. LC3B-II is already extensively shown to be localized to both 
the inner and outer membranes of autophagosomes (318, 319). Upon autophagosome-lysosome 
fusion, inner membrane LC3B is degraded with the cytosolic components while the outer 
membrane LC3B is removed by Atg4 through delipidation to be recycled (320). This same 
process will occur with the GFP-LC3B construct, but as GFP is much more resistant to 
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proteases, it is released into the cytosol at LC3B cleavage (281, 282, 321). Impediment of GFP 
cytosolic accumulation would suggest inhibition of autophagolysosome maturation, which does 
not occur in our assay (Figure 34).  
 Another flux assay we used was p62 degradation. The nuclear membrane protein p62 is 
used extensively in autophagy assays. p62 was found to have a LIR, and can serve as a linking 
protein between LC3B and ubiquitinated substrates (267, 268, 322). It has been proposed to be 
specifically degraded through autophagy, and therefore p62 protein levels should inversely 
correlate with autophagic flux (267, 271, 272). However, recent research has shown that there 
exist other sub-populations of p62 beyond those associated with autophagosomes (273). In 
addition, a recent publication has demonstrated that p62 associates with the 26S proteasome, and 
inhibition of proteasome activity leads to p62 accumulation (274). 
 HIV PIs have already extensively been shown to inhibit proteasome activity (223, 323-
325). In addition, this inhibition is dose-dependent, with HIV PIs having moderate activity when 
compared to other pharmacological agents. HIV PI proteasome inhibition has been proposed to 
be the inducer of ER stress, as it will cause an inhibition of nascent protein degradation (223). In 
this particular study cited, while ER stress activation and proteasome inhibition occurred in 
HepG2 and 3T3-L1 cells with HIV PI treatments, it was not elucidated which activity occurred 
first. As we have not conducted sufficient studies to determine if direct inhibition of proteasome 
activity is the result of UPR activation, and the downstream affects shown, we cannot refute this 
as being a possible underlying mechanism. However, our previous data suggests that in fact 
accumulation of cholesterol in the ER membrane is the underlying issue, which would lead to 
inhibition of the Ca
2+ 
ATP-pump, and result in depletion of ER Ca
2+ 
stores (Figure 13 and (51)).  
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 We hypothesize that the accumulation of p62 protein seen with the higher concentrations 
of HIV PIs in our assays is due to inhibition of proteasome activity, not inhibition of 
autophagolysosome activity (Figures 33, 47). While we are currently confident of our results 
demonstrating HIV PIs are inducing autophagy with no affect on flux, further experiments will 
be conducted in support of our work. One such study, of which we show in Chapter 5, is the use 
of lysosomal inhibitors to demonstrate accumulation of LC3BII is due to activation of autophagy 
and not inhibition of LC3BII degradation in the autophagolysosome (281).  
An even better determinant is degradation of long-lived proteins. This classical method 
utilizes isotope-labeling of long-lived proteins. The output result may be the most precise 
measurement of autophagolysosome activity (326, 327). However, degradation of many long-
lived proteins occurs through the proteasome. Therefore, to clarify the degradation pathway, 
inclusion of autophagy inhibitors (such as 3-methyladenine) is necessary. This leads to two 
pitfalls in the study. One, some inhibitors such as 3-methyladenine must be used at very high 
concentrations to fully inhibit autophagy. Another, HIV PI-inhibition of proteasomes may also 
affect the output of this assay. As such, positive and negative controls are even more essential in 
our particular investigations and will be considered in future experiments. 
While flux is not apparently altered, LC3B protein increase may not be attributable only 
to increased autophagy. In contrast, we believe some of this protein is also aiding in LD fusions. 
LC3B has been demonstrated to localize at LDs (201, 317), and also be involved in lipososomal 
fusion in drosophili (328). In a recent study of hepatic stellate cells, it was shown that platelet-
derived growth factor increased LC3B accumulation to LDs (317). While we are investigating 
different cell types with different drug treatments, this result demonstrates the capacity of an 
extracellular substance inducing differential localization of LC3B.  
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With the above studies, it can be hypothesized that HIV PIs induce an increase of LC3B 
protein levels, some of which will accumulate at adipocyte LDs (in a non-elucidated manner). 
With LC3B now shown to have tethering capacity, this protein may aid in the fusion of LDs, as 
well as direct fusion to autophagosomes. In addition, this increase of LC3B will allow more 
substrate for autophagosome production, a basis for the significant results shown in Chapter 4. 
Indeed, we have shown how HIV PIs can increase LC3B protein through the activation of ER 
stress.  
We first investigated an HIV PI-induced UPR and autophagy link with the transcription 
factor CHOP, as we had seen CHOP
-/-
 to abrogate HIV PI alterations in adipogenesis (Chapter 
3). While knockdown of CHOP resulted in a decrease of LC3B protein levels in 3T3-L1s, CHOP 
overexpression did not affect LC3B in either non-treated or HIV PI treated 3T3-L1s (Figure 35). 
This could be due to the methods we used (GFP-tagged CHOP may impede action of CHOP) 
and/or an already saturated system. The next step will be to reintroduce CHOP into a CHOP
-/- 
adipocyte and test LC3B response. In addition, we are continuing our experiments focused on 
HIV PI treated CHOP knockdown 3T3-L1s. Our initial results are very similar to our inhibition 
of adipogenesis assay, demonstrating the central role CHOP plays in HIV PI-induced 
dysregulation of lipid metabolism.   
Nonetheless, we also wanted to determine if this connection also occurred upstream of 
CHOP. As previously mentioned, others have demonstrated a UPR-PERK-autophagy connection 
(120, 130, 269). ATF-4, the transcription factor activated through this pathway, is a direct 
activator of CHOP (329, 330). In addition, RITV, a dose-dependent activator of autophagy 
(shown by EM to even be a more significant than LOPV) activated ATF-4 more so than CHOP 
in our models. As shown, ATF-4 knockout abrogates LOPV and LOPV/RITV upregulation of 
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LC3B protein (Figure 36). These findings are most intriguing and well connected to above 
discussions. Please see HIV PI-Induced UPR and Induction of Autophagy below for a further 
discussion of this matter. 
HIV PIs in Hepatocytes 
 In contrast to adipocytes, extensive work on HIV PI-induced metabolic side effects has 
focused in the liver and hepatocytes. The reasons are simple - the liver is central in many 
metabolic diseases, is one of the first organs HIV PIs come into contact, and is the major organ 
responsible for HIV PI metabolism. Nonetheless, it was not until most recent years that specific 
mechanisms underlying HIV PI-induced side effects in this organ were proposed. 
 Of most interest that formulated was the induction of ER stress. This mechanism seemed 
lucrative as it could so easily explain how one drug had so many deleterious cellular affects such 
as the inflammatory cascade, insulin resistance, and lipid metabolism dysregulation. In addition, 
more recent clinical findings demonstrate that many patients on HIV PIs have NAFLD, which 
ER stress has also been proposed to underlie (213, 214). Our laboratory has already extensively 
demonstrated that HIV PIs lead to the activation of the UPR in hepatocytes, and subsequent 
dysregulation of lipid metabolic-essential transcription factors (49, 50, 222).  
 More recently, autophagy is now understood to be a major player in lipid metabolism in 
hepatocytes, and may also underlie NAFLD/NASH (205, 225, 284). As we had investigated, and 
found, HIV PIs to induce autophagy in adipocytes, we were also interested if autophagy 
dysregulation was occurring in hepatocytes. And as shown in Chapter 5, this is indeed the case 
with LOPV/RITV 4:1. 
 We also took these findings a step further. Raltegravir, an integrase inhibitor, was found 
by our laboratory to not induce the UPR or lipid accumulations in hepatocytes as do HIV PIs. 
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Importantly, addition of raltegravir with LOPV/RITV treatment actually inhibited their induction 
of lipid accumulations (222). We hypothesized that this phenomenon could be explained through 
raltegravir-inhibition of LOPV/RITV-induced autophagy. 
 Indeed, as shown in Figures 39-42, raltegravir inhibits LOPV/RITV activation of 
autophagy. Excited by these findings, we moved forward to elucidate the mechanism. Significant 
evidence came by utilization of our previously acquired CHOP
-/- 
model. Here, we found 
significant abrogation of raltegravir-inhibition of LOPV/RITV-induced LC3B conversion 
(Figure 43). However, in vivo raltegravir did not alter LOPV/RITV increased LC3BII:I, but only 
inhibited the total LC3B protein increase (Figures 44, 45). 
 We do not believe this result is a lack of correlation between our in vitro and in vivo 
assays. Isolation and separation of protein is in fact a crude method of analyzing in vivo 
processes, especially in tissue with high proteolytic enzymes such as the liver. Although all 
experiments were handled with as much care as possible, we cannot disprove that some of these 
small proteins were not degraded before analysis. In addition, the liver is composed of more than 
just hepatocytes, but also macrophages and endothelial cells. We have not analyzed if HIV PIs 
induce autophagy in either of these other cell types, and therefore cannot exclude that their 
alterations are not also affecting our Western results. 
Upon further investigation of this data, we believe our in vitro results are translatable. In 
the wild type mice fed a normal diet, the „n‟ may not be large enough. Additionally, in the high 
fat diet experiment, lack of raltegravir activation of LC3B is significantly abrogated with loss of 
CHOP. And although not significant with this „n,‟ there is a trend loss in raltegravir inhibition of 
LOPV/RITV-induced LC3B activation. Nonetheless, more extensive investigations should be 
undertaken to definitively ascertain the in vivo ability of raltegravir inhibition in LOPV/RITV-
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induced autophagy. One example would be the use of GFP-LC3B transgenic mice (281). This 
model allows direct monitoring of autophagosome formations by sectioning tissue and analyzing 
with fluorescent microscopy, and may aid greatly in our investigations.  
Nevertheless, our in vivo results highly correlate to our results from Chapter 4. In fact, 
when CHOP is downregulated in 3T3-L1s, there was a total decrease of LC3B protein, not a 
decrease of LC3BII:I. Going farther upstream lead to this same finding. In fact, it has been 
proposed the PERK pathway connects ER stress to autophagy through ATF-4 transcriptional 
regulation of LC3B.  
HIV PI-Induced UPR and Induction of Autophagy 
 Hypoxia is one known inducer of ER stress as protein folding is oxygen dependent (331). 
Autophagy induction has been shown to occur at times of oxygen depletion (332, 333), with a 
direct connection to ER stress proposed by Rzymski et. al in 2010 (130). In hypoxic conditions, 
this group found an upregulation of ATF-4 lead to a subsequent increase in LC3B protein. By 
using a siRNA targeted to ATF-4, they saw a decrease in total LC3B protein levels, as we have 
also shown in our model. Even more, they were able to define an ATF-4 binding site in the 
5'UTR of the LC3B promoter, and demonstrated strong and specific binding at times of hypoxia.   
 ER stress can be induced by multiple mechanisms. Other investigators have proposed 
UPR-autophagy links during such differential alterations such as inhibition of nascent protein 
degradation (131), oxidative stress (334), and radiation (129). Our studies investigate only one 
mechanism of ER stress activation, but have many similarities to others who show a PERK-
autophagy link. Particularly, HIV PIs significantly upregulate both ATF-4 and CHOP in all cell 
models we study, and knockdown of ATF-4 leads to a decrease in total LC3B protein levels. 
150 
 
 Many investigators are under the impression that conversion of LC3B is the key 
necessary for increased autophagosome formation. While we do not refute the necessity of this, it 
should also follow that an upregulation of LC3B will ultimately lead to more of the substrate 
essential in autophagosome formation. In fact, our findings are highly supported by Rzymski's 
results that ATF-4 may be able to directly upregulate LC3B protein leading to autophagosome 
increase (131, 335).  
 Our results demonstrate that CHOP also plays a major role in HIV PI-induced ER stress 
and autophagy induction. Knockdown of CHOP caused a significant decrease in LC3B within 
adipocytes, and raltegravir inhibition of LOPV/RITV LC3B induction was dependent on CHOP 
in hepatocytes. These results are novel, and demonstrate an exclusive relationship downstream 
CHOP has on LC3B regulation.  
 We have not yet defined the mechanism underlying CHOP‟s ability to alter LC3B protein 
levels. Rouschoup et. al have recently shown CHOP to bind to the Atg5 promoter (275). Atg5 is 
an E3-like ligase essential in LC3B lipidation, and therefore directly controls LC3BII:I levels. 
However, we have no current evidence this is occurring, and some of our results refute this 
hypothesis. Indeed, CHOP
-/-
 primary hepatocytes resulted in increased LOPV/RITV-induced 
LC3B conversion relative to wild type control (Figure 43). More intricate assays are thus needed 
to determine if CHOP does indeed play a transcriptional role in autophagy regulation. This may 
be via Atg5, or one of the other 30+ proteins involved in autophagy.  
Targeting HIV PI-Induced Metabolic Side Effects 
 While all our findings above are intriguing and give insight into a multitude of cellular 
pathways and regulations, the ultimate goal is unearthing a potential target to inhibit HIV PI-
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induced cellular lipid metabolism dysregulation. Unfortunately, current approaches in the clinic 
do not target the issue at hand, but rather treat the symptoms.  
For instance, when a physician notes an alteration in lipidemia, the first conclusion is 
often a change of diet with a lipid lowering agent. This may not be enough to combat cellular 
alterations induced by a chronic drug therapy. In addition, switching to alternative HAART 
regimens may not be beneficial to the patient due to viral load and mutations, physical condition 
of the patient such as ability to clear drug, and other induced side effects. Therefore, an optimal 
approach would be inhibition of HIV PI cellular perturbations that lead to these chronic clinical 
effects. 
 Some have attempted addition of direct interventions during HIV PI treatment. One such 
example is addition of thiazolidinediones, direct stimulators of PPARγ. These drugs are often 
used in the treatment of insulin resistance, but have also been shown to have great potential in 
treatment of genetic lipodystrophies (336, 337). However, addition of rosiglitazone did not 
improve lipid profile in patients on HIV PI-therapy (338-340). Probing into the molecular effects 
of HIV PIs gives the reasons for such a failure – as shown in our studies.  
Others have attempted to add homeopathic agents into the treatment and test if this could 
alleviate some HIV PI side effects. There has not been any success in this avenue, either. 
Importantly, clinical investigators must be cautious in such studies. Although many herbs have 
minimal side effects, they may disrupt the metabolism of drugs, affecting the concentration and 
action of essential therapies such as HIV PIs. One well known example is St. John‟s wort, which 
inhibits cytochrome P450 3A4, the same enzyme that metabolizes HIV PIs. 
While our laboratory was initially investigating such alternative therapies, focusing on 
the Chinese herbal medicine Berberine (191), the results we show here may ultimately change  
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Figure 49: HIV PI-Induced ER stress activates autophagy and dysregulates cellular lipid 
metabolism. Our current model based on the findings presented in this dissertation. 
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focus to agents already within the HAART class. Specifically, we show raltegravir to inhibit 
LOPV/RITV-induced lipid accumulations in hepatocytes. 
 In the clinic, there is currently no data suggesting an unfavorable lipid profile in patients 
on raltegravir therapy (341, 342). In fact, some propose a switch from HIV PIs to raltegravir 
would be beneficial. A few clinical trials, such as the SWITCH study, have investigated this, but 
it is currently not recommended. While the results demonstrate an improvement of lipid profile, 
it is at the cost of worsening viral load (343), so much so that one study had to terminate early 
(344). It is apparent, however, that raltegravir can have a positive impact on HIV PI-induced 
lipidemia. 
 Our investigations demonstrate that raltegravir has a direct affect on these lipid metabolic 
alterations at the cellular level. However, our current studies with raltegravir are only completed 
in hepatocytes. While this is a key cell type involved in lipidemia, it must be determined if this 
phenomenon also occurs in adipocytes. One recent study has shown raltegravir to have no effects 
on adipogenesis of 3T3-L1s (345). This suggests to us that raltegravir may have similar 
beneficial results in adipocytes, and we will therefore continue our studies in this direction.   
Conclusion 
 Chronic side effects induced by HIV PIs have placed a major pitfall on these otherwise 
beneficial agents. Elucidating HIV PI cellular metabolism alterations can lead to better therapies. 
We have shown that HIV PIs induce two major pathways involved in cellular lipid metabolism, 
ER stress and autophagy, which are not mutually exclusive. We propose raltegravir addition in 
HAART will relieve this activation, inhibiting HIV PI-induced lipid metabolism dysregulation. 
Future investigations should focus on the metabolic benefits of such a therapy. 
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